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ABSTRACT OF THE DISSERTATION 
Methods and Mechanisms of DNA methylation in Development and Disease 
By 
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Doctor of Philosophy in Biology and Biomedical Sciences 
 Molecular Genetics and Genomics 
Washington University in St. Louis, 2014 
Professor Robi D. Mitra, Chair 
	  
DNA methylation is a mechanism for long-term transcriptional regulation and is required for 
normal cellular differentiation. Failure to properly establish or maintain DNA methylation patterns leads to 
cell dysfunction and diseases such as cancer and neurological disorders. The goal of this thesis is to 
understand the role of DNA methylation in oncological cellular transformation and in normal development. 
To achieve this goal, I have developed a novel method for mapping genome-wide DNA methylation 
patterns and have applied the method to gonadectomy-induced adrenocortical neoplasms and to 
maturing motor neurons. The novel method, called Laser Capture Microdissected-Reduced 
Representation Bisulfite Sequencing (LCM-RRBS), accurately and reproducibly profiles genome-wide 
methylation of DNA extracted from microdissected fresh frozen or formalin-fixed paraffin-embedded 
tissue samples. Using this method, I find that significant DNA methylation changes, associated with 
attendant expression changes, occur in transformed adrenocortical cells. My work has also uncovered 
significant DNA methylation configuration in maturing motor neurons associated with dramatic expression 
changes. I show that demethylated regions are enriched for known neuron-specific transcription factor 
binding sites and that genetic disruption of the active demethylation machinery significantly inhibits motor 
neuron differentiation and maturation. Together, these experiments demonstrate that DNA methylation 
plays a role in the transformation of normal cells to cancer cells and that DNA methylation is critical to 
proper motor neuron formation. I conclude that aberrant DNA methylation controls gene expression in 
gonadectomy-induced adrenocortical neoplasms and that neuron-specific transcription factors could 
recruit demethylating enzymes to regions that lose DNA methylation in motor neurons upon maturation.
1 
CHAPTER 1: INTRODUCTION 
 
OVERVIEW 
 The genetic code of life is incredibly static and robust. From one cell, with two genome copies, 
results a multi-cellular organism made of over 100 distinct cell types (Gilbert 2013). Each cell contains an 
(almost) exact copy of that original genome present in the first cell, yet can exhibit unique cellular 
morphologies and functions (Gilbert 2013; Lodish 2013). What’s more, scientists have observed that as a 
fertilized egg develops into a mature embryo, daughter cells of the first, totipotent cell gradually lose the 
ability to differentiate into any cell type. Indeed, as early cells differentiate toward one of three germ 
layers, which specialize into different cell types, cells lose the potential to revert to a different germ layer 
and become committed to the lineage. As a blastocyst develops, these intermediate progenitor cells 
further differentiate to the terminal states of fully formed, specialized adult cells. These seemingly 
contradictory observations have long perplexed scientists: How could such a diverse cadre of functionally 
and morphologically distinct cell types result from genetically identical cells? How does a dividing cell 
(e.g. liver) know to replicate into the same cell type (another liver cell)? 
 Conrad Waddington first introduced the concept of an “epigenetic landscape” to describe this 
phenomenon in which differentiating cells lose the ability to return to a more pluripotent state (Waddington 
1940; Gilbert 2012). Waddington’s use of “epigenesis” or “epigenetics” referred to the path cells take 
during development from genotype to phenotype and also incorporated the understanding that 
neighboring cells influence the differentiation of each other (Waddington 1939). The contributions of 
neighboring cells (e.g. Shh signaling), or ‘extrinsic’ factors, have since been expanded to include any 
environmental effects both ex vivo and in vivo. Modern definitions of “epigenetics” try to include the notion 
of non-genetic heritability, traversing either cell divisions or generations, of such factors or phenomenon 
to evoke the notion of cell identity “memory” (Hemberger et al. 2009). 
 In my opinion, the term “epigenetics” is highly sensationalized and used to describe observations 
that go beyond the intention of its original definition, which has led to confusion and over use. For these 
reasons, I avoid the use of the word “epigenetics,” but instead describe my observations and 
understanding of the literature in the most concrete manner possible. On those occasions I do use the 
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term “epigenetics,” I broadly refer to any modification of DNA or DNA architecture that does not change 
the nucleic acid sequence. This work focuses on one of these modifications of DNA, the methylation of 
cytosine residues, which plays an important role in bringing a cell from “genotype to phenotype” and in 
determining cellular identity. 
 
DNA METHYLTRANSFERASES CATALYZE THE METHYLATION OF CYTOSINE RESIDUES 
 The existence of methyl-modified cytosine (5mC) in nature was first discovered in 1925 by 
Johnson and Coghill as a structural unit of nucleic acids isolated from tubercle bacillus (Johnson and 
Coghill 1925) as anticipated by Wheeler and Johnson, the first to synthesize 5-methyl-cytosine in 1904 
(Wheeler and Johnson 1904). More than two decades after Johnson and Coghill’s discovery, G. R. Wyatt 
showed that 5mC occurred in the nucleic acids of higher animals and plants (Wyatt 1950). Studies would 
later show that, unlike in plants (Gruenbaum et al. 1981), most animal 5mC occurs at the cytosine of a 
cytosine-guanidine dinucleotide known as a CpG (Grippo et al. 1968). The only mammalian 5mC 
occurring outside the CpG context was observed in embryonic stem cells and thought to be lost in adult 
tissues (Ramsahoye et al. 2000; Meissner et al. 2008) until methylation studies of the developing mouse 
and human brain revealed the presence of potentially biologically relevant levels of CpH (H = A, C, T) 
methylation in neuronal cell types (Xie et al. 2012; Lister et al. 2013). The role of non-CpG methylation, 
however, is still unclear. Mammalian genomes are depleted of CpG dinucleotides due to the propensity of 
5mC to deaminate to thymine (Coulondre et al. 1978). This deamination has resulted in genomes 
containing unmethylated CpG-rich regions, known as CpG Islands, primarily located in gene promoters 
(Bird et al. 1985). CpGs outside of CGIs are typically methylated.  
 A family of proteins, known as the DNA methyltransferases (DNMTs), catalyzes the transfer of a 
methyl group from S-adenosylmethionine to a cytosine residue (Gold et al. 1963; Grippo et al. 1968). 
Four known DNMT proteins exist in mammals: Dnmt1 (Bestor et al. 1988), Dnmt3A/B (Okano et al. 1998), 
and Dnmt3l (Aapola et al. 2000).  
 Work by Bessman et al. in 1958 characterizing the function of DNA polymerase showed that the 
enzyme cannot distinguish between the methylated and unmethylated cytosine nucleotide (Bessman et 
al. 1958) prompting the possibility for the existence of a methyltransferase responsible for propagating 
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5mC through DNA replication. Dnmt1 serves this role due to its high affinity for hemi-methylated, newly 
synthesized DNA (Gruenbaum et al. 1982; Bestor and Ingram 1983) and is primarily responsible for 
faithfully copying the parental-strand methylation pattern onto the daughter strand after each round of 
DNA replication (Stein et al. 1982), though some evidence exists that suggests Dnmt1 may have some de 
novo methylase activity (Vertino et al. 1996). The localization of Dnmt1 to DNA replication foci (Leonhardt 
et al. 1992) and its interaction with PCNA (Chuang et al. 1997), a protein that stabilizes the binding of 
DNA polymerase to DNA, further strengthen the role it plays in maintaining DNA methylation states 
through cellular division. 
 Dntm3a and Dnmt3b are responsible for the de novo methylation of unmethylated DNA (Okano et 
al. 1998; Okano et al. 1999) and have both overlapping and disparate DNA sequence affinities. Although 
somatic tissues show very little expression of Dnmt3a or Dnmt3b, Dnmt3a is ubiquitously expressed 
throughout the early embryo while Dnmt3b expression is specific to the forebrain and eyes (Okano et al. 
1999). The primarily role of Dnmt3b is to methylate minor satellite repeats of pericentric regions (Okano et 
al. 1999) while Dnmt3a has been shown to methylate all CpGs regardless of genomic context (Shirane et 
al. 2013). Beyond their role as de novo methylases, Dnmt3a and Dnmt3b seem to play a role in 
methylation maintenance. Early knockout studies showed that embryonic stem cells lacking Dnmt3a and 
Dnmt3b enzymes lose nearly all 5mC over progressive cell divisions, indicating Dnmt1 is insufficient to 
fully maintain 5mC (Jackson et al. 2004). The most striking evidence of maintenance capability was 
shown in Dnmt1 null colorectal carcinoma cells: even after 300 cell generations the cancer cells retained 
~60% of their global 5mC (Rhee et al. 2000). A similar study using the same cell line but shRNA 
knockdown, however, showed a dramatic loss of global and gene-specific methylation (Robert et al. 
2003).  
 Dnmt3l has no active methylase domain but seems to play a role in ensuring proper methylation 
of imprinted loci and transposable elements through the interaction with Dnmt3a and Dnmt3b. The 
expression of Dnmt3l is confined to germ cells where it regulates the methylation status of the maternally 
imprinted regions Snrpn, Necdin, Zfp127, Kcnq1ot1, and Peg3 (Bourc'his et al. 2001). Furthermore, 
Dnmt3l has been shown to ensure methylation of transposons in male but not female germ cells 
(Bourc'his and Bestor 2004). Dnmt3l directly binds to each of the catalytic domains of Dnmt3a and 
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Dnmt3b, which increases their de novo methylation activity and ability to bind DNA (Gowher et al. 2005), 
and directly binds histone modifications to recruit Dnmt3a to imprinted regions (Ooi et al. 2007). More 
recently, Dnmt3l together with Dnmt3a have been shown to be responsible for CpG and non-CpG 
methylation in oocytes (Shirane et al. 2013)  
 
DNA METHYLATION IS IMPORTANT FOR MAINTAINING CELLULAR IDENTITY 
 The symmetry of a CpG dinucleotide on the forward and reverse strand provides a natural means 
for ensuring 5mC states are faithfully inherited across DNA replication. Hence, DNA methylation is 
thought to be the predominant mechanism by which cells maintain their cellular identity through cellular 
divisions. The first evidence for a role of 5mC in maintaining cellular identity came two decades after 
Wyatt’s discovery of vertebrae 5mC when Vanyushin et al. showed slight differences in the total 5mC 
content of DNA between various animal tissues (Vanyushin et al. 1970). Using methylation sensitive and 
insensitive enzymes, Waalwiik and Flavell showed significant 5mC difference between rabbit sperm, 
brain, and liver DNA at an intron of the beta-globin gene locus (Waalwijk and Flavell 1978). Ehlrich et al. 
would definitively demonstrate that global 5mC levels varied between tissue and cell types a few years 
later (Ehrlich et al. 1982). These studies laid down the foundation for understanding the role of DNA 
methylation in maintaining and determining cellular identify.  
 Several recent 5mC mapping studies at base pair resolution have demonstrated that cell types 
show tissue-specific 5mC and are characterized by unique 5mC profiles that overlap among tissues of 
similar origin. Varley et al. mapped the genome-wide distribution of 5mC across a diverse collection of 82 
human cell lines and tissues and showed that individual cell types have very distinct 5mC profiles. They 
show in vitro propagation of cell lines can cause a divergence from primary tissue 5mC levels (Varley et 
al. 2013). This observation suggests loci that change 5mC levels in culture are dispensable, since these 
cultured cells maintain their cellular identity. Ziller et al. mapped the entire 5mC landscape of 30 cell and 
tissue types (Ziller et al. 2013); they find that roughly 22% of 5mC loci differ among normal cell types and 
that tissues originating of similar origin share similar 5mC signatures. 
 The turn of the century saw the ushering in of cell reprogramming and induced pluripotent stem 
(iPS) cells whereby somatic cells regain the capacity to differentiate into various germ cell types 
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(Robinton and Daley 2012). The ability to restore pluripotency to somatic cells has provided significant 
insight into the epigenetic mechanisms that underlie reprogramming and has shown that DNA methylation 
plays a part in fixing a cell’s differentiated state and in conferring cellular memory (Kim et al. 2010; Polo et 
al. 2010). Kim et al. rigorously showed that the cell type of origin influences the differentiation potential of 
iPS cells (Kim et al. 2010). They showed that neural progenitor-derived iPS cells (NP-iPSCs) differentiate 
much less efficiently into cells of hematopoietic lineage than iPS cells derived from bone marrow cells 
(blood-derived; B-iPSCs), which are responsible for producing hematopoietic cells. The few 
hematopoietic progeny that were differentiated from NP-iPSCs were reprogrammed to iPS cells (NP-
derived-blood-derived; B-NP-iPSCs), which subsequently were able to differentiate to hematopoietic 
lineages at a very high efficiency. The poor blood forming potential of NP-iPSCs suggests that NPs either 
have epigenetic marks that restrict the differentiation into blood fates or lack the epigenetic marks that 
enable blood formation. Furthermore, Kim et al. demonstrated that treatment during differentiation of NP-
iPS cells with 5-azacytidine, a DNA methylation inhibitor, and TSA, a histone deacetylase inhibitor, 
dramatically enhanced hematopoietic lineage formation. Most interestingly, derived iPS cells retained 
residual DNA methylation that was indicative of their tissue of origin. Polo et al. also showed that iPSCs 
derived from various cell types exhibited distinguishing DNA methylation signatures representative of their 
cell type of origin (Polo et al. 2010). They expanded upon this understanding and showed that continuous 
passaging erased these DNA methylation signatures to attenuate cell of origin effects. 
 Loss-of-function experiments in mice further support the important role of 5mC and the 
methyltransferase machinery in maintaining cell identity (Broske et al. 2009; Sen et al. 2010; Dhawan et 
al. 2011b). A study of the epidermal progenitor population showed that Dnmt1 is necessary for proper 
differentiation into keratinocytes and for maintaining a self-renewing state (Sen et al. 2010). Dnmt1 
knockdown with shRNAs in progenitors resulted in induced differentiation and a loss of self-renewal 
ability. Wild-type DNMT1, but not a catalytically inactive mutant, reversed the observed proliferation 
defects, suggesting that the methylation of DNA controls proliferation and differentiation induction in 
epidermal progenitors. Furthermore, differentiation induction also occurred in human muscle progenitors 
upon Dnmt1 knockdown.  
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 The functional disruption of Dnmt1 in mice was shown to abrogate the differentiation of 
hematopoietic stem cells (HSCs) into myeloerythroid and lymphoid lineages (Broske et al. 2009). Broske 
et al. show that Dnmt1 maintains high methylation levels at myeloerythroid-specific genes to repress 
transcription. Failure to maintain methylation at these genes in HSCs prevents the differentiation into 
lymphoid progeny. Indeed, Dnmt1-depleted HSCs differentiated only down the myeloid lineage 
suggesting hypermethylation of myeloerythroid genes is necessary for proper differentiation into lymphoid 
cells. Interesting, the removal of Dnmt1 from committed lymphoid cells did not disrupt lymphoid identity or 
maturation, suggesting the maintenance of methylation is only necessary for lymphoid differentiation and 
not necessary for the maintenance of lymphoid cellular identity.  
 Most striking is a study demonstrating that pancreatic β cells, which produce insulin, undergo 
transdifferentiation to glucagon-producing α cells upon the conditional disruption of Dnmt1 (Dhawan et al. 
2011b). Using a genome-wide profiling method, they found that a short region upstream of Arx, a gene 
expressed specifically in α cells, lost methylation in Dnmt1-null β cells. Upon demethylation of Arx, β cells 
began to downregulate β cell markers and upregulate α cell markers. The inhibition of DNA methylation 
with 5-azacytidine also induced an upregulation of Arx de-repression, α cell marker activation, and 
glucagon production demonstrating that the methylation state of Arx determines the cellular identity of 
pancreatic β cells. 
 
DNA METHYLATION AS A MECHANSIM OF STABLE GENE SILENCING 
 The mechanistic function of 5mC did not become apparent until 1977 when Christman et al. 
observed gene expression increases of globin genes in erythroleukemia cells cultured in the presence of 
L-ethionine (Christman et al. 1977). They showed that L-ethionine resulted in a loss of global 5mC. Using 
methylation sensitive endonucleases, McGhee and Ginder were the first to interrogate the 5mC levels of 
a specific locus to understand its correlation with gene expression (McGhee and Ginder 1979). By 
assessing 5mC and expression levels of the β globin gene in normal chicken tissues, they showed 
tissues that expressed or that had expressed β globin had sites at the ends of the gene sequence that 
were fully unmethylated; the same sites were at least partially methylated in tissues that did not express β 
globin. Desrosiers et al. documented a similar observation in virus producing and non-producing cells 
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(Desrosiers et al. 1979). Gene transfection experiments further showed that in vitro methylation of gene 
constructs inhibits their expression (Fradin et al. 1982) while many endogenous genes can be activated 
from a repressed state by treatment with 5-azacytidine, an inducer of demethylation (Jones and Taylor 
1980). Global methylation and gene expression profiling would eventually show that the methylation of 
CpGs upstream of genes results in their down-regulation (Walsh et al. 1998; Bird and Wolffe 1999) and 
would establish 5mC as a transcription regulator.  
 The effects of DNA methylation, however, are strongly dependent on genomic context. Although 
5mC in gene promoters and enhancers are correlated with gene silencing, gene body methylation is 
associated with transcriptionally active genes (Hellman and Chess 2007; Ball et al. 2009). Many genome-
wide studies have shown poor overall correlations of 5mC with gene expression (Eckhardt et al. 2006; 
Zilberman et al. 2007; Brenet et al. 2011; Hartung et al. 2012). These inconsistencies are most likely a 
result of our inability to accurately identify the regulatory regions for all genes, as most can occur very 
distal to transcription start sites.  
 The covalent bond attaching the methyl group to the 5` carbon of a cytosine ensures methyl 
markers are stable and not easily lost. The durable nature of DNA methylation allows for the long-term 
silencing of genes and other genomic elements within specific cellular contexts. Dormant transposable 
elements pose a threat to the stability of the genome if reactivated. DNA methylation functions to silence 
transposable elements and maintain chromosomal integrity (Slotkin and Martienssen 2007) by preventing 
the reactivation of endoparasitic sequence that cause translocations and gene disruptions (Esteller 2007). 
DNA methylation is also responsible for silencing the inactive X chromosome during female X inactivation 
(Mohandas et al. 1981) and for ensuring allele-specific expression from paternal or maternal copies at 
imprinted regions (Reik et al. 1987; Sapienza et al. 1987). 
 The mechanism by which DNA methylation represses transcription can be direct, by excluding 
the binding of proteins that affect transcription (Watt and Molloy 1988), or indirect, by recruiting methyl-
CpG-binding proteins and their associated repressive chromatin remodelers (Robertson 2005). 
The chromatin boundary element binding protein, CTCF, acts to insulate the effects of enhancer regions 
from gene promoters by binding between these genomic elements. Its DNA binding sequence contains a 
CpG which when methylated inhibits (Ohlsson et al. 2001) CTCF from binding DNA. The imprinted gene 
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H19 is repressed on the paternal chromosome through the methylation of an imprinted-control region 2 
kilobases from its transcription start site. The same imprinted-control region is unmethylated on the 
maternal chromosome where CTCF binds to block the effects of a H19 enhancer on the Igf2 gene and 
maternally repress the Igf2 gene (Hark et al. 2000). Other methylation sensitive and insensitive binding 
proteins abound, but their role in regulating expression is unclear (Tate and Bird 1993). While CTCF is 
inhibited by 5mC, several proteins explicitly bind 5mC. Mecp-1 (now known as Mecp2) was the first 
protein shown to bind specifically to methylated DNA sequences (Boyes and Bird 1991), but several 
others have since been described (Wade 2001). Methyl-binding proteins mediate gene silencing by 
recruiting histone-modifying factors that shift the chromatin architecture to a closed, inaccessible, and, 
therefore, repressed state (Jones et al. 1998; Nan et al. 1998). MECP2, for example, recruits the arginine 
methyltransferase, PRMT6, among others, to add repressive chromatin marks and remove activating 
chromatin marks at the Arx locus to repress transcription (Dhawan et al. 2011b).  
 
DNA METHYLATION AND NEURONAL DEVELOPMENT AND FUNCTION 
 The past decade has accumulated significant insights into the role DNA methylation plays in 
neuronal development and postnatal function. Lister et al have shown that the mouse and human brain 
undergo significant methylation reconfiguring during development and highlight the potential importance 
of non-CpG methylation (Lister et al. 2013). They show that the fetal cortex is practically devoid of CpH 
methylation but rapidly gains global methylation at CpH dinucleotides shortly after birth during a time of 
high synaptogenesis. CpH methylation in gene bodies was inversely correlated with gene expression 
which is consistent with the role of 5mC in repressing transcription. Large, non-centromeric megabase 
regions of the genome, however, were resistant to CpH methylation gains and contained genes that 
encode receptors required for sensory neuron function and immune function. This study suggests 
neurons of the brain undergo significant gene repression via 5mC gains in the CpH context between fetal 
and adult stages. Several studies characterizing 5mC levels show that the human cerebral cortex 
undergoes significant 5mC changes throughout an individual’s lifespan showing gradual as well as sharp 
gains in 5mC levels at various promoters (Siegmund et al. 2007). Many 5mC changes were associated 
with transcriptional decline, though the consequences, if any, of these changes are not clear (Hernandez 
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et al. 2011). Contrary to these studies, Lister et al showed CpG and CpH methylation declines with age 
post-adolescence. The discordance of these studies most likely lies in the fact that Lister et al 
interrogated the whole genome while the previous studies were much less comprehensive. 
 The adult brain can undergo significant neurogenesis in response to external stimuli resulting in 
advanced structural plasticity. The methylation of DNA plays an important role in this observed plasticity, 
including in synaptic formation (Levenson et al. 2006), learning and memory (Day and Sweatt 2010; Miller 
et al. 2010; Zovkic et al. 2013), emotional behavior (Lubin et al. 2008; LaPlant et al. 2010), adult 
neurogenesis (Ma et al. 2009), and age-related cognitive decline (Oliveira et al. 2012). Most interestingly, 
is the role of 5mC in neural plasticity and neurogenesis, as various studies have shown that neuronal 
activity leads to significant gains and losses of 5mC in the brain (Nelson et al. 2008; Miller et al. 2010).  
For example, the promoter of Bdnf, a gene important for adult neurogenesis, is regulated in an activity-
dependent manner (Martinowich et al. 2003; Ma et al. 2009). Upon synchronized electro-convulsion of the 
hippocampus, the Bdnf promoter is demethylated by Gadd45b within 4 hours, which causes a release of 
the MECP2 repressor complex and increased expression of Bdnf. The study further shows that Gadd45b 
is essential for neural progenitor proliferation and activity-induced dendritic development (Ma et al. 2009). 
Global profiling studies have revealed the plasticity of 5mC in the brain across several genes (Guo et al. 
2011a). Persistent activity in neurons, as occurs during electroconvulsive stimulation or exercise, leads to 
subtle yet significant 5mC losses at Per2, Crebbp, and Grip1 and also 5mC gains at Zfhx2 and Ccdc44. 
Most of these 5mC changes occur at exonic and intronic regions, which may explain why these 5mC 
alternations do not correlate well with gene expression. These studies showing that significant 5mC 
configuration occurs after neuronal activity are helping to expel the belief that DNA methylation is highly 
stable in terminally differentiated cells. 
 Glial cells (i.e. astrocytes, oligodendrocytes, and microglia) and neurons are both derived from 
the same neuron progenitor cell population. Proper DNA methylation establishment seems to play an 
important role in the fate determination of neural progenitor cells into neurons and glial cells. Neuron and 
non-neuron cells display unique global methylation profiles, which ensures the regulation of neuronal- and 
glial-specific transcription (Iwamoto et al. 2011). Glial cells support the viability of neurons and therefore 
arise after the formation of neurons from the same neuronal progenitor cells (NPCs) (Qian et al. 2000). 
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Indeed, during development, NPCs gradually acquire competence for gliogenesis (Sauvageot and Stiles 
2002). Once NPCs are gliogenic, they simultaneously lose the ability to differentiate into neurons, 
suggesting the existence of a neurogenic to gliogenic switch that occurs during central nervous system 
development. Indeed, neurons appear at embryo day 11.5 (E11.5) while astrocytes begin to appear at 
E14.5. This switch in differentiation ability is regulated by 5mC. Before E14.5, the promoter of Gfap, an 
astrocyte marker, is methylated at a Stat3 binding site in neuroepithelial (progenitor) cells (Takizawa et al. 
2001). At E14.5, neuroprogenitor cells lose methylation at this site which leads to Stat3 binding, Gfap 
activation, and astrocyte differentiation. Studies of conditional Dnmt1 knockout mice further validate the 
role of 5mC in neuron/glial differentiation. Fan et al. show that Dnmt1-deficient NPCs are marked by 
hypomethylation at the Gfap promoter and spontaneously differentiate into glial cells (Fan et al. 2005). 
Upon Dnmt1 inactivation, glia-associated transcription factors, but not neuronal-specific genes are 
activated. 
 Direct experimental findings have shown that the DNA methyltransferases Dnmt1 and Dnmt3a 
are important for learning, memory, and synaptic plasticity. Conditional mutant mice lacking Dnmt3a in 
the entire central nervous system develop normally but have significant neuromuscular defects, reduced 
number of motor neurons in the brain stem, and shortened life spans (Nguyen et al. 2007). Because the 
knockout induction occurrs in neuron progenitor cells, these experiments highlight the importance of 
Dnmt3a in neuron differentiation. Exclusive conditional knockout of Dnmt1 and Dnmt3a in post-mitotic 
neurons of mice results in learning and memory deficits (Feng et al. 2010). Here, Dnmt gene deletion only 
occurs in mature, post-mitotic neurons of the central nervous system allowing researchers to understand 
their role in mature neuron function. Dnmt1 and Dnmt3a single knockout mice did not show an 
appreciable phenotype while double knockout animals had normal lifespans but smaller hippocampi. 
Furthermore, double knockout mice showed an appreciable loss of neuronal DNA methylation, induction 
of immune genes, and impaired synaptic plasticity. As we continue to profile the methylation and 
transcriptional landscapes of neurons under various conditions, the role of 5mC in neuron function will 
only become more evident. Furthermore, the reversibility and ability to regulate gene expression makes 
DNA methylation an attractive target for therapies that may be able to activate aberrant gene silencing or 
silence aberrant expression profiles. 
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DNA METHYLATION IN HUMAN HEALTH 
 The importance of DNA methylation in development has been well describing using transgenic 
and knockout mice. Deletion of Dnmt1 is lethal to embryonic development (Li et al. 1992); Dnmt3b-
deficient mice do not reach full term while mice lacking Dnmt3a die within 4 weeks of birth (Okano et al. 
1999). Dnmt3l-null mice are viable and develop normally (Bourc'his et al. 2001); The heterozygous 
offspring of female mice lacking Dnmt3l, however, die before the mid-gestation period from the biallelic 
expression of imprinted genes normally methylated and silenced on the allele of maternal origin while 
male mice lacking Dnmt3l are sterile due to a lack of germ cells in the adult. The importance of DNA 
methylation is further emphasized by the growing number of human diseases that are known to occur 
when 5mC is not properly established and/or maintained (Robertson 2005; Jakovcevski and Akbarian 
2012). Indeed, aberrant DNA methylation has been broadly implicated in cancer and in numerous 
neurological diseases. 
 
Cancer 
 DNA methylation was first implicated in cancer by Feinberg and Vogelstein in 1983 when they 
observed significant 5mC differences at specific loci between normal and diseased tissues of four cancer 
types (Feinberg and Vogelstein 1983). They also found the lowest level of 5mC in the metastasis of a 
lung tumor, first demonstrating that cancer cells lose methylation as they progress. The aberrant 
methylation patterns observed in cancers have since been well documented (Portela and Esteller 2010; 
Sharma et al. 2010; Taby and Issa 2010). Tumors are often characterized by global hypomethylation 
(Goelz et al. 1985; Wilson et al. 2007) as well as by locus-specific hypermethylation of genes involved in 
the main cellular pathways (Portela and Esteller 2010). The global hypomethylation, which can occur in 
large megabase regions and unmethylates repetitive regions (Hansen et al. 2011), is thought to 
destabilize the genome and result in transposon-mediated rearrangements. Loss of methylation also 
causes the aberrant activation of growth promoting genes (Wilson et al. 2007) and the loss of imprinting 
(Reik and Lewis 2005). Hypermethylation primarily at CGIs of promoters, on the other hand, contributes 
to tumorigenesis by silencing tumor suppressor and DNA repair genes and could thus serve as the 
second hit in Knudson’s two-hit model (Suzuki et al. 2004; Weinberg 2007). Roughly 5-10% of CGIs that 
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are constitutively unmethylated in adult tissues are hypermethylated in cancer (Bird 2002; Weinberg 
2007). The aberrant methylation of normally unmethylated tumor-suppressor genes can causes loss of 
heterozygosity and uncontrolled cell division and proliferation in countless cancers (Jones and Baylin 
2002; Chen et al. 2003). Today, hypermethylation events are being used as biomarkers to screen for 
colorectal cancer, among others (Lofton-Day et al. 2008). Abnormal 5mC in conjunction with disruptions 
in histone modifications may be key initiating events in some forms of cancer (Feinberg et al. 2006a). 
 The onset of whole genome and exome sequencing efforts have revealed the presence of 
mutations in chromatin modifying proteins as well as DNA methyltransferases across many tumor types 
suggesting the aforementioned methylation aberrations could be downstream of genetic abnormalities. To 
date, over 15% of hematopoietic and lymphoid cancers catalogued in the COSMIC database show 
mutations in the de novo methyltransferase DNMT3A, with enrichment in patients with de novo acute 
myeloid leukemia (AML) (Ley et al. 2010). Mutations in DNMT3A were correlated with poor patient 
survival, suggesting DNMT3A is involved in AML disease progression. Despite most mutations occurring 
in the methylase domain of DNMT3A, genome-wide 5mC analysis of AML genomes with and without 
DNMT3A mutations did not reveal an appreciable difference in 5mC between the two samples. 
Furthermore, the few differences that were observed did not result in an expression change of the nearest 
genes. These observations suggest that the function of DNMT3A in cancer progression may not be due 
to altered DNA methylation, but rather related to its ability to bind DNA and recruit histone modifiers (Ley 
et al. 2010). Few mutations are observed in DNMT3B for any cancer type, highlighting the primarily role 
of DNMT3B in early development. Similarly, very few mutations have been observed in DNMT3L of 
tumors catalogues in the COSMIC database. Over 50% of lung cancers, however, show copy number 
variations of DNMT1 and most ????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????? 
 The observation that pharmacological DNA methylation inhibitors, such as 5-azacytidine, results 
in gene activation (Venolia et al. 1982) demonstrated that 5mC is reversible and has since ushered in 
DNA methylation inhibitors as potent cancer therapies. Several DNA methyltransferase inhibitors have 
been approved in the past decade by the FDA for the treatment of patients with AML or myelodysplastic 
syndrome (Kaminskas et al. 2005). The response rates to the drugs, however, are low and highly variable 
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among patients. Furthermore, it is unclear whether the beneficial effects of treatment are associated with 
DNA methylation (Silverman et al. 2002; Figueroa et al. 2009).  
 
Neurological Diseases 
 DNA methylation has been strongly implicated in diseases affecting the nervous system either 
directly, by the aberrant methylation of DNA (Kumari and Usdin 2009; Buiting 2010), or indirectly, through 
functional loss of the DNA methyltransferases machinery (Jin et al. 2008; Chestnut et al. 2011; de Greef 
et al. 2011; Klein et al. 2011) or through the disruption of methyl-binding proteins (Amir et al. 1999). 
Fragile X Syndrome, a form of mental retardation, is caused by inactivation of the FMR1 gene through 
aberrant methylation of its promoter sequence. Aberrant methylation is also responsible for loss of 
imprinting in Prader-Willi Syndrome and Angelman Syndrome, which disrupts cognitive development in 
childhood. Mutations in DNMT3B and DNMT1 and the resultant disruption of proper methylation is the 
cause of two rare neuropathies Immunodeficiency, Centromere instability and Facial anomalies 
Syndrome 1/2 (ICF1/2) and Hereditary Sensory and Autonomic Neuropathy type 1, respectively, while all 
three methyltransferases have recently been implicated in Amyotrophic Lateral Sclerosis (ALS), the motor 
neuron degenerative disease. Finally, Rett Syndrome, one of the most studied neurological diseases, is 
caused by the disruption of the methyl-CpG-binding protein, MECP2, and characterized by early-stage 
cognitive decline. 
 Several neurological diseases are directly caused by the aberrant loss or gain of 5mC at a single 
locus including repeat-instability disease (Kumari and Usdin 2009) and imprinting disorders (Robertson 
2005). Fragile X Syndrome, a common form of mental retardation (Martin and Bell 1943), is caused when 
the CGG trinucleotide-repeat within the 5`-UTR of the FMR1 gene extends beyond 200 repeats. At this 
length, the CGG-repeat becomes methylated and the FMR1 gene is silenced leading to improper 
synthesis of neuron-specific proteins (Penagarikano et al. 2007). Recent work has shown that repression 
occurs because FMR1 mRNA hybridizes to the complementary CGG-repeat portion of the FMR1 gene 
(Colak et al. 2014). Future work will reveal how the DNA methyltransferase machinery is recruited to the 
RNA·DNA duplex and whether the hypermethylation can be permanently reversed. Two forms of mental 
impairment can occur when a single imprinted locus is not properly methylated and regulated. Prader-
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Willi Syndrome and Angelman Syndrome are caused by a loss of imprinting either through chromosomal 
loss or by aberrant methylation at the 15q11q13 chromosomal region (Buiting 2010). Prader-Willi occurs 
when imprinting is lost on the paternal allele while Angelman occurs when imprinting is lost from the 
maternal allele (Glenn et al. 1993).  
 Hereditary sensory and autonomic neuropathy type 1 (HSAN1) is the only disease known to be 
caused by mutations in the DNA targeting domain of DNMT1 (Klein et al. 2011). Patients with HSAN1 
suffer from late onset dementia, hearing loss, and loss of pain sensation due to peripheral and central 
neuron degeneration. The disruption of this domain results in premature protein degradation, reduced 
methyltransferase activity, and impaired heterochromatin binding during the G2 cell cycle phase which 
leads to a moderate global loss of methylation, primarily in repetitive satellite elements, and modest site-
specific hypermethylation (Klein et al. 2011). Although DNMT1 is primarily considered to only function in 
dividing cells, these studies ascribe a novel function to DNMT1 in post-mitotic neurons, namely in 
ensuring the proper methylation of pericentric and other condensed portions of the genome (Easwaran et 
al. 2004). 
 The ICF syndromes affect multiple organs and are characterized by mental retardation and 
defective brain development. ICF1 is caused by partial loss-of-function mutations in the catalytic domain 
of DNMT3B and the attendant loss of 5mC at pericentric repeats and gene promoters, which leads to 
dysregulation of genes involved in neurogenesis, immune function, and development (Jin et al. 2008). 
Interestingly, patients with ICF2, a syndrome with identical pathologies as ICF1, have completely 
functional DNA methyltransferase proteins but lack functional copies of the putative transcriptional 
repressor, ZBTB24 (de Greef et al. 2011). Hypomethylation defects are also present in ICF2 patients but 
occur at slightly different pericentric satellites, which implicates ZBTB24 in regulating DNA methylation.  
 ALS is one of a handful of neurodegenerative diseases that results as a consequence of motor 
neuron axonal degradation. Unlike the previously discussed neurological disorders, ALS is an affliction of 
the upper and lower somatic motor neurons located in the spinal cord that enervate skeletal muscles to 
control movement and locomotion. Although less well established, DNA methylation may be associated 
with ALS. One recent study showed that DNA methyltransferases play a role in regulating apoptosis in 
motor neurons, which suggests a novel function for the methyltransferase machinery (Chestnut et al. 
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2011). They show that Dnmt3a mediates apoptosis in chemically or physically challenged motor neurons 
through interactions with the mitochondria and through increasing genomic and mitochondrion 5mC. 
Inhibition of the methyltransferases prevents the induction of apoptosis demonstrating their role in 
maintaining motor neuron viability. Remarkably, motor neurons affected by ALS showed a significant 
overexpression of Dnmt3a as well as hypermethylation of genomic and mitochondrion DNA. This study 
alludes to the possibility of treating ALS with methyltransferase inhibitors. 
 The early onset autism spectrum disorder, Rett Syndrome, is caused by dysfunction of the 
aminergic neurons of the brainstem. The X-linked gene methyl-CpG-binding protein, MECP2, is 
responsible for regulating a cadre of genes involved in neurogenesis and neuron function. MECP2 has 
been shown to act by binding 5mC and recruiting chromatin-modifying factors that reorganize the 
chromatin into a closed and repressive state (Amir et al. 1999) although various studies have suggested 
an activating role of MECP2 (Li et al. 2011). Mutations in MECP2 preclude effective binding to methylated 
cytosines and recruitment of these repressive factors (Chahrour et al. 2008). Encouragingly, the 
restoration of Mecp2 in the post-mitotic neurons of Mecp2-deficient mice recovers most Rett syndrome 
symptoms (Guy et al. 2007) demonstrating that the lack of Mecp2 does not irreversibly damage neurons 
and that Rett is not strictly a neurodevelopment disorder.  
 The occurrence of DNA methylation-associated neurological diseases highlights an under-
appreciated role of DNA methylation, namely in ensuring proper function of post-mitotic cells. Previously, 
DNA methylation was only thought of in the context of cell division and early development. These 
diseases – and the ability to recover normal function in the case of Rett Syndrome – have shifted the 
notion of 5mC as a static, permanent mark, important only in development, to a dynamic mark of 
significant relevance to the human postnatal and adult brain. As we continue to explore the role of 5mC in 
post-mitotic neurons, we will undoubtedly uncover new regulatory functions of the DNA methylation 
machinery and associated binding partners.  
 
TECHNOLOGICAL CHALLENGES AND LIMITATIONS FOR MAPPING DNA METHYLATION  
 Current technologies that measure DNA methylation are limited by cost, sample throughput, the 
requirement for a large amount of starting material, and the inability to analyze DNA methylation of 
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complex tissues. Because PCR amplification erases DNA methylation patterns, a methylation-dependent 
treatment is required before methylation readout. The two main approaches to determining methylation 
patterns or profiles are affinity enrichment and bisulfite treatment. Where previous technologies limited 
DNA methylation analysis to a single locus, the introduction of microarray hybridization experiments and 
next-generation sequencing has permitted the profiling of 5mC at the genomic scale (Laird 2010a). Many 
of the earliest techniques used to measure DNA methylation have been supplanted by next-generation 
sequencing approaches (Esteller 2007). Today, discovery and profiling studies use genome-wide 
approaches while validation and targeted experiments use locus-specific approaches to determine the 
methylation status of the genome in disease and development. 
 
Genome-wide approaches 
 Current genome-wide sequencing-based approaches for DNA methylation analysis vary in 
resolution, coverage, and accuracy (Bock et al. 2010; Harris et al. 2010). Affinity enrichment-based 
techniques (e.g. MeDIP-seq, MethylCap-seq, and MBD-seq) can theoretically cover 100% of the genome 
but at a 100-1,000 base pair resolution. The actual 1x and 10x coverage of affinity enrichment published 
experiments is about 60-67% and 10-20% respectively, which indicates that increased coverage would 
require significant sequencing to reach saturation (Beck 2010). Furthermore, 70-80% of reads of whole 
genome sequencing provide no information of CpG methylation due to the non-uniform distribution of 
CpG dinucleotides (Ziller et al. 2013). Recently developed algorithms when coupled with the methylation-
depletion technique MRE-seq have increased the resolution of these tools to CpG resolution (Stevens et 
al. 2013). The benefit of these methods is the unbiased representation of the genome to include inter- 
and intragenic regions, promoters, and repetitive regions. An alternative whole genome approach to 
methyl-affinity enrichment is whole genome bisulfite shotgun sequencing (MethylC-seq)(Lister et al. 
2009). The treatment of DNA with sodium bisulfite transforms the epigenetic methylation mark into a 
genetic mark by only converting unmethylated Cs to Ts (by uracil)(Frommer et al. 1992) and can 
therefore be translated using sequencing. Bisulfite approaches have quickly become the gold standard for 
methylation analysis because of its single base pair resolution, independence of CpG methylation status, 
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and ability to interrogate almost any region in the genome. The most inclusive platform, MethylC-seq, 
however costs an estimated $30,000 per sample (personal calculation).  
 A more economical alternative to MethylC-seq is reduced representation bisulfite sequencing 
(RRBS), which capitalizes on the non-uniform distribution of CpGs across the genome (Meissner et al. 
2008). Most CpGs are concentrated in CpG Islands (CGI). CGI appear in 60% of promoters and often 
show aberrant methylation in cancer (Jones and Baylin 2007). RRBS enriches for these regions with high 
CpG content, so that, instead of covering the entire genome, RRBS effectively reduces the portion of the 
genome that is sequenced to ~10% (Bock et al. 2010). Furthermore, when detecting differentially 
methylated regions (DMR) between two embryonic stem cell lines, RRBS was able to detect 1,000 DMRs 
with only 15 million reads per sample whereas MeDIP-seq required more than 30 million reads to detect 
1,000 DMRs (Bock et al. 2010). RRBS is an attractive choice for analyzing promoter and CGI 
methylation, which play an important role in regulating genes in human cancers (Jones and Baylin 2007). 
 Until recently, genome-scale DNAme profiling technologies requires a significant amount of 
starting DNA. Targeted padlock probes require >200 ng of bisulfite treated DNA (Deng et al. 2009); 
MeDIP-seq has been optimized for 30-120 ng (Borgel et al. 2010); and MethylC-seq requires several 
micrograms of DNA (Lister et al. 2009). New innovations in Illumina library preparations using 
transposon-mediated adapter insertions, however, have allowed for whole genome bisulfite sequencing 
on 10 ng of DNA (Adey and Shendure 2012). At present, RRBS can be reproducibly performed on <1 ng 
of purified input DNA (Smith et al. 2012). Furthermore, LCM-RRBS, presented in this thesis, functions on 
<2 ng of DNA extracted from laser capture microdissected tissues (Schillebeeckx et al. 2013).  
 
Locus-specific approaches 
 Low-throughput validation assays are common for interrogating the 5mC status of a limited 
number of genomic loci. Whole genome or genome-wide discovery studies identify differentially 
methylated regions, which must be validated independently by orthogonal methods. Various locus-
specific methods exist that vary in complexity, labor, quantitative resolution, and number of CpGs 
interrogated. The most useful and most commonly used techniques fall into three categories: 
18 
endonuclease techniques, methylation-specific PCR techniques, and bisulfite sequencing techniques. 
Each category has many variations of the basic assay; the basic principals are described here. 
 Methods leveraging the specificity of endonucleases are able to interrogate the qualitative level of 
5mC at one specific CpG or CpH (Xiong and Laird 1997). In this method, broadly referred to as COBRA, 
bisulfite-treated DNA is amplified using primers specific to converted DNA. The DNA is then digested with 
the endonucleases, BstUI and TaqI, which contain a converted or unconverted CG sequence in their 
binding sites. Methylated DNA would prevent bisulfite conversion and therefore eliminate the binding site 
whereby preventing digestion, whereas unmethylated DNA would allow digestion. Various methods 
employ different endonucleases depending on the sequence of the site of interest. The HELP assay does 
not rely on bisulfite conversion (Khulan et al. 2006). Instead, the methylation sensitive and insensitive 
enzyme, HpaII and MspI, are used to digest DNA. The HpaII-digested DNA fraction represents 
unmethylated DNA while the MspI-digested fraction serves as the background, “input” control. Digested 
DNA can either be amplified with site-specific primers or ligated with universal oligonucleotides and 
hybrized to microarrays. COBRA provides a fairly quick qualitative assessment of 5mC at one or two 
specific sites, but is limited by interrogating 5mC at sites with an endonuclease’s sequence recognition 
motif. 
 Methylation-specific PCR techniques also rely on bisulfite conversion to translate 5mC into a 
nucleic acid mark. One such assay, called MethylLight, is quantitative and highly sensitive, capable of 
detecting methylated alleles in the presence of 10,000-fold excess unmethylated alleles (Eads et al. 
2000). In the MethylLight assay, genomic DNA is first bisulfite treated to create methylation-dependent 
sequence differences. Quantitative PCR is next performed using primers that overlap CpG regions and 
only anneal if methylated (unconverted). The PCR reaction can also be done under non-quantitative 
conditions and visualized on an agarose gel to qualitatively assess methylation levels. Like restriction-
based assays, methylation-specific PCR only interrogates one CpG per reaction, which significantly limits 
the assay’s throughput and utility. 
 The most common locus-specific methylation mapping method, bisulfite-specific PCR, consists of 
bisulfite conversion, PCR amplification, and sequencing (Sasaki et al. 2003). Bisulfite conversion of DNA 
can result in the creation of abasic DNA backbones resulting in brittle DNA that easily degrades or 
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sheers. Large amplicons are, therefore, difficult to amplify by bisulfite-specific PCR. Nonetheless, 600-
1,000 base pair amplicons can readily be amplified from bisulfite converted DNA using primers designed 
to anneal to converted DNA. Here, the primers do not contain any CpG sequence which allows for 
unbiased, methylation-agnostic amplification. Amplified products can be sequenced using next-gen (e.g. 
Illumina) sequencing, Sanger sequencing, or pyrosequencing. For Illumina sequencing, primers are 
typically designed with Illumina adapters in the tails; amplicons can also be sequenced using standard 
library preparation methods. Percent methylation is calculated by determining the fraction of total reads 
that are methylated. Sanger sequencing requires that amplicons be ligated into a vector and individual 
clones sequenced. Because each clone represents an individual molecule, 10-15 clones must be 
sequenced to accurately quantify the percent methylation. Finally, if a biotinylated primer is used during 
the PCR amplification, the amplicon can be sequenced using a pyrosequencing machine. Here, additional 
primers designed roughly 30 base pairs from a CpG are annealed to complete the sequencing reaction. 
Because pyrosequencing is inherently quantitative, percent methylation can be directly calculated from 
the reaction. Successful bisulfite-specific PCR on a single locus has been performed on as little as 8 cells 
collected from an embryo and laser capture microdissected tissue samples. (Millar et al. 2002). Bisulfite-
specific PCR is robust, sensitive, and allows for the interrogation of all CpGs within an individual 
amplicon. 
 
SCOPE OF THESIS WORK 
 Although often considered homogenous, tumors consist of histologically diverse tissues 
(Weinberg 2007) that display intratumor heterogeneity in gene expression, genotype, and metastatic and 
proliferative potential (Fidler et al. 1979; Heppner 1984). This heterogeneity impedes the investigation 
and treatment of tumors because tissue samples may not be representative of the entire tumor (Michor 
and Polyak 2010). Therefore, the ability to profile methylation genome-wide in a small number of cells is 
crucial to analyzing 5mC in complex tissues like tumors. Such a tool would enable the use of laser 
capture microdissection to separate heterogeneous cell types from one another. This thesis describes a 
novel method, called Laser Capture Microdissection-Reduced Representation Bisulfite Sequencing (LCM-
RRBS), that accurately maps genome-wide 5mC of cells isolated using laser capture microdissection. 
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The method was applied to understand what 5mC changes, if any, occur in gonadectomy-induced 
adrenocortical neoplasias in mice. Furthermore, LCM-RRBS was applied to pure motor neuron cultures at 
early and late stages to elucidate the role of 5mC in motor neuron maturation. 
 Chapter 2 addresses the need for a novel technique that can map 5mC genome-wide of very few 
cells. I show that LCM-RRBS accurately and reproducibly profiles genome-wide methylation of DNA 
extracted from microdissected fresh frozen or formalin-fixed paraffin-embedded tissue samples. The 
LCM-RRBS method adapts Illumina library preparation techniques to minimize sample loss and to pool 
multiple samples together and uses laser capture microdissection (LCM) to isolate specific populations of 
cells. I applied LCM-RRBS to character the methylation of adrenocortical neoplasias and was able to map 
genome-wide 5mC of isolated neoplastic and adjacent normal tissue using less than 10 mm2 of fresh 
frozen tissue. In one multiplexed experiment, we interrogated the methylation status of >13,000 
promoters and >13,000 CpG Islands of 6 tissue samples (3 neoplastic and 3 normal representing 3 
different mice) across an average of >800,000 CpGs per sample. We identified 37 and 8 promoters of 
genes implicated in adrenal and gonadal function that showed significant loss or gain of 5mC, 
respectively, in neoplastic relative to normal tissues. This chapter is the proof-of-concept for LCM-RRBS 
and demonstrates the method’s utility. 
 Chapter 3 is a follow-up to the study described in Chapter 2. We hypothesized that adrenocortical 
neoplasms that result from gonadectomy develop a gonadal phenotype. To test this hypothesis, we took 
several approaches. First, we show that Igfbp6 and Foxs1, which are differentially methylated, are also 
differentially expressed at the transcript and protein level between neoplastic and normal adrenal tissues. 
Second, we applied transcriptome profiling to identify three novel gonadal markers that were upregulated 
in adrenocortical neoplasms. Finally, enrichment analysis demonstrated that genes upregulated in the 
adrenal glands of gonadectomized mice were more likely to be highly expressed in ovary or testis but not 
in the non-steroidogenic tissue brain. Furthermore, genes downregulated in the adrenal glands of 
gonadectomized mice were more likely to be highly expressed in the normal adrenal tissue. Together, 
these findings suggest that adrenal neoplasms exhibit mixed characteristics of male and female gonadal 
somatic cells and, therefore, represent a possible example of cell type transformation involving 5mC 
configuration. 
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 In Chapter 4, I describe the 5mC profiles of early and late stage maturing motor neurons using 
LCM-RRBS. The Hb9-puro RW4 mouse embryonic stem cells have a puromycin transgene driven by the 
Hb9 enhancer. Hb9 is exclusively expressed in motor neuron precursors and early differentiated motor 
neurons allowing for the selection of pure populations of motor neurons in culture. We find that motor 
neurons lose and gain 5mC at 2,894 and 1,147 CpGs, respectively, between 24 hours and four days after 
selection with puromycin. Many of the hypomethylated CpGs were near genes important for motor neuron 
function that showed a gain in expression over time. I show that hypomethylated regions are enriched for 
known motor neuron-specific transcription factors like Isl1, Lhx3, Phox2a, and Tbx20. Furthermore, we 
show that motor neurons gain 5-hydroxymethylation (5hmC) as they mature. Because Hb9-expressing 
cells are post-mitotic, this configuration in 5mC is due to active pathways suggesting a role for Dnmt3a, 
Dnmt3b, and the Tet family of proteins. To test this hypothesis, we derived Tet1, Tet2, and Tet3 single, 
double, and triple knockout Hb9-puro lines using the CRISPR/Cas9 genome engineering system. We find 
that individual Tet genes are dispensable for motor neuron differentiation and maturation and, therefore, 
play redundant roles. Knockout of Tet1 and Tet2 together significantly reduced differentiation potential but 
resulted in mature motor neurons and normal 5hmC gains over time. Finally, knockout of all three Tet 
genes prevented efficient differentiation and resulted in the differentiation of very few mature motor 
neurons. Together, our findings highlight a new role for 5mC and 5hmC in motor neurons suggesting 
5mC and 5hmC configuration during motor neuron development is necessary for proper functional 
maturation. 
 This body of work makes several contributions to the field of DNA methylation. First, the 
development of LCM-RRBS allows for genome-wide 5mC mapping of laser capture microdissected 
tissues and of limited DNA input. Second, this study provides the first detailed examination of 5mC 
patterns in gonadectomy-induced adrenocortical neoplasms. Finally, this study provides the first 
evaluation of 5mC and 5hmC in maturing motor neurons and provides the first evidence of an important 
role for the Tet demethylation machinery in normal motor neuron maturation.   
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CHAPTER 2: LASER CAPTURE MICRODISSECTION-REDUCED REPRESENTATION BISULFITE 
SEQUENCING (LCM-RRBS) MAPS CHANGES IN DNA METHYLATION ASSOCIATED WITH 
GONADECTOMY-INDUCED ADRENOCORTICAL NEOPLASIA IN THE MOUSE 
Published in Nucleic Acids Research (2013). 
ABSTRACT 
 DNA methylation is a mechanism for long-term transcriptional regulation and is required for 
normal cellular differentiation. Failure to properly establish or maintain DNA methylation patterns leads to 
cell dysfunction and diseases such as cancer. Identifying DNA methylation signatures in complex tissues 
can be challenging due to inaccurate cell enrichment methods and low DNA yields. We have developed a 
technique called Laser Capture Microdissection-Reduced Representation Bisulfite Sequencing (LCM-
RRBS) for the multiplexed interrogation of the DNA methylation status of CpG Islands and promoters. 
LCM-RRBS accurately and reproducibly profiles genome-wide methylation of DNA extracted from 
microdissected fresh frozen or formalin-fixed paraffin-embedded tissue samples. To demonstrate the 
utility of LCM-RRBS, we characterized changes in DNA methylation associated with gonadectomy-
induced adrenocortical neoplasia in the mouse. Compared to adjacent normal tissue, the adrenocortical 
tumors showed reproducible gains and losses of DNA methylation at genes involved in cell differentiation 
and organ development. LCM-RRBS is a rapid, cost-effective, and sensitive technique for analyzing DNA 
methylation in heterogeneous tissues and will facilitate the investigation of DNA methylation in cancer and 
organ development. 
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INTRODUCTION 
 DNA methylation has long been recognized to play a role in normal cellular differentiation and 
development. Methylation most often occurs at the cytosine of a cytosine-guanine dinucleotide (CpG) and 
acts to down-regulate gene expression (Bird and Wolffe 1999). Disruption of the DNA methylation 
machinery can lead to imprinting disorders (Robertson 2005), repeat-instability disease (Kumari and 
Usdin 2009), and neurological defects (Chahrour et al. 2008; Jin et al. 2008). 
 DNA methylation has been shown to play an important role in cancer progression. Tumors often 
display a global loss of methylation, or hypomethylation, at repetitive elements, which is thought to 
destabilize the genome through transposon-mediated rearrangements (Goelz et al. 1985; Wilson et al. 
2007), activate growth promoting oncogenes (Wilson et al. 2007), and cause de-differentiation through 
the loss of imprinting (Reik and Lewis 2005). An abnormal gain of methylation, or hypermethylation, at 
gene regulatory elements also contributes to tumorigenesis by silencing tumor suppressor genes involved 
in DNA damage repair, cell cycle control and other processes (Jones and Baylin 2002). This aberrant 
methylation may be due, at least in part, to recurring mutations in genes that are involved in epigenetic 
regulation (Stratton 2011; Ryan and Bernstein 2012), such as DNA methyltransferases, which are 
commonly mutated in acute myeloid leukemia (Ley et al. 2010), and chromatin remodeling enzymes, 
which are frequently mutated in renal carcinomas and pancreatic neuroendocrine tumors (Dalgliesh et al. 
2010; Jiao et al. 2011). 
 Accurate analysis of DNA methylation is complicated by the heterogeneous nature of normal and 
diseased tissues. Normal tissues contain cells at different stages of differentiation/maturity. Tumors also 
consist of histologically diverse cell types (Weinberg 2007; Shackleton et al. 2009) and display intratumor 
heterogeneity in gene expression (Dalerba et al. 2011), genotype (Navin et al. 2010; Navin et al. 2011), 
and metastatic and proliferative potential (Fidler et al. 1979; Heppner 1984). Therefore, the analysis of 
gross tumor samples often obscures the diverse cell types that comprise the entire tumor (Michor and 
Polyak 2010). To assess cell type specific DNA methylation of complex tissues, cell isolation techniques 
must be used. Laser capture microdissection (LCM) has enabled researchers to separate specific cell 
types from heterogeneous tissues (Espina et al. 2006). DNA yields from such samples, however, are too 
small to use with current methods for genome-wide DNA methylation analysis. Moreover, clinical samples 
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are typically fixed in formalin and embedded in paraffin, further compromising DNA quality. For these 
reasons, the genome-wide mapping of DNA methylation in LCM samples has not been previously 
demonstrated. 
 Current DNA methylation analysis methods are limited by the number of loci interrogated, 
quantity and quality of DNA input required, and sample throughput (Laird 2010b). Methods that function 
on a very small number of cells interrogate only a few genomic loci and are challenging to implement 
(Dietrich et al. 2009; Herrmann et al. 2011). Furthermore, few methods function on clinical samples that 
are formalin-fixed and paraffin-embedded (FFPE) (Dietrich et al. 2009). Genome-wide DNA methylation 
methods are limited by the input of DNA. Affinity enrichment techniques like MeDIP-Seq (Taiwo et al. 
2012), MDB-seq (Serre et al. 2010), MethylCap-seq (Brinkman et al. 2010) require 0.16 – 5 µg of DNA 
input and are limited to a 150- to 200-bp resolution. Other global methods, like CHARM (Irizarry et al. 
2008) and padlock probes (Ball et al. 2009; Diep et al. 2012) also require large DNA inputs. MethylC-seq, 
the only truly whole genome approach (Lister et al. 2009), is prohibitively expensive when many samples 
need to be analyzed. Reduced Representation Bisulfite Sequencing (RRBS) can map genome-wide DNA 
methylation of limited DNA samples (Smith et al. 2012), but has not been demonstrated to function on 
small amounts of DNA recovered from FFPE samples or on samples collected by LCM. 
 Here, we describe a new technique termed Laser Capture Microdissection-Reduced 
Representation Bisulfite Sequencing (LCM-RRBS) that can interrogate genome-wide DNA methylation 
patterns in samples collected from complex heterogeneous tissues. As a proof of principle, we have used 
LCM-RRBS to analyze global DNA methylation changes associated with adrenocortical neoplasia in the 
mouse. In response to gonadectomy (GDX) and the ensuing rise in serum gonadotropin levels, sex 
steroid-producing neoplasms accumulate in the subcapsular region of the adrenal cortex of certain strains 
of mice, including DBA/2J (Bielinska et al. 2006b). This phenomenon is thought to reflect gonadotropin-
induced metaplasia of stem/progenitor cells in the adrenal cortex, although the term neoplasia is used 
more often than metaplasia to describe the process (Bielinska et al. 2006b).The molecular basis of GDX-
induced adrenocortical neoplasia is unknown (Bernichtein et al. 2008b; Krachulec et al. 2012), but it has 
been hypothesized that DNA methylation and other epigenetic modifications may impact the phenotypic 
plasticity of adrenocortical stem/progenitor cells allowing them to respond to the rise in circulating 
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gonadotropins (Bielinska et al. 2009). GDX-induced adrenocortical neoplasia in the mouse is an ideal 
phenomenon to study using LCM-RRBS because of the limited amounts of tissue that can be collected. 
 
RESULTS 
LCM-RRBS 
 Reduced Representation Bisulfite Sequencing (RRBS) is an established methylation analysis 
method that can interrogate most CGIs and promoters across the entire genome. Current RRBS 
protocols however, do not allow for multiplexing and have not been demonstrated on samples isolated by 
LCM. Furthermore, although RRBS has been used to analyze small amounts of high quality DNA (Smith 
et al. 2012), it has not been applied to less than 1 µg of DNA extracted from formalin-fixed paraffin-
embedded (FFPE) samples (Gu et al. 2010), the most common method used to preserve clinical tissue 
samples. We therefore sought to develop a method to analyze small amounts (1 ng) of DNA from laser 
capture microdissected samples and from FFPE-preserved samples and to interrogate multiple samples 
in parallel.  
 Our protocol removes most clean-up steps, which ensures DNA samples are not lost, and 
leverages the capabilities of Illumina indexing to pool samples prior to size selection and sequencing, 
thus dramatically increasing the number of samples that can be processed in parallel (Figure 2.1). LCM-
RRBS digests genomic DNA with MspI to create fragments with a 5` CpG end. Digested fragments are 
blunted, adenylated, and ligated with methylated sequencing adapters then column purified to remove 
excess adapters. To convert the epigenetic methylation mark into a genetic mark that can be read 
through genomic sequencing, adapter-ligated fragments are treated with bisulfite. At this stage, converted 
DNA is amplified with a low-cycle PCR to introduce sample-specific indexes. Once each sample is 
‘indexed,’ samples are pooled prior to gel electrophoreses and the isolation of 40-220 base pair 
fragments. The purified, pooled library is PCR enriched using universal primers and sequenced on the 
Illumina platform to generate 42 base pair reads. Using our modified method, we can interrogate CpGs 
genome-wide from laser capture microdissected samples freshly frozen or previously preserved through 
formalin-fixing and paraffin-embedding. 
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LCM-RRBS accurately measures genome-wide DNA methylation of fresh frozen and formalin-fixed 
paraffin-embedded samples 
 To evaluate the performance of LCM-RRBS, we benchmarked it against RRBS. Using 1 ng and 
400 ng for LCM-RRBS and RRBS, respectively, we compared the genome-wide DNA methylation status 
of DNA isolated from human blood leukocytes. We did not do LCM on the 1 ng of purified DNA; instead, 
we only applied the downstream library preparation of the LCM-RRBS protocol (Figure 2.1). LCM-RRBS 
was able to interrogate >75% of CGIs and >65% of gene promoters, results that were similar to those 
obtained by RRBS (Figure 2.S1). LCM-RRBS was able to accurately measure the DNA methylation levels 
of CGIs and core promoters (Figure 2.2A) as well as individual CpG dinucleotides (Figure 2.S2). 
Increasing the required coverage for each CpG considered for CGI methylation did not significantly alter 
the concordance between RRBS and LCM-RRBS (Figure 2.S3). For CGIs (n = 18,448) and promoters (n 
= 8,500) having at least 50 methylation measurements, we observed a Pearson correlation of 0.98 and 
0.94, respectively, between 1 ng and 400 ng (Figure 2.2A). Most CGIs are either highly methylated (80-
100%) or highly unmethylated (0-20%). We therefore sought to test how well LCM-RRBS could call a CGI 
as methylated or unmethylated. For CGIs with at least 50 high-quality CpG measurements, LCM-RRBS 
identified methylated CGIs with 91% sensitivity and 99% specificity and unmethylated CGIs with 97% 
sensitivity and 94% specificity when compared to the RRBS dataset. We therefore conclude that LCM-
RRBS functions on as little as 1 ng of genomic DNA, interrogates most CGIs and promoters, and is very 
accurate. 
 Human clinical samples are usually stored as either fresh frozen or FFPE specimens. Mapping 
DNA methylation in the latter, however, can be challenging because formalin fixation degrades DNA. 
Most DNA methylation techniques that have been used on FFPE samples require greater than 1 µg of 
DNA or can only interrogate a few loci. To validate the reproducibility of LCM-RRBS and demonstrate its 
universal clinical applicability, we performed methylation profiling on 1 ng samples of DNA from a primary 
endometrial carcinoma, half of which was fresh frozen and the remainder which was formalin-fixed and 
paraffin-embedded. Methylation of CGIs and promoters was highly concordant between fresh frozen and 
FFPE samples (Pearson correlation 0.98 and 0.97, respectively; Figure 2.2B). CGI and promoter 
methylation correlated strongly between FFPE technical replicates (Pearson correlation 0.97 and 0.95, 
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respectively; Figure 2.S4). We also observed high concordance across individual CpGs between fresh 
frozen and FFPE tumor samples with a Pearson correlation of 0.96 (Figure 2.S2). LCM-RRBS, therefore, 
can accurately interrogate genome-wide methylation of 1 ng extracted from FFPE samples. 
 
LCM-RRBS is robust across fresh frozen and formalin-fixed paraffin-embedded laser capture 
microdissected samples 
 In situ analysis of DNA methylation is challenging due to the heterogeneous nature of complex 
tissues. In order to interrogate only cells of interest in biological and clinical samples, LCM techniques 
must be used to enrich for a specific cell type. Current genome-wide DNA methylation methods, however, 
have not been demonstrated to function on LCM-collected samples. We therefore set out to evaluate the 
performance of LCM-RRBS on fresh frozen and FFPE samples collected by LCM.  
 Because the cellular architecture of a normal liver is homogeneous, the methylation state should 
be very similar throughout the organ. Thus, the liver serves as the ideal tissue for benchmarking the LCM-
RRBS method against the RRBS gold standard, since each microdissected region should have a very 
similar methylation pattern to that of the bulk tissue. We harvested the liver of C57BL/6J mice and 
prepared the liver using standard preservation techniques. Separate regions of the liver were either 
directly snap frozen, preserved in Tissue-Tek O.C.T. compound and then snap frozen, or preserved using 
formalin-fixation and paraffin-embedding. Bulk DNA was extracted from the snap frozen sample and used 
for downstream RRBS analysis. To determine whether the process of LCM alters the methylation of DNA 
and to assess the lower limits of LCM-RRBS, we applied LCM-RRBS to samples collected from 20 mm2, 
10 mm2, 5 mm2, and 2 mm2 of the fresh frozen and FFPE mouse liver and compared the DNA 
methylation patterns to those determined by performing RRBS on 400 ng of DNA extracted from the bulk 
fresh frozen liver tissue. As observed with 1 ng of DNA, most CGIs and promoters were represented even 
when only 2 mm2 of tissue was collected (Figure 2.S5). Furthermore, CGI (mean Pearson = 0.98) and 
promoter (mean Pearson = 0.96) methylation showed high concordance across all fresh frozen samples 
(Figure 2.3A) when compared to 400 ng of DNA. For samples collected from 2 mm2 of microdissected 
tissue, LCM-RRBS identified unmethylated (0-20%) CGIs with 88% sensitivity and 99% specificity and 
methylated (80-100%) CGIs with 99% specificity and 87% sensitivity. While the interrogation of DNA 
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methylation of 2 mm2 of fresh frozen tissue was robust, 20 mm2 of FFPE tissue was required for accurate 
analysis. Using 20 mm2 of FFPE starting material, LCM-RRBS showed 79% sensitivity and 99% 
specificity for calling unmethylated (0-20%) CGIs and 99% sensitivity and 78% specificity for calling 
methylated (80-100%) CGIs with a Pearson correlation of 0.95 (Figure 2.3B). Samples collected from less 
than 20 mm2 of FFPE tissue, however, showed poor CGI, promoter, and CpG correlations as compared 
to 400 ng (data not shown). We conclude that the process of LCM does not alter DNA methylation and 
that LCM-RRBS accurately determines methylation patterns from as little as 2 mm2 of fresh frozen tissue. 
FFPE tissue is more problematic requiring an area of at least 20 mm2 to achieve acceptable, but not 
exceptional performance. 
 
Evaluation of PCR Bias 
 PCR amplification of small amounts of bisulfite-treated DNA can result in PCR bias and 
inaccurate DNA methylation calling (Warnecke et al. 1997). In DNA samples obtained from females, the X 
chromosome serves as a good internal control for assessing PCR bias, since X inactivation methylates 
one copy of the X chromosome at most loci. To determine if LCM-RRBS suffers from PCR bias, we 
analyzed the fraction of molecules that were methylated at loci known to be affected by X inactivation.   
As expected, the majority (>70%) of CGIs on the X chromosome showed an intermediate level (30-70%) 
of DNA methylation across all fresh frozen samples and the 20 mm2 FFPE sample (Figure 2.S6), 
demonstrating that LCM-RRBS shows little PCR bias. We conclude that LCM-RRBS shows little PCR 
bias across 2 mm2 of fresh frozen tissue and 20 mm2 of FFPE tissue. 
 
Analysis of GDX-induced adrenocortical neoplasia in the mouse using LCM-RRBS 
 To demonstrate the utility of LCM-RRBS in a biological setting, we applied the method to analyze 
the DNA methylation of neoplasms that arise in the adrenal cortex of DBA/2J mice after GDX. Although 
genetic factors have been identified that influence susceptibility to GDX (Bernichtein et al. 2008b; 
Krachulec et al. 2012), little is known about the role DNA methylation plays in the formation of GDX-
induced neoplasia. Molecular characterization is further complicated because mice adrenal glands are 
only 0.1 cm2 in size and neoplasms arise among normal tissues requiring LCM enrichment methods for 
29 
tissue isolation. We therefore applied LCM-RRBS to neoplastic and adjacent normal mouse adrenal 
tissues (Figure 2.4). 
 In one multiplexed experiment, we interrogated the methylation status of >13,000 promoters and 
>13,000 CGIs of 6 tissue samples (3 neoplastic and 3 normal representing 3 different mice) across an 
average of >800,000 CpGs per sample (Figure 2.4 and Table 2.S1). Using a threshold difference of at 
least 10%, 37 promoters were significantly hypomethylated and 8 promoters were significantly 
hypermethylated (P < 0.05, FDR adjusted; Table 2.1 and Table 2.S2) in the neoplasms compared to 
adjacent normal tissue. Many of the top hypo- and hypermethylated genes have been implicated in cell 
fate determination and differentiation, including adrenocortical formation (Tinagl1), gonad development 
(Foxs1, Wdr63, Tmem184a), pancreas development (Nsmce1), kidney development (Hoxc10, Dpep1), 
prostate development (Il17rc, Ano7), and muscle and skeletal development (Myo18b, Trim63, Lmod3, 
Meox1). The observed methylation changes suggest the neoplastic tissue may arise due to aberrant gene 
expression of genes normally silent in adrenocortical cells or the silencing of adrenal-specific markers. To 
validate our findings, we performed bisulfite-specific polymerase chain reaction (BSP) followed by 
sequencing of 3 hypomethylated promoters and 1 hypermethylated promoter on neoplastic and normal 
tissues isolated by LCM. For all promoters tested, BSP showed a significant difference (Fisher’s exact 
test, P < 10-15) in DNA methylation between the neoplasia and normal tissue as predicted by LCM-RRBS 
(Figure 2.5). Taken together, these results demonstrate that LCM-RRBS can identify differentially 
methylated genes in a complex tissue and reveal functionally relevant epigenetic effects. 
 
DISCUSSION 
 Current DNA methylation mapping techniques are limited by input and the number of loci 
interrogated. RRBS, a genome-wide DNA methylation mapping technique, was recently shown to function 
on 0.5 to 10 ng of genomic DNA isolated from mouse embryos (Smith et al. 2012). RRBS, however, has 
not been demonstrated to function on LCM samples collected from FFPE tissue nor is it amenable to 
large scale sample processing. We have developed a new method, LCM-RRBS, which can accurately 
profile genome-wide DNA methylation of many LCM samples in parallel at single base pair resolution. 
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 Our method can be implemented in 3-4 days, and the bulk of the protocol can be automated for 
high-throughput 96-well experiments. While traditional RRBS requires each processed sample to undergo 
gel extraction, a laborious process when processing more than a few samples, our method pools all 
samples together prior to gel extraction, reducing the required number of gel extractions to one. Thus, a 
large number of samples can be easily processed at a single time. Furthermore, because high DNA loss 
results from gel extraction, pooling samples prior to gel extraction allows the use of low (1 ng) DNA 
inputs. 
 The LCM-RRBS protocol affords a significant reduction in sequencing costs compared to whole 
genome bisulfite sequencing.  We typically collect 1.5 gigabases (GB) per sample, which is considerably 
less than the ~60 GB needed for 20x coverage of a whole genome bisulfite library. The sequencing cost 
per sample can be reduced further if fewer CpGs are interrogated. For example, if a smaller size fraction 
is isolated during gel extraction, only about 0.75 GB are required per sample. 
 We found that although formalin-fixation and paraffin-embedding does not alter DNA methylation 
per se, at least 20 mm2 of tissue must be isolated for accurate DNA methylation profiling. We were able to 
create LCM-RRBS libraries from 10 mm2, 5 mm2, and 2 mm2 of FFPE tissue and obtained similar 
numbers of sequencing reads as with fresh frozen samples, but overall mapping quality was very low 
(~30% aligned) in the FFPE samples, precluding an accurate analysis of DNA methylation. On the other 
hand, LCM-RRBS generated high quality methylation maps from 2 mm2 of microdissected fresh frozen 
tissue, as demonstrated by our analysis of mouse liver. 
 To demonstrate the utility of LCM-RRBS, we analyzed the DNA methylation patterns of GDX-
induced adrenocortical neoplasms using an average of 5.5 mm2 of fresh frozen tissue. We hypothesized 
that aberrant DNA methylation changes could be involved in the formation of these neoplastic tissues. 
Indeed, recent studies have shown that altered DNA methylation can redirect cell fate in endocrine 
tissues (Dhawan et al. 2011a).  Conditional mutagenesis of the mouse Dnmt1 gene, which encodes the 
maintenance DNA methyltransferase, converts insulin-producing pancreatic β-cells into glucagon-
producing α-cells (Dhawan et al. 2011a).  It is thought that because of a common developmental origin, β- 
and α-cells share general epigenetic programs that provide a compatible environment for cell fate 
conversions (Akerman et al. 2011). GDX-induced adrenocortical neoplasia may be another example of 
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DNA methylation-regulated cell fate conversion in an endocrine tissue; in this case, adrenocorticoid-
producing cells become sex-steroid producing cells (Bielinska et al. 2003b; Bielinska et al. 2005; Johnsen 
et al. 2006b).  The changes in DNA methylation we observe around the transcription start site (TSS) 
could lead to changes in gene expression (Brenet et al. 2011; Hartung et al. 2012). Several of the genes 
we found to be differentially methylated in GDX-induced adrenocortical neoplasms have established roles 
in adrenocortical or gonadal development.  For example, Tinagl1, a gene implicated in adrenal zonation 
(Mukai et al. 2003; Li et al. 2007), showed a gain in DNA methylation, which could lead to down-
regulation. Wdr63, Foxs1, and Tmem184a, genes involved in gonadal development (Svingen et al. 2007; 
Best et al. 2008; Bonilla and Xu 2008; Sato et al. 2008), showed a loss of DNA methylation, which could 
lead to the aberrant expression of these gonadal-like markers in the adrenal cortex. Furthermore, Srd5a3, 
a gene involved in the biosynthesis of the potent androgen 5α-dihydrotestosterone (Uemura et al. 2008), 
showed a loss of DNA methylation, which could enhance the ectopic production of sex steroids in the 
adrenal gland (Payne and Hales 2004). Future studies will explore the role of these methylation changes 
in the pathogenesis of GDX-induced adrenocortical neoplasia. 
 In conclusion, LCM-RRBS is a robust, cost-effective method for the DNA methylation analysis of 
heterogeneous tissues. This technique allows the study of tumor evolution and epigenetic heterogeneity 
in situ of less than 1 ng (~150 cells) and can also be applied to investigate the role of DNA methylation in 
cell fate specification during tissue development. LCM-RRBS is an important milestone toward highly 
parallel in situ analysis of single cells. We anticipate that this protocol will greatly facilitate the analysis of 
any sample that contains multiple cell types. 
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MATERIALS AND METHODS 
 
Experimental mice 
 Procedures involving mice were approved by an institutional committee for laboratory animal care 
and were conducted in accordance with NIH guidelines for the care and use of experimental animals. 
C57BL/6J and DBA/2J mice were purchased from Jackson Laboratories (Bar Harbor, ME).  Mice were 
anesthetized and ovariectomized at 3-4 weeks of age (Bielinska et al. 2005). 
 
DNA extraction 
 Human tumor specimens were collected under an Institutional Review Board (IRB)-approved 
protocol. Immediately after surgery, a human endometrial tumor was divided in half. One half was fresh 
frozen while the other was formalin-fixed and paraffin-embedded (FFPE). 50 mg of fresh frozen 
endometrial tumor was cut into small pieces with a sterile scalpel blade and DNA extracted using the 
Maxwell 16 Tissue DNA Purification Kit (AS1030, Promega). The formalin-fixed paraffin-embedded 
preserved portion was cut into 6-µm sections onto microscope slides. Four 4 mm2 slices were scratched 
off the slide with a sterile scalpel blade, combined in 80 µl buffer and proteinase K (740901.50, Clontech), 
and incubated overnight at 65°C. Liver tissue was harvested from C57BL/6J mice and divided in half. One 
half was preserved in Tissue-tek optimal cutting temperature (O.C.T.) compound (25608-930, VWR) and 
snap frozen, while the other half was formalin-fixed and paraffin-embedded for downstream bulk DNA 
extraction and LCM. Fresh frozen, FFPE, and LCM samples were purified using NucleoSpin Tissue XS 
columns (740901.5, Clontech) following the protocol for laser-microdissected tissue and eluted in 20 µl of 
nuclease-free water. Genomic DNA was quantified using the Quant-it dsDNA High Sensitivity kit 
(Invitrogen) and the Qubit fluorometer (Invitrogen). 
 
Laser Capture Microdissection 
 Adrenal glands were harvested from mice 3 months after ovariectomy. Liver and adrenal 
cryosections (10 µm) were collected on membrane slides (PEN-Membrane 2.0 µm; Leica) designed to 
free the dissectate from the remainder of the tissue section.  Adrenal tissue sections were fixed in 
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acetone (5 sec, -20°C), stained with hematoxylin and eosin (H&E) or crystal violet, and dehydrated by 
passage through successively higher concentrations of ethanol followed by xylene. FFPE livers sections 
were deparaffinised and dehydrated using standard methods.  LCM was performed using a Leica 
LMD6000 microscope.  Dissectates were collected in SDS/proteinase K for genomic DNA isolation 
(740901.5, Clontech). 
 
RRBS and LCM-RRBS 
 RRBS was performed on 400 ng of commercially purchased leukocyte genomic DNA (D1234148, 
Amsbio) and genomic DNA extracted from a mouse liver as previously described (Gertz et al. 2011). For 
LCM-RRBS, leukocyte genomic DNA (1 ng), extracted endometrial tumor genomic DNA (1 ng), and LCM 
DNA samples were incubated overnight at 37°C with 20 U of the methylation insensitive restriction 
enzyme MspI (R0106S, NEB) and 2 µl of 10 x NEBuffer 2 in a 18 µl reaction. Without subsequent 
purification, fragment ends were filled in and an adenosine added with 10 U of Klenow Fragment (3` à 5` 
exo-, M0212L, NEB), 0.04 mM dGTP, 0.04 mM dCTP, 0.4 mM dATP, and 1x NEB Buffer 2 in a final 
volume of 22.4 µl. The reaction was incubated at 30°C for 20 min, 37°C for 20 min, and heat inactivated 
at 75°C for 20 min. Pre-annealed methylated paired-end Illumina indexing adapters (Adap1: 
ACACTCTTTCCCTACACGACGCTCTTCCGATCT, Adap2: P-
GATCGGAAGAGCACACGTCTGAACTCCAGTCAC; P = phosphate) at a concentration of 0.26 mM were 
ligated overnight at 16°C to the ends of the DNA fragments using 1200 U of T4 DNA Ligase (M0202L, 
NEB) in 1x Ligase Buffer at a final volume of 28.9 µl. These adapter oligonucleotides are only 
complementary at 13 bases which, after annealing, form a “Y” structure. Because excess adapters 
prevent the complete conversion of CpGs at the MspI digestion site, adapter-ligated fragments are 
purified using MinElute columns (Qiagen) and eluted twice with 11 µl of warm EB buffer. The purified 
products were treated using the EZ DNA Methylation Gold Kit (D5005, Zymo). Samples were eluted in 11 
µl of M-Elution buffer. To incorporate the sample-specific index, 3 µl of each bisulfite treated sample was 
amplified in triplicate with 0.2 µM of indexed primers (PCR1: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT; PCR2: 
CAAGCAGAAGACGGCATACGAGATNNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCCGA, 
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N=index), 5 U of Platinum Taq Polymerase (10966-034, Invitrogen), 1x PCR buffer, 2 mM MgCl2, 0.5 M 
betaine (B0300, Sigma), 1 mM dNTP, in a 10 µl reaction using the following cycling conditions: 98°C for 2 
min, 12 cycles of 98°C for 30 sec and 65°C for 2 min. All PCR products and replicates were pooled and 
analyzed by electrophoresis on a 3% 1X Tris-acetate-EDTA (TAE) NuSieve agarose gel (50090, Lonza) 
using a voltage of 5 V/cm until the blue loading dye was 6-7 cm away from the loading well. Fragments 
between 150 bp and 350 bp were extracted and purified using MinElute columns (Qiagen) and 15 µl of 
warmed EB buffer. Prior to final library PCR enrichment, the minimum cycle number must be determined 
to ensure no PCR bias. Using 2 µl of eluted product and 0.2 µM universal primers (Pool1: 
CAAGCAGAAGACGGCATACGAGAT, Pool2: AATGATACGGCGACCACCGAGATCT), multiple PCR 
reactions with a final volume of 50 µl are set up using the previous conditions but varying the cycle 
number from 10 – 16 cycles. 10 µl of each PCR product is analyzed through electrophoresis on a 4-20% 
Precast TBE gel (3450059, BioRad) and stained with Sybr Gold (S-11494, Invitrogen) for 15 min and 
imaged. In order to minimize PCR bias, the final PCR library is amplified in quadruplicate using the 
previous PCR conditions and the minimum cycle number (typically ~14) that shows amplification only 
within the 150-350 bp range on the Sybr Gold stained TBE gel. The four replicates are pooled and gel 
extracted as previously mentioned to remove remaining adapter dimers and primers, then purified, and 
sequenced on Illumina HiSeq 2000 machines.  
 
Bisulfite-specific PCR 
 Neoplastic and adjacent normal mouse adrenocortical tissue was collected and bisulfite treated 
using the EZ DNA Methylation-Direct kit following the manufacturer’s instructions for LCM samples eluting 
with 15 µl of Nuclease-free water (D5020, Zymo). Bisulfite-specific PCR primers were designed using 
MethPrimer (http://www.urogene.org/methprimer/). To amplify the promoter regions of interest, 2 µl of 
bisulfite-treated DNA was combined with 2.5 U of Jumpstart Taq (Sigma), 1x PCR buffer, 1 M betaine 
(B0300, Sigma), 0.2 mM dNTP, and 0.4 µM of each primer in a total reaction volume of 25 µl. The 
reaction was incubated at 95°C for 5 min, followed by 5 cycles of 94°C for 30 sec, 60°C for 30 sec, and 
72°C for 90 sec, followed by 5 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°C for 90 sec, followed 
by 30-33 cycles of 94°C for 30 sec, 50°C for 30 sec, and 72°C for 90 sec, followed by 72°C for 5 min. 
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PCR products were prepared for sequencing on the MiSeq following the manufacturer’s protocol 
(Illumina). 
 
Sequence alignment and methylation calling 
 All analysis was performed using the February 2009 (GrCh37/hg19) build of the human genome 
and the July 2007 (NCBI37/mm9) build of the mouse genome. On average 25 million single-end 42-bp 
raw high quality reads per sample were either aligned to the cytosine-poor strand reference using the 
bisulfite mode of MAQ (Li et al. 2008a) or aligned to the reduced reference using RRBSMAP (Xi et al. 
2012) filtering against reads that contain adapter sequence. Reads that showed less than 90% bisulfite 
conversion (~1 unconverted non-CpG cytosine per read) were filtered to remove those that resulted from 
incomplete bisulfite converted molecules. Aligned reads with a mapping quality of zero were also 
discarded. The resulting high quality uniquely mapped reads were used for methylation calling. We 
identified the genomic coordinates of all CpGs in the reference sequence and assessed percent DNA 
methylation by calculating the fraction of reads that had an unconverted cytosine at the CpG position 
relative to the total reads. We required that each read have either a “TG” or “CG” dinucleotide at the 
expected CpG coordinate to be considered for analysis. 
 
Genomic feature annotation and statistical analysis 
 Cytosine methylation levels were determined for two classes of genomic features downloaded 
from the UCSC genome browser (Rhead et al. 2010). CpG Islands (CGIs) were defined as a region 
greater than 200 base pairs with a GC content of 50% or greater and observed-to-expected ratio of CG 
dinucleotides greater than 0.6 (Gardiner-Garden and Frommer 1987). Promoters were defined as a 2 kb 
region centered on the annotated transcription start site of RefSeq genes (Pruitt et al. 2012). For LCM-
RRBS, RRBS, fresh frozen, and FFPE comparisons, only genomic features with at least 100 methylation 
measurements in each pairwise comparison were considered for analysis. 
 To identify differentially methylated promoters in adrenocortical neoplasia and normal samples, 
the DNA methylation status of all CpGs within a 2 kb region of all RefSeq annotated transcription start 
sites were compared. Those promoters with at least 50 methylation measurements that showed greater 
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than 10% methylation difference were considered for statistical analysis. Promoters were considered 
statistically significant with a P < 0.05 using Student’s t-test after p-values were adjusted using a false-
discovery rate (FDR) of 5%. Statistical significance across bisulfite-specific PCR samples was determined 
using the Fisher’s exact test. All statistical analysis was performed using R. 
 
Data Release 
 The DNA methylation data generated for this study can be found under the NCBI Gene 
Expression Omnibus (GEO) accession number GSE45361. DNA methylation and raw sequence data are 
also publically available at the Center for Genome Sciences (www.cgs.wustl.edu/~maxim/). 
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FIGURE 2.1 
 
Figure 2.1 LCM-RRBS workflow. A complex tissue is dissected using LCM. Extracted DNA is digested 
by the methylation insensitive enzyme MspI, end repaired, and ligated with methylated Illumina adapters. 
After bisulfite conversion, each sample is ’barcoded’ by introducing a sample-specific index (shown as 
green, blue, or violet boxes) through low cycle PCR. Samples are pooled and loaded onto a high 
percentage gel for fragment separation and size selection. Using universal primers, the final library is 
amplified and sequenced on the Illumina platform. 
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FIGURE 2.2 
 
Figure 2.2 LCM-RRBS is reproducible and robust across 1 ng extracted from bulk fresh frozen and 
formalin-fixed paraffin embedded (FFPE) samples. CpG Island methylation (top panels) and the 
methylation at 2 kb regions flanking the transcription start site (bottom panels) were compared between 
(A) 1 ng (LCM-RRBS) and 400 ng of purified leukocyte genomic DNA (RRBS); and (B) 1 ng of FFPE 
DNA and 1 ng of fresh frozen genomic DNA extracted from the same endometrial tumor (LCM-RRBS). 
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FIGURE 2.3 
 
Figure 2.3 LCM-RRBS is robust across microdissected samples collected from fresh frozen and 
FFPE tissues. Fresh frozen and formalin-fixed paraffin-embedded (FFPE) mouse liver was collected for 
DNA methylation profiling. LCM was used to collect tissue from areas ranging in size from 20 to 2 mm2. 
CpG Island methylation (top panels) and methylation at 2 kb regions flanking the transcription start site 
(bottom panels) were compared between (A) fresh frozen samples (LCM-RRBS) and 400 ng of purified 
mouse liver genomic DNA (RRBS); and (B) FFPE samples (LCM-RRBS) and 400 ng of purified mouse 
liver genomic DNA (RRBS). 
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FIGURE 2.4 
 
 
Figure 2.4 DNA methylation profiling of GDX-induced adrenocortical neoplasms and adjacent 
normal tissue using LCM-RRBS. The adrenal glands of 3 ovariectomized DBA/2J mice were fresh 
frozen in Tissue-tek O.C.T. compound, cryosectioned, and stained. Shown are representative 
cryosections pre- and post-LCM. Normal cells in the zona fasciculata (ZF) contain large lipid droplets that 
are easily recognized. In contrast, neoplastic cells distort the normal adrenal zonal architecture and 
contain relatively few lipid droplets. The microdissected normal tissue included zona glomerulosa and 
zona fasciculata cells; care was taken to avoid dissection of X-zone (X), medulla (M), or capsule cells, as 
these cell types have distinct developmental origins (Morohashi and Zubair 2011) and therefore may have 
different epigenetic fingerprints. An average of 5.5 mm2 of neoplastic (red) and normal (green) tissue per 
adrenal pair was collected and analyzed using LCM-RRBS.  
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FIGURE 2.5 
 
Figure 2.5 Validation of differentially methylated promoters. The DNA methylation of one 
hypermethylated and three hypomethylated promoters was interrogated by bisulfite-specific PCR (BSP) 
and sequencing across enriched neoplastic and normal samples. All genes show a statistically significant 
difference (Fisher’s exact test, P < 10-15) in DNA methylation using bisulfite-specific PCR. Each colored 
box represents an individual CpG dinucleotide within a 2 kb region centered around the transcription start 
site. High (yellow), moderate (black), low (blue), and undetermined methylation levels are shown for each 
CpG. The mean methylation of each region interrogated is shown to the right of each heatmap. The red 
box indicates the region of the promoter that was interrogated by LCM-RRBS and BSP. 
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TABLE 2.1 
 
 
Table 2.1 Top hypermethylated and hypomethylated genes in GDX-induced adrenocortical 
neoplasms of the mouse. 
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SUPPLEMENTARY FIGURES AND TABLES 
FIGURE 2.S1 
 
Figure 2.S1 LCM-RRBS can interrogate the DNA methylation status of most CpG Islands and core 
promoters. For all UCSC annotated CpG Islands and core promoters, defined as a 2 kb region centered 
on the transcription start site, we determined the read coverage. Coverage is defined as the total number 
of reads covering a CpG within a given genomic interval. 
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FIGURE 2.S2 
 
Figure 2.S2 LCM-RRBS is reproducible and robust at the CpG level across 1 ng of formalin-fixed 
paraffin-embedded DNA. LCM-RRBS and RRBS were applied to 1 ng and 400 ng of commercially 
purchased leukocyte genomic DNA, respectively, and showed a high concordance across individual 
CpGs (Pearson, 0.93). LCM-RRBS was applied to 1 ng of DNA extracted from fresh frozen or formalin-
fixed paraffin-embedded endometrial tumor tissue. CpG methylation was highly concordant between fresh 
frozen and FFPE samples and FFPE technical replicates (Pearson, 0.96 and 0.94, respectively). Only 
CpGs covered by at least 20 reads in each sample were considered. 
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FIGURE 2.S3 
        
Figure 2.S3 Increasing individual CpG coverage does not significantly alter the concordance of 
CGI methylation between data collected by RRBS (400 ng) and LCM-RRBS (1 ng). The methylation 
of each CGI was calculated by determining the mean methylation of only those CpGs within the region 
that were covered by at least 10 reads in both datasets. Only CGIs that were covered by a total of 100 
reads were considered for concordance analysis. 
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FIGURE 2.S4 
   
Figure 2.S4. LCM-RRBS is reproducible and robust across 1 ng extracted from bulk FFPE 
samples. CpG Island methylation (top panels) and the methylation at 2 kb regions flanking the 
transcription start site (bottom panels) were compared between two technical replicates of 1 ng of FFPE 
endometrial tumor DNA using LCM-RRBS.  
48 
FIGURE 2.S5 
 
Figure 2.S5 LCM-RRBS interrogates most CpG Islands and core promoters of liver mouse 
samples collected by laser capture microdissection (LCM). For CpG Islands and core promoters, 
defined as a 2 kb region centered on the RefSeq transcription start site, we determined the mean read 
coverage of samples collected by LCM from fresh frozen and FFPE tissues. Coverage is defined as the 
total number of reads covering a CpG within a given genomic interval.  
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FIGURE 2.S6 
 
Figure 2.S6 DNA methylation distribution of CpG Islands on chromosome X. The DNA methylation 
status of all UCSC annotated CpG islands across the X chromosome was determined for 1 ng of fresh 
frozen DNA extracted from bulk liver tissue and fresh frozen and FFPE samples collected by LCM to 
assess the presence of PCR bias. Due to X-inactivation, we expect the majority of CpG Islands to be 
moderately methylated (30-70%), as observed, confirming that LCM-RRBS is largely immune to PCR 
bias down to 2 mm2 of fresh frozen and 20 mm2 of FFPE tissue. 
  
50 
TABLE 2.S1 
http://nar.oxfordjournals.org/content/suppl/2013/03/27/gkt230.DC1/nar-01911-met-h-2012-File009.xlsx 
Table 2.S1 DNA Methylation of core promoters (2kb centered around the TSS) across normal and 
neoplasia adrenocortical samples. Percent DNA methylation of annotated CpG Islands. ND: Not 
determined. The URL address above contains a link to Table 2.1S. 
 
 
TABLE 2.S2 
http://nar.oxfordjournals.org/content/suppl/2013/03/27/gkt230.DC1/nar-01911-met-h-2012-File010.xlsx 
Table 2.S2 Gene promoter DNA methylation analysis of normal and neoplasia tissue. Promoters are 
defined as the regions within 1 kb upstream and downstream of the transcription start site. This table lists 
the genes and respective DNA methylation levels for those that pasted multiple hypothesis corrections 
(FDR adjusted). The URL address above contains a link to Table 2.2S. 
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CHAPTER 3: NOVEL MARKERS OF GONADECTOMY-INDUCED ADRENOCROTICAL NEOPLASIA 
IN THE MOUSE AND FERRET 
In review at Molecular Cellular Endocrinology (2014). 
ABSTRACT 
 Gonadectomy (GDX) induces sex steroid-producing adrenocortical tumors in certain mouse 
strains and in the domestic ferret.  Complementary approaches, including DNA methylation mapping and 
microarray expression profiling, were used to identify novel genetic and epigenetic markers of GDX-
induced adrenocortical neoplasia in female DBA/2J mice.  Markers were validated using a combination of 
laser capture microdissection, quantitative RT-PCR, in situ hybridization, and immunohistochemistry.  
Two genes with hypomethylated promoters, Igfbp6 and Foxs1, were upregulated in post-GDX 
adrenocortical neoplasms.  The neoplastic cells also exhibited hypomethylation of the fetal adrenal 
enhancer of Sf1, an epigenetic signature that typifies descendants of fetal adrenal cells.  Expression 
profiling demonstrated upregulation of gonadal-like genes, including Spinlw1, Insl3, and Foxl2, in GDX-
induced adrenocortical tumors of the mouse.  One of these markers, FOXL2, was detected in 
adrenocortical tumor specimens from gonadectomized ferrets.  These new markers may prove useful for 
studies of steroidogenic cell development and for diagnostic testing. 
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INTRODUCTION 
 Steroidogenic cells in the adrenal cortex and gonads arise from a common pool of progenitors in 
the adrenogonadal primordia, but the mechanisms that determine whether a given precursor cell adopts 
an adrenocortical or gonadal phenotype are not fully understood (Val et al. 2006; Hu et al. 2007; 
Morohashi and Zubair 2011; Wood and Hammer 2011; Laufer et al. 2012; Shima et al. 2012; Simon and 
Hammer 2012; Bandiera et al. 2013; Pihlajoki et al. 2013b; Wood et al. 2013).  One experimentally 
tractable model for the study of steroidogenic cell fate determination is gonadectomy (GDX)-induced 
adrenocortical neoplasia.  In response to GDX and the ensuing changes in serum hormone levels [↑ 
luteinizing hormone (LH), ↓ inhibins, etc.], sex steroid-producing tumors arise in the adrenal glands of 
certain mouse strains and ferrets (Bielinska et al. 2005; Bielinska et al. 2006a; Johnsen et al. 2006a; 
Bernichtein et al. 2007; Bernichtein et al. 2008a; Bernichtein et al. 2009; Doghman and Lalli 2009; 
Beuschlein et al. 2012; Miller et al. 2013).  This phenomenon is thought to reflect gonadotropin-induced 
metaplasia of stem/progenitor cells in the adrenal capsule or cortex, although the term “neoplasia” is used 
more often than “metaplasia” to describe the process (Bielinska et al. 2006a).  The neoplastic tissue 
resembles luteinized ovarian stroma and expresses gonadal-like differentiation markers, including LH 
receptor (Lhcgr), anti-Müllerian hormone (Amh) and its receptor (Amhr2), inhibin-α (Inha), transcription 
factors Gata4 and Wt1, and enzymes required for sex steroid biosynthesis (Cyp17a1, Cyp19a1) 
(Bielinska et al. 2003a; Bielinska et al. 2005; Bielinska et al. 2006a; Johnsen et al. 2006a; Krachulec et al. 
2012; Bandiera et al. 2013).  Prototypical markers of adrenocortical cell differentiation, such as the ACTH 
receptor (Mc2r) or corticoid biosynthetic enzymes (Cyp21, Cyp11b1, Cyp11b2), are not expressed in the 
neoplastic tissue (Bielinska et al. 2003a; Bielinska et al. 2005; Bielinska et al. 2006a; Johnsen et al. 
2006a).   
 The genetic basis of GDX-induced adrenocortical neoplasia has been investigated in the mouse.  
Hypophysectomy, parabiosis, and transplantation experiments have shown that the adrenal glands of 
susceptible strains of mice exhibit an inherent predisposition to develop tumors in response to 
gonadotropin stimulation [reviewed in (Bielinska et al. 2005; Bielinska et al. 2006a)].  Linkage analysis of 
crosses between susceptible (DBA/2J) and non-susceptible (C57Bl/6) inbred strains has established that 
post-GDX adrenocortical neoplasia is a complex trait influenced by multiple genetic loci (Bernichtein et al. 
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2007; Bernichtein et al. 2008a; Bernichtein et al. 2009).  Targeted mutagenesis of Gata4, a gene normally 
expressed in gonadal but not adrenal steroidogenic cells of the adult mouse, attenuates post-GDX 
adrenocortical tumor formation in susceptible strains (Krachulec et al. 2012), and transgenic expression 
of Gata4 induces adrenocortical neoplasia in a non-susceptible strain (Chrusciel et al. 2013). 
In addition to genetic factors, epigenetic changes such as DNA methylation may contribute to the 
pathogenesis of GDX-induced adrenocortical neoplasia.  Altered methylation of cytosine residues in CpG 
dinucleotides has been shown to modulate gene expression and progenitor cell fate in various tissues, 
including endocrine organs (Aranda et al. 2009; Hoivik et al. 2011).  For example, conditional 
mutagenesis of the mouse Dnmt1 gene, which encodes the maintenance DNA methyl-transferase, 
causes reprogramming of pancreatic β-cells into α-cells (Akerman et al. 2011; Dhawan et al. 2011a).  It 
has been suggested that GDX-induced adrenocortical neoplasia may be another example of DNA 
methylation-regulated cell fate interconversion in an endocrine tissue (Bielinska et al. 2009; Schillebeeckx 
et al. 2013).  According to this hypothesis, epigenetic alterations affect the phenotypic plasticity of 
adrenocortical stem/progenitor cells, allowing them to respond to the hormonal changes associated with 
GDX (Feinberg et al. 2006b; Bielinska et al. 2009).  
 The current study was undertaken to identify novel genetic and epigenetic markers of GDX-
induced adrenocortical neoplasia, so as to gain a better foothold for investigations into the mechanistic 
basis of tumorigenesis.  Complementary approaches, including genome-wide DNA methylation mapping 
and microarray expression profiling, were used to screen for genes that are hypomethylated and/or 
overexpressed in post-GDX adrenocortical neoplasms of the mouse.  Candidate genes were validated 
using a combination of laser capture microdissection (LCM), quantitative RT-PCR (qRT-PCR), and in situ 
hybridization or immunohistochemistry.  One of the validated genes was found to be a marker of post-
GDX adrenocortical neoplasia in not only mice but also ferrets. 
 
RESULTS AND DISCUSSION 
Genes identified as hypomethylated by genome-wide analysis are upregulated in GDX-induced 
adrenocortical neoplasms of the mouse   
 In a prior report, we used a highly sensitive method of global DNA methylation analysis, termed 
LCM-RRBS, to identify gene promoters that are differentially methylated in neoplastic vs. normal 
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adrenocortical tissue from ovariectomized DBA/2J mice (Schillebeeckx et al. 2013).  We reasoned that 
promoters that are hypomethylated in the neoplastic tissue could be novel markers of GDX-induced 
adrenocortical tumorigenesis.  In the current study, we subjected these hypomethylated candidate genes 
to a series of validation studies.  To be considered a bona fide marker of GDX-induced adrenocortical 
neoplasia, we stipulated that three criteria had to be met: 1) qRT-PCR analysis of mRNA isolated from 
whole adrenal glands had to show a significant increase in expression of the gene in gonadectomized vs. 
intact mice, 2) qRT-PCR analysis of mRNA isolated by LCM had to show a significant increase in 
expression of the gene in neoplastic vs. adjacent normal adrenocortical tissue, and 3) in situ hybridization 
or immunohistochemistry of adrenal tissue from gonadectomized mice had to demonstrate expression in 
the neoplastic cells.  Of the 37 hypomethylated genes identified in the genome-wide screen, we assessed 
the expression difference for 31 genes using whole adrenal qRT-PCR (criteria 1), 6 genes using LCM 
qRT-PCR (criteria 2), and 5 genes using in situ staining or immunohistochemistry (criteria 3).  Two 
hypomethylated genes, Igfbp6 and Foxs1, fulfilled all three criteria (Figure 3.1A-F).   
 Igfbp6 encodes a member of a family of insulin-related growth factor binding proteins (IGFBPs), 
which modulate the interaction of insulin-related growth factors (IGFs) with their cell surface receptors.  
IGFBP6 differs from the other 5 members of the IGFBP family in that it has a 30- to 100-fold preferential 
binding affinity for IGF2 over IGF1 (Bach et al. 1993).  Both IGF2 and IGF1 impact the growth, 
differentiation, and function of adrenocortical cells (Weber et al. 1999), and IGFBP6 has been shown to 
inhibit the actions of IGF2 in experimental systems (Bach et al. 1994).  Hormone-dependent Igfbp6 
expression has been documented in somatic cells of the rodent ovary (Rohan et al. 1993).  It is 
conceivable that IGFBP6 produced in post-GDX adrenocortical neoplasms serves an insulator function by 
blocking the activity of IGF2, thereby favoring gonadal-like differentiation over adrenocortical 
differentiation.   
 Foxs1 (Fkhl18) encodes a forkhead-domain transcription factor that is expressed in Sertoli cells 
and periendothelial cells of the developing mouse fetal testis (Sato et al. 2008).  Male and female Foxs1 
knockout mice are viable and fertile, but the mutant males accumulate blood in the fetal testis, 
presumably due to apoptosis of periendothelial cells (Sato et al. 2008).  Foxs1 is also expressed in 
gonadal-like cells that accumulate in the adrenal subcapsule of Gata6flox/flox; Sf1-cre mice (Pihlajoki et al. 
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2013a).  In addition to gonadal(-like) cells, Foxs1 is expressed in neural crest derivatives (Heglind et al. 
2005; Montelius et al. 2007); consistent with this notion, in situ hybridization showed strong Foxs1 
expression in the neoplastic adrenocortical cells and weak expression in chromaffin cells of the adrenal 
medulla (Figure 3.1E). 
 That only two of the hypomethylated genes identified in the original screen fulfilled all three 
validation criteria is not surprising.  Hypermethylation is correlated with increased gene expression, but 
the relationship is not absolute.  Whole adrenal qRT-PCR may not detect small, but significant, 
expression differences.  The small amounts of RNA isolated by LCM precluded qRT-PCR validation of a 
large number of genes.   
 
Locus-specific DNA methylation analysis of a fetal adrenal enhancer in GDX-induced 
adrenocortical neoplasms 
 LCM-RRBS does not interrogate all methylated loci. To supplement the genome-wide screen, we 
performed locus-specific DNA methylation analysis of an intronic enhancer of steroidogenic factor-1 (Sf1, 
AdBP4, Nr5a1), a transcription factor that regulates steroidogenic cell differentiation in the adrenal cortex 
and gonads (Buaas et al. 2012).  The fetal adrenal enhancer (FAdE) of Sf1 (Zubair et al. 2006; Zubair et 
al. 2008; Morohashi and Zubair 2011) is hypomethylated both in the fetal adrenal and adult adrenal cortex 
(Hoivik et al. 2011; Hoivik et al. 2013).  In contrast, the FAdE is hypermethylated in other tissue types, 
including tissues that express Sf1 (ventromedial nucleus of the hypothalamus, pituitary gonadotropes) 
and those that do not (pituitary nongonadotropes, liver) (Hoivik et al. 2011).  The adrenal cortex of the 
adult mouse is derived from fetal adrenal cells in which the FAdE was transiently active during 
development (Zubair et al. 2008; Morohashi and Zubair 2011), implying that once demethylation has 
occurred in the fetal adrenal, the methylation pattern is maintained during subsequent cell divisions and 
conserved in the adult cortex.  We hypothesized that the methylation status of the Sf1 FAdE in post-GDX 
adrenocortical neoplastic cells could serve as an epigenetic marker for the neoplastic tissue. To assess 
the DNA methylation status of the Sf1 FAdE, we performed bisulfite-specific PCR on tissue isolated by 
LCM (Figure 3.2).  Consistent with published reports (Hoivik et al. 2011; Hoivik et al. 2013), the FAdE was 
hypermethylated in the liver and hypomethylated in both the adrenal X-zone [a remnant of the fetal 
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adrenal (Morohashi and Zubair 2011)] and the adult adrenal cortex (zF + zG).  Importantly, the FAdE was 
also hypomethylated in post-GDX adrenocortical neoplasms.  
 To determine whether FAdE methylation status could distinguish the embryonic origin of the 
neoplastic cells (fetal adrenal vs. ectopic ovarian cells), we measured FAdE methylation in whole ovary.  
Ovarian tissue exhibited an intermediate level of FAdE methylation that was statistically greater than that 
of adult adrenal cortex (P < 0.01) and X-zone (P < 0.005) but not that of post-GDX tumors (P = 0.085, not 
significant).  We conclude that GDX-induced tumor cells, like adjacent normal adrenocortical cells, carry 
an epigenetic mark (FAdE hypomethylation) that typifies descendants of fetal adrenal cells; however, the 
methylation status of this locus cannot exclude a gonadal origin for the neoplastic cells. 
 
RNA expression profiling identifies novel markers of GDX-induced adrenocortical neoplasia in the 
mouse 
 Since differential DNA methylation is only one of several mechanisms that can influence gene 
expression, we performed microarray hybridization to screen for additional transcripts that are 
upregulated during GDX-induced adrenocortical tumorigenesis.  For this analysis we used mRNA isolated 
from whole adrenal glands of ovariectomized vs. intact DBA/2J mice.  We identified 89 and 38 genes that 
were upregulated and downregulated, respectively, in adrenal glands from gonadectomized mice 
(Supplemental Table 1).  We hypothesized that the upregulated genes were enriched for markers of 
gonadal tissue. To test this hypothesis, genes that were differentially expressed in the adrenal glands of 
gonadectomized mice were compared to pooled GEO microarray data for different mouse tissues, using 
an established algorithm (Chen et al. 2013).  Enrichment analysis demonstrated that genes upregulated 
in the adrenal glands of gonadectomized mice were more likely to be highly expressed in ovary (Figure 
3.3A; P = 2.01 x 10-8) or testis (Figure 3.3B; P = 2.16 x 10-7) but not in the non-steroidogenic tissue brain 
(Figure 3.3D; P = 0.90).  Genes downregulated in the adrenal glands of gonadectomized mice were more 
likely to be highly expressed in the normal adrenal tissue (Figure 3.3C; P = 7.83 x 10-4) than in brain 
(Figure 3.3E; P = 1.00).  This systematic, transcriptomic comparison reinforces the longstanding tenet 
that GDX induces the selective accumulation of gonadal-like cells in the adrenal glands of DBA/2J mice.  
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 Among the genes upregulated in the microarray analysis were gonadal-like markers known to be 
expressed in post-GDX adrenocortical neoplasms, such as Cyp17a1 (460-fold), Lhcgr (43-fold), Inha (17-
fold), and Amhr2 (6.2- to 9.1-fold on different microarray probes) (Bielinska et al. 2006a).  Two well-
documented markers of GDX-induced adrenocortical neoplasia, Gata4 and Amh (Bielinska et al. 2006a), 
were not upregulated, underscoring the inherent limitations of microarray technology (each of these 
genes was represented by a single probe on the microarray and showed a non-significant expression 
change of ~0.5-fold).  Two genes identified in the microarray screen, Spinlw1 and Insl3, were validated as 
novel markers of GDX-induced adrenocortical neoplasia in the mouse, using the same rigorous criteria 
described above (Figure 3.4A-E).   
 Spinlw1, which was upregulated 16- to 51-fold on different microarray probes, encodes EPPIN, a 
serine protease inhibitor secreted by Sertoli cells and epididymal epithelial cells (O'Rand et al. 2011) but 
not by cells of the ovary or uterus (Sivashanmugam et al. 2003; Silva et al. 2012).  Thus, EPPIN is 
generally considered to be a “male-specific” marker.  Consistent with this notion, expression of Spinlw1 
has been shown to be androgen-dependent (Denolet et al. 2006; Schauwaers et al. 2007; Willems et al. 
2010; Silva et al. 2012).   
 Insl3, which was upregulated 50-fold on the microarray, encodes insulin-like 3, a hormone that is 
secreted by fetal Leydig cells.  INSL3 mediates the trans-abdominal phase of testicular descent (Ivell et 
al. 2013), and loss-of-function mutations in Insl3 cause cryptorchidism (Ivell and Anand-Ivell 2011).  
Additionally, INSL3 is constitutively secreted by adult Leydig cells and serves as a serum biomarker of 
this cell type (Anand-Ivell et al. 2009), although the function of INSL3 in the adult testis remains unclear 
(Ivell et al. 2013).  Insl3 is also expressed in the ovary, particularly in theca interna cells of the maturing 
follicle (Satchell et al. 2013), where it induces androgen production (Glister et al. 2013).  It is conceivable 
that serum levels of INSL3 could be a biomarker of post-GDX adrenocortical neoplasms, and future 
experiments will explore this possibility. 
 Foxl2, a gene that was marginally upregulated (1.3-fold) in the microarray analysis, was found to 
be another bona fide marker of GDX-induced adrenocortical neoplasia in the mouse (Figure 3.5A-F).  
Foxl2 encodes a forkhead transcription factor that is expressed in granulosa and interstitial cells of the 
ovary (Schmidt et al. 2004; Mork et al. 2012).  Consequently, FOXL2 is generally considered to be a 
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“female-specific” marker (Georges et al. 2013).  Mice harboring null mutations in Foxl2 develop ovaries 
that express testicular differentiation markers (Schmidt et al. 2004; Uda et al. 2004; Ottolenghi et al. 2005; 
Garcia-Ortiz et al. 2009; Uhlenhaut et al. 2009).  Of note, extracts of adrenal glands from non-
gonadectomized mice have been shown to contain FOXL2 mRNA and protein at levels 40-50 times lower 
than extracts of ovary (Yang et al. 2010).  The significance of this low level expression of Foxl2 in non-
neoplastic adrenal glands is unclear. 
 None of these validated, gonadal-like genes showed evidence of differential methylation in the 
LCM-RRBS analysis (Schillebeeckx et al. 2013).  The degree of methylation of the Foxl2 promoter was 
<1% in both neoplastic and normal tissue, and the degree of methylation of the Insl3 promoter was 
comparable in neoplastic and normal tissue (13% vs. 16%; σ = 4.1 and σ = 5.3, respectively).  Coverage 
of the Spinlw1 promoter was inadequate for quantification of its methylation status.  
In addition to gonadal-like markers, 3 mast cell enzyme genes, Cma1, Cma2, and Cpa3, were 
upregulated (2.5- to 8.4-fold) in the adrenal glands of gonadectomized mice (Supplemental Table 1).  This 
finding is consistent with the well-documented phenomenon of mast cell infiltration of post-GDX 
adrenocortical neoplasms (Kim et al. 1997; Bielinska et al. 2005). 
 
FOXL2 is a marker of adrenocortical neoplasia in gonadectomized ferrets 
Sex steroid-producing neoplasms arise in up to 20% of gonadectomized ferrets and are a major cause of 
morbidity and mortality in this species (Bielinska et al. 2006a; Beuschlein et al. 2012).  Immunostaining of 
archival veterinary pathology specimens showed that FOXL2 is a marker of post-GDX adrenocortical 
neoplasia in the ferret (Figure 3.6A-F; Figure 3.S1).  The specimens were obtained from gonadectomized 
ferrets with signs of ectopic sex steroid production (e.g., alopecia, vulvar hyperplasia, or stranguria) and 
included examples of adrenocortical carcinoma, adenoma, and nodular hyperplasia.  Several of the 
specimens contained residual normal cortex, which served as a negative control (Figure 3.6A, C, E).  
Nuclear FOXL2 immunoreactivity was detected in 50% of the specimens examined [4 of 10 cases of 
adrenocortical carcinoma, 4 of 6 cases of adrenocortical adenoma, and 1 of 2 cases of nodular 
hyperplasia].  FOXL2-positive tumors were seen in both female (Figure 3.6) and male (Figure 3.S1) 
ferrets.  Only a minority of the cells within a given tumor reacted with FOXL2 antibody (Figure 3.6D; 
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Figure 3.S1).  By comparison, nuclear GATA4 immunoreactivity has been observed in >90% of ferret 
adrenocortical tumors (Peterson et al. 2004), and GATA4 antibody typically stains a higher percentage of 
cells within a given tumor (Figure 3.6F).   
 We conclude that FOXL2 is a marker of GDX-induced adrenocortical tumors in not only the 
mouse but also the ferret.  This observation expands the list of genes known to be expressed in sex 
steroidogenic adrenocortical neoplasms of the ferret (Schoemaker et al. 2002; Peterson et al. 2003; 
Peterson et al. 2004; Bielinska et al. 2006a; Wagner et al. 2008; de Jong et al. 2013; de Jong et al. 2014).  
The relatively low percentage of FOXL2 immunoreactive cells within ferret adrenocortical tumors may limit 
the diagnostic utility of this marker.  It remains to be determined whether the other markers of 
adrenocortical neoplasia that emerged from our screens of gonadectomized mice are also markers of 
tumorigenesis in ferrets.  
 
Summary 
 Using complementary approaches, including DNA methylation analysis and microarray 
expression profiling, we have identified novel epigenetic (Igfbp6, Foxs1) and genetic (Spinlw1, Insl3, 
Foxl2) markers of GDX-induced adrenocortical neoplasia in the mouse.  That both “male-specific” 
(Spinlw1) and “female-specific” (Foxl2) markers were detected is noteworthy and implies that the 
neoplasms exhibit mixed characteristics of male and female gonadal somatic cells.  Such indeterminate 
steroidogenic cell phenotypes have been reported in other experimental models (Heikkila et al. 2002; Val 
et al. 2006).  One of the markers, FOXL2, was observed in adrenocortical tumor specimens from 
gonadectomized ferrets.  These new markers may prove useful for studies of steroidogenic cell 
development and for tumor classification. 
 
Highlights 
• Igfbp6 & Foxs1 are hypomethylated and upregulated in murine post-GDX adrenocortical tumors. 
• The Sf1 FAdE is hypomethylated in murine post-GDX adrenocortical tumors. 
• Spinlw1, Insl3, & Foxl2 are upregulated in murine post-GDX adrenocortical tumors. 
• FOXL2 immunoreactivity is evident in adrenocortical tumors from gonadectomized ferrets.  
60 
• Post-GDX adrenocortical tumors exhibit properties of female and male gonadal cells. 
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MATERIALS AND METHODS 
 
Experimental animals 
 Procedures involving mice were approved by an institutional committee for laboratory animal care 
and were conducted in accordance with NIH guidelines for the care and use of experimental animals.  
DBA/2J mice were purchased from Jackson Laboratories (Bar Harbor, ME).  Female mice were 
anesthetized and gonadectomized at 3-4 weeks of age (Bielinska et al. 2005).  We limited our analysis to 
females because they develop post-GDX adrenocortical neoplasms more readily than their male 
counterparts (Bielinska et al. 2006a; Beuschlein et al. 2012).  Adrenal tissue was harvested for analysis 3 
months later. 
 
Isolation of neoplastic and normal tissue using LCM 
 Cryosections (10 µm) of adrenal glands from ovariectomized or intact mice were collected on 
membrane slides (PEN-Membrane 2.0 µm; Leica), fixed in acetone (for collecting DNA) or ethanol (for 
collecting RNA) at -20º C, stained with hematoxylin and eosin (H&E) or crystal violet, and then 
dehydrated by passage through successively higher concentrations of ethanol followed by xylene 
(Pihlajoki et al. 2013a; Schillebeeckx et al. 2013).  LCM was used to isolate samples from GDX-induced 
adrenocortical neoplasms, adjacent normal adrenocortical tissue [zona glomerulosa (zG) + zona 
fasciculata (zF) cells], and the adrenal X-zone.  Dissectates were collected in SDS/proteinase K for 
genomic DNA isolation or in RNA extraction buffer (RNeasy Mini Kit, Qiagen, Valencia, CA).  
 
Global and locus-specific DNA methylation analyses 
 DNA from neoplastic or normal adrenocortical tissue was subjected to genome-wide methylation 
analysis using LCM-reduced representation bisulfite sequencing (LCM-RRBS) (Schillebeeckx et al. 
2013).  Locus-specific DNA methylation of the Sf1 enhancer locus was measured via bisulfite-specific 
PCR and pyrosequencing as described previously (Schillebeeckx et al. 2013).  
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Microarray expression profiling 
 RNA was isolated from whole adrenal glands of intact, virgin (n = 3) or ovariectomized (n = 3) 
female DBA/2J mice using RNeasy® Mini Kit (Qiagen, Valencia, CA), amplified using the TotalPrep RNA 
amplification kit (Illumina, San Diego, CA), and hybridized on an Illumina Mouse6v2 oligonucleotide array.  
Array hybridization was performed by the GTAC Microarray Core facility at Washington University 
according to standard protocols.  Probes with a hybridization signal less than signal background were 
excluded from the analysis, leaving 15,066 probes.  Probes that did not show at least a 2-fold change in 
either direction were then excluded, leaving 628 probes (Table 3.S1).  Finally, we determined statistical 
significance using the Student’s t test and correcting for multiple hypothesis testing using the Benjamini-
Hochberg method, leaving a total of 127 probes (q-value < 0.05). Statistically significant upregulated (n = 
89) and downregulated (n = 38) probes correspond to 85 and 36 genes, respectively (Table 3.S1).  
 Genes that were differentially expressed in adrenal glands from gonadectomized vs. intact mice 
were compared to pooled Gene Expression Omnibus (GEO) data for different mouse tissues, using non-
parametric statistical testing (Chen et al. 2013).  Genes with a statistically significant expression 
specificity (q-value < 0.01; Benjamini-Hochberg corrected) for adrenal, brain, ovary, or testis tissues were 
considered to be tissue-specific (Table 3.S2).  Enrichment for upregulated or downregulated genes within 
the tissue-specific gene dataset was determined using the Fisher’s Exact Test. 
 
qRT-PCR 
 Total RNA was isolated and subjected to qRT-PCR analysis as described (Slott et al. 1993).  
Expression was normalized to the housekeeping genes Actb and Gapdh. Primer pairs are listed in Table 
3.3S.   
 
In situ hybridization 
 Nonradioactive in situ hybridization was performed (Val et al. 2006) using paraformaldehyde-
fixed, paraffin-embedded adrenal sections (5 µm).  To prepare riboprobes, cDNA fragments of Igfbp6, 
Foxs1, Spinlw1, and Foxl2 were amplified by RT-PCR (annealing temperature = 52º C) and cloned into 
the vector pCRII-TOPO (Invitrogen, Carlsbad, CA) using the manufacturer’s guidelines.  RT-PCR primers 
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and cDNA fragment sizes are specified in Table 3.S4.  Digoxygenin-labeled antisense riboprobes were 
synthesized from EcoRV-linearized plasmids using Sp6 RNA polymerase (Heikinheimo et al. 1994).  
Bound riboprobe was detected using an alkaline phosphatase conjugated anti-digoxigenin antibody, as 
described (Val et al. 2006).  Sections were subsequently counterstained with nuclear fast red. 
 
Immunohistochemistry 
 Mouse tissues were fixed overnight in 4% paraformaldehyde in PBS, embedded in paraffin, 
sectioned (5 µm), and subjected to immunoperoxidase staining (Anttonen et al. 2003).  Formalin-fixed, 
paraffin-embedded, adrenocortical neoplasms from gonadectomized ferrets were obtained from the 
archives of a veterinary diagnostic laboratory, as reported previously (Peterson et al. 2003; Peterson et 
al. 2004; Wagner et al. 2008); included were cases of adrenocortical carcinoma, adenoma, and nodular 
hyperplasia.  Criteria for classification of these tumors are listed elsewhere (Peterson et al. 2003).  The 
primary antibodies were: a) rabbit anti-INSL3 (sc-134587; Santa Cruz Biotechnology, Santa Cruz, CA; 
1:200 dilution), b) goat anti-GATA4 (sc-1237, Santa Cruz Biotechnology; 1:200 dilution), and c) goat anti-
FOXL2 (IMG-3228; Imgenex, San Diego, CA; 1:400 dilution).  Secondary antibodies were: a) goat anti-
rabbit biotinylated IgG (NEF-813, NEN Life Science, Boston, MA; 1:2000 dilution) and b) donkey anti-goat 
biotinylated IgG (Jackson Immunoresearch, West Grove, PA; 1:1000 dilution).  The avidin-biotin 
immunoperoxidase system (Vectastain Elite ABC Kit, Vector Laboratories, Inc., Burlingame, CA) and 
diaminobenzidine were used to visualize the bound antibody. The analysis included negative control 
studies in which the primary antibodies were omitted.   
 
Data Release 
 The DNA methylation data generated for the study can be found under GEO accession number 
GSE45361. DNA methylation and raw sequence data are also publically available at the Center for 
Genome Sciences (www.cgs.wustl.edu/~maxim/). The microarray hybridization data has been 
deposited under GEO accession number GSE54393. 
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FIGURE 3.1 
 
Figure 3.1 Two genes identified as hypomethylated by genome-wide mapping, Igfbp6 and Foxs1, 
are upregulated in GDX-induced adrenocortical neoplasms of the mouse.  (A) qRT-PCR analysis of 
Igfbp6 and Foxs1 in whole adrenal mRNA from non-gonadectomized (nGDX) or gonadectomized (GDX) 
female DBA/2J mice (n = 4 per group).  (B) qRT-PCR analysis of Igfbp6 and Foxs1 in normal or tumor 
tissue isolated by LCM from the adrenal cortex of ovariectomized DBA/2J mice (n = 4 per group).  qRT-
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PCR results were normalized to expression of Actb (*, P < 0.05); normalization to Gapdh yielded similar 
results. Statistical significance was determined using the Student’s t test. (C) In situ hybridization of 
adrenal tissue from an ovariectomized DBA/2J mouse using an Igfbp6 antisense riboprobe.  (D) H&E 
staining of an adjacent tissue section.  Igfbp6 mRNA localized to neoplastic cells in the subcapsular 
region.  (E) In situ hybridization of adrenal tissue from an ovariectomized DBA/2J mouse using a Foxs1 
antisense riboprobe.  (F) H&E staining of an adjacent tissue section.  Foxs1 mRNA localized to neoplastic 
tissue in the subcapsular region and to cells in the medulla (m).  Bars = 50 µm.   
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FIGURE 3.2 
 
Figure 3.2 The Sf1 FAdE is hypomethylated in normal and neoplastic adrenocortical cells.  Tissue 
from female DBA/2J mice was subjected to DNA methylation analysis using bisulfite-specific PCR.  (A) 
The graph compares the level of methylation across 7 of 8 CpG dinucleotides in the Sf1 FAdE for various 
tissues.  The 8th CpG (CpG-2) was omitted from the analysis because the data did not pass quality control 
measures for pyrosequencing. (B) The inset shows P values for paired t-tests among the different tissue 
types.  Synthetic DNA is included as a negative control.  Note that the FAdE is hypomethylated in the X-
zone, normal cells of the zona fasciculata + zona glomerulosa (zF + zG), and post-GDX adrenocortical 
tumor tissue. 
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FIGURE 3.3 
 
Figure 3.3 Systematic transcriptome analysis shows that genes upregulated in the adrenal glands 
of gonadectomized mice are more likely to be highly expressed in ovary or testis than in other 
tissues.  Probes that were differentially expressed in microarrays of whole adrenal glands from 
gonadectomized vs. non-gonadectomized female DBA/2J mice were compared to pooled GEO 
microarray data for different mouse tissues using an established rank sum algorithm (Chen et al. 2013).  
Probes specific for ovary, testis, adrenal or brain are shown as yellow circles. Probes that were 
upregulated in adrenal glands from gonadectomzied mice are shown as red circles (↑ GDX).  Probes that 
were downregulated in adrenal glands from gonadectomzied mice are shown as blue circles (↓ GDX).  
Enrichment analysis demonstrated that genes upregulated in the adrenal glands of gonadectomized mice 
were more likely to be highly expressed in ovary (A) or testis (B) than in brain (D).  Genes downregulated 
in the adrenal glands of gonadectomized mice were more likely to be highly expressed in the normal 
adrenal tissue (C) than in brain (E). 
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FIGURE 3.4 
 
Figure 3.4 Two genes identified by microarray expression profiling, Spinlw1 and Insl3, are 
upregulated in GDX-induced adrenocortical neoplasms of the mouse.  (A) qRT-PCR analysis of 
Spinlw1 and Insl3 in whole adrenal mRNA from non-gonadectomized (nGDX) or gonadectomized (GDX) 
female DBA/2J mice (n = 4 per group). (B) qRT-PCR analysis of Spinlw1 and Insl3 in normal or tumor 
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tissue isolated by LCM from the adrenal cortex of ovariectomized DBA/2J mice (n = 4 per group).  qRT-
PCR results were normalized to expression of the housekeeping gene Actb (*, P < 0.05); normalization to 
Gapdh yielded similar results. Statistical significance was determined using the Student’s t test. (C) In situ 
hybridization of adrenal tissue from an ovariectomized DBA/2J mouse using a Spinlw1 antisense 
riboprobe.  (D) H&E staining of an adjacent tissue section.  Spinlw1 mRNA localized to neoplastic cells in 
the subcapsular region. (C) Immunoperoxidase staining of adrenal tissue from an ovariectomized DBA/2J 
mouse using anti-INSL3.  (D) H&E staining of an adjacent tissue section.  INSL3 immunoreactivity was 
evident in lipid-laden type B neoplastic cells [see (Bielinska et al. 2006a) for a description of this cell type].  
Control experiments demonstrated INSL3 immunoreactivity in Leydig cells of the adult testis (data not 
shown).  Bars = 50 µm.   
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FIGURE 3.5 
 
Figure 3.5 Foxl2 is upregulated in GDX-induced adrenocortical neoplasms of the mouse.  (A) qRT-
PCR analysis of Foxl2 in whole adrenal mRNA from non-gonadectomized (nGDX) or gonadectomized 
(GDX) female DBA/2J mice (n = 4 per group).  (B) qRT-PCR analysis of Foxl2 in normal or tumor tissue 
isolated by LCM from the adrenal cortex of ovariectomized DBA/2J mice (n = 4 per group).  qRT-PCR 
results were normalized to expression of the housekeeping gene Actb (*, P < 0.05); normalization to 
Gapdh yielded similar results. Statistical significance was determined using the Student’s t test.  (C) In 
situ hybridization of adrenal tissue from an ovariectomized DBA/2J mouse using a Foxl2 antisense 
riboprobe.  (D) H&E staining of an adjacent tissue section.  Bar = 50 µm.  (E) Immunoperoxidase staining 
of adrenal tissue from an ovariectomized DBA/2J mouse using anti-FOXL2.  (F) H&E staining of an 
adjacent tissue section.  Nuclear FOXL2 immunoreactivity was evident in both small, basophilic type A 
neoplastic cells and large, lipid-laden type B neoplastic cells [see (Bielinska et al. 2006a) for a description 
of these cell types].  Control stainings demonstrated nuclear FOXL2 immunoreactivity in granulosa cells 
of the adult ovary (data not shown).  Bar = 50 µm.    
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FIGURE 3.6 
 
Figure 3.6 FOXL2 immunoreactivity in neoplastic adrenocortical cells from a gonadectomized 
female ferret with clinical evidence of ectopic sex steroid production.  Sections of normal (A,C,E) or 
neoplastic (B,D,F) adrenal cortex were subjected to H&E staining (A,B) or to immunoperoxidase staining 
with anti-FOXL2 (C,D) or anti-GATA4 (E,F).  The neoplastic tissue contained a mixture of small, 
basophilic cells and large, polyhedral cells. Nuclear GATA4 immunoreactivity was evident in both the 
small and large neoplastic cells, whereas nuclear FOXL2 immunoreactivity was limited to the large 
neoplastic cells in this specimen.  Bar = 50 µm.  Abbreviations: c, capsule; zF, zona fasciculata; zG, zona 
glomerulosa; zI, zona intermedia [a zone characteristic of ferrets and other carnivores (Holmes 1961)]. 
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SUPPLEMENTARY FIGURES AND TABLES 
FIGURE 3.S1 
 
Figure 3.S1 FOXL2 immunoreactivity in an adrenocortical tumor from a gonadectomized male 
ferret with clinical signs of ectopic sex steroid production.  Nuclear FOXL2 staining is evident a 
subset of the neoplastic cells (arrowheads) but not in normal adrenocortical cells (arrow). Bar = 50 µm.   
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TABLE 3.S1 
https://cgs.wustl.edu/~maxim/Thesis/Chapter3/Table3.S1.xlsx 
Table 3.S1 Microarray expression profiling of adrenal glands from gonadectomized (GDX) vs. non-
gonadectomized (nGDX) female DBA/2J mice.  Genes that were significantly upregulated or 
downregulated (> 2-fold) are listed in the first tab.  Genes that survived the Benjamini-Hochberg 
correction are listed in the second tab.  See Materials and Methods for details. 
 
TABLE 3.S2 
https://cgs.wustl.edu/~maxim/Thesis/Chapter3/Table3.S2.xlsx 
Table 3.S2 Genes deemed tissue-specific for adrenal, brain, ovary, and testis based on analysis of 
pooled GEO microarray data.  See Materials and Methods for details. 
 
TABLE 3.S3 
Gene Primer sequence (5' → 3') cDNA size (bp) Reference 
Actb F: GCGTGACATCAAAGAGAAGC 187 NM_007393.2 
R: AGGATTCCATACCCAAGAAGG 
Foxl2 F: GCAAGGGAGGCGGGACAACAC 154 NM_02020.2 
R: GAACGGGAACTTGGCTATGATGT 
Foxs1 F: TACCTCGCCCTCACCGTGCC 167 NM_010226 
R: CAAGGCCTGGGTCAGTCCCCA 
Gapdh F: GCTCACTGGCATGGCCTTCCGTG 200 NM_008084.2 
R: TGGAAGAGTGGGAGTTGCTGTTGA 
Igfbp6 F: CAGAGACCGGCAGAAGAATC 289 NM_008344 
R: GCTTCCTTGACCATCTGGAG 
Insl3 F: CACGCAGCCTGTGGAGACCC 134 NM_013564.7 
R: CGCTGGCGCTGAGAAGCCT 
Spinlw1  F: TGACTTGCTGTTTCCCAGGAG 191 NM_029325.2 
R: AAGCCATACAGTAGCCGGAG 
 
Table 3.S3 Primers used for qRT-PCR. 
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TABLE 3.S4 
Gene Primer sequence (5' → 3') Size (bp) 
Spinlw1 
F: GTGCTATTTGGCCTGCTTGC     
513 
R: TAGGACCCCACAACTGGGAA 
Foxl2 
F: CAAGTACCTGCAATCGGGGT 
490 
R: TGCGTCTCAGACACTTCGAC 
Foxs1 
F: TCACCGTGCCCAGCATTCGG 
513 
R: CCCCAAGGGACCTGCCTGACT 
Igfpb6 
F: TGTTGGTTCGTTGCGGGCTCA 
561 
R: CCTGCGAGGAACGACCTGCTG 
 
Table 3.S4 Primers used to generate riboprobes for in situ hybridization. 
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CHAPTER 4: ACTIVE METHYLATION AND DEMETHYLATION IN MOTOR NEURON MATURATION 
 
ABSTRACT 
 Cytosine methylation (5mC) and hydroxymethylation (5hmC) play important roles in 
transcriptional regulation in post-mitotic neurons. Neuronal activity-induced gene activation in the adult 
brain is mediated through the Tet oxidation of 5mC to 5hmC, which is replaced with unmodified cytosine 
by the base excision repair pathway to complete the demethylation cycle. Little is known about the 
dynamics of how 5mC and 5hmC are established in adult neurons partially owing to the difficulty of 
studying neuron maturation ex vivo. Here, we leverage a recently developed 5mC genome-wide mapping 
technique and a motor neuron puromycin-selectable transgenic embryonic stem cell line to characterize 
the DNA methylome of motor neurons (MNs) as they differentiate and mature. We show that motor 
neuron differentiation and maturation is characterized by a loss of 5mC at genes critical for neuron 
function and by a global gain in 5hmC. These changes in cytosine modification result in attendant gene 
activation and show enrichment for known sequence motifs of motor neuron-specific transcription factors. 
Furthermore, single, double, and triple knockout experiments show that individual Tet proteins are not 
required for MN maturation and that Tet3 is sufficient for proper MN differentiation and maturation, and 
that MN can differentiate and form without the presence of any TET enzymes. Our study suggests that 
transcription factor-mediated active demethylation of 5mC through the 5hmC intermediate occurs in a 
temporal manner and that the TET proteins play redundant and compensatory roles in MN differentiation 
and maturation. 
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INTRODUCTION 
 Motor neurons (MNs) connect the central nervous system and skeletal muscle to direct muscle 
contractions and movement. They are primarily located in the ventral horn of the spinal cord where axons 
extend to muscle cells at neuromuscular junctions. MN diseases, like amyotrophic lateral sclerosis (ALS), 
result in axon degeneration and eventual paralysis, organ failure, and death. In normal development, MNs 
are completely formed by embryonic day 13 (E13) in the mouse and gestation week 5.5 in humans 
(Altman J. 2001). In vivo studies have shown that MN maturation is characterized by changes in 
morphology and electrophysiology. As MNs mature, they increase in cell body size, extend peripheral 
axons, and form dendrites (Cullheim et al. 1987; Nunez-Abades and Cameron 1995; Burke and Glenn 
1996; Altman J. 2001; Carrascal et al. 2005; Li et al. 2005), and are able to fire multiple action potentials 
to propagate synaptic signaling (Ziskind-Conhaim 1988; Martin-Caraballo and Greer 1999; Carrascal et 
al. 2005). Previously, McCreedy et al. developed a transgenic mouse embryonic stem cell line that allows 
for the selection of motor neurons in culture. This in vitro differentiation method, and others, have 
demonstrated that normal cell morphology and electrophysiology can be recapitulated in cultured MNs 
(Wichterle et al. 2002; Miles et al. 2004; Wichterle and Peljto 2008; Takazawa et al. 2012).  
 The covalent modification of cytosine in the genome is associated with gene silencing and is vital 
for normal development (Reik 2007) and for maintaining cellular identity (Dhawan et al. 2011b). The 
methylation of cytosine (5mC) has been extensively studied in neurons of the brain (Iwamoto et al. 2011; 
Lister et al. 2013; Kozlenkov et al. 2014) and has been shown to influence synaptic formation (Levenson 
et al. 2006), learning and memory (Day and Sweatt 2010; Miller et al. 2010; Zovkic et al. 2013), emotional 
behavior (LaPlant et al. 2010), adult neurogenesis (Ma et al. 2009), and age-related cognitive decline 
(Oliveira et al. 2012). Although originally thought to be a permanent covalent modification in neurons, 
5mC levels change in response to external stimuli (Guo et al. 2011a). Recent studies have identified 
CpGs that are modified in postnatal neural tissues upon neuronal activity induced by voluntary exercise 
(Guo et al. 2011a), social stress conditions (McGowan et al. 2009; Elliott et al. 2010), and 
electroconvulsive stimulation (Guo et al. 2011a). The necessity for functional DNA methyltransferase and 
CpG-binding proteins in ensuring long-term neural plasticity and cognition further highlights the 
importance of 5mC in normal neuron function (Moretti et al. 2006; Feng et al. 2010). Although the 
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importance of 5mC in neurons of the brain is well established, little is know about the role 5mC plays in 
motor neuron maturation. 
 The discovery of the hydroxymethylation of cytosine (5hmC) has introduced an additional role of 
cytosine modification in the brain (Penn et al. 1972; Tahiliani et al. 2009). 5hmC occurs primarily at gene 
bodies and is associated with gene activation (Branco et al. 2012). The presence of 5hmC varies across 
tissue types but is highest in the hypothalamus and cerebral cortex (Globisch et al. 2010) suggesting it 
plays an important role in neuron function. 5hmC is an intermediate for the demethylation of 5mC 
(Tahiliani et al. 2009; Guo et al. 2011b) and knockout experiments have shown that the oxidation of 5mC 
to 5hmC by TET1 is necessary for ??????????????????????????????????????????????????????????????????????
??????????????????????????Although significant progress has been made in understanding the role of 5mC 
and 5hmC in neurons of the developing brain, it is unknown whether 5hmC is present in motor neurons 
and whether the Tet demethylating machinery is necessary for normal motor neuron function. 
 In this study, we used Laser Capture Microdissection-Reduced Representation Bisulfite 
Sequencing (LCM-RRBS) to profile the genome-wide 5mC and used immunocytochemistry to profile 
global 5hmC of a pure population of differentiating and maturing MNs in vitro. We show that post-mitotic 
MNs undergo significant methylome remodeling upon differentiation and functional and morphological 
maturation. The observed methylation changes are associated with transcriptional changes of genes 
important for motor neuron function. Furthermore, we show that the presence of 5hmC in MNs occurs 
post-differentiation upon cellular maturation and that the Tet demethylation machinery is necessary for 
proper motor neuron differentiation and maturation. We provide the first global view of the changing DNA 
methylation landscape at base pair resolution in developing motor neurons. 
 
RESULTS 
In vitro selected motor neurons model morphological and electrophysiological motor neuron 
maturation in culture 
 Current in vitro studies of MN maturation are limited by the presence of proliferating glial cells that 
prevent the isolation of individual neurons. Previously, McCreedy et al. characterized a transgenic Hb9-
driving puromycin (Hb9-puro) transgenic embryonic stem cell line that, upon retinoic acid and sonic 
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hedgehog induction, differentiates into physiologically normal MNs. Induced neural progenitor cells 
(NPCs) express the spinal motor neuron-specific transcription factor, Hb9, and therefore also express 
Puromycin N-acetyltransferase, which can be used to select for MNs (Figure 4.1). To better understand 
the utility of the Hb9-puro line as a model for studying MN maturation, we characterized the morphology 
and electrophysiology of maturing MNs at 24 hours (D0), two days (D2), and four days (D4) after 
differentiation and selection. We first assessed the formation of neurites, branch points, neuronal 
networks, cell area, and neurite length as a function of time. β-tubulin class III staining, imaging, and 
quantification showed a statistically significant increase (ANOVA, P<0.05) in neurite number, neurite 
length, neurite branch points, and cell body area from D0 to D4 (Figure 4.2 and 4.3). Furthermore, as 
MNs developed neurites, they formed an increasing number of contacts with neighboring cells to 
establish closed networks as represented by a decrease in independent networks across time (Figure 
4.3). Most neurite growth and branching occurred from D0 to D2 after which neurite growth slowed 
(Figure 4.2 and 4.3). We conclude that cultured MNs are morphologically mature at four days after 
differentiation. 
 We next investigated the electrophysiological properties of D0, D2, and D4 MNs. Previous work 
by McCreedy et al. showed that D4 MNs have the ability to fire multiple action potentials during periods of 
prolonged depolarization and exhibit adaptation in both spike frequency and amplitude. To evaluate the 
functional properties of selected MNs over time, we performed whole-cell current-clamp recordings 
between 0 and 6 days after differentiation (puromycin selection; Figure 4.4). To test for expression of 
functional neurotransmitter receptors, we exposed cells to selective agonists for AMPA/kainate, NMDA, 
glycine, and GABA receptors and recorded the resulting inward current. Figure 4.4 (top panel) shows that 
the amplitude of agonist-evoked total whole-cell current density increases with time (Pearson, P<10-4) 
after puromycin selection, suggesting the number of channels expressed on the surface of each cell 
increases over time. Interestingly, currents evoked by AMPA/kainite, NMDA, and glycine agonists showed 
the greatest increase from D2 to D4 while the largest increase in current density evoked by the GABA 
agonists was observed between D0 and D2, suggesting GABA receptor expression occurs earlier than 
AMPA/kainite, NMDA, and glycine receptors. Furthermore, whole-cell capacitance, which is proportional 
to surface area, significantly increased from 22.6 ± 1.5 pF (n=11) at D0 to 61.2 ± 4.0 pF (n=16) at D6 
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(ANOVA, P<10-4) while input resistance decreased significantly between D0 and D2 but not between D2 
and D4 or D6 (ANOVA, P<10-4), which confirms our morphology experiments that a significant increase in 
cell size occurs between D0 and D4 (Figure 4.4, bottom panel). Our results and those from McCreedy et 
al. together demonstrate that selected MNs mature into functional neurons by four days after puromycin 
selection.  
 
Maturing motor neurons show active gains and losses in DNA methylation at genes implicated in 
neurogenesis 
 Little is known about the role DNA methylation plays in MN maturation. To determine whether 
DNA methylation changes occur in maturing MNs, we applied LCM-RRBS (Schillebeeckx et al. 2013) to 
three biological replicates of D0, D2, and D4 MNs. Using LCM-RRBS, we were able to interrogate the 
DNA methylation status of 1,074,439 CpGs at all three time points. Although >99% of CpGs did not show 
a significant change in DNA methylation from D0 to D4, 2,894 CpGs and 1,147 CpGs showed a 
statistically significant loss and gain of at least 25 percent methylation, respectively (Figure 4.5, left panel; 
Table 4.S1). Although LCM-RRBS enriches for CpGs in promoter regions (Figure 4.S1; top left panel), we 
observed that most CpG changes occurred >10 kilobases from the nearest gene (Figure 4.S1; bottom 
panel). We, therefore, assessed whether there was an enrichment at introns, exons, promoters, or 
intergenic regions. We see a significant depletion of differentially methylated CpGs in promoters (p-
value<10-16; OR<0.32) and a significant enrichment for differentially methylated CpGs at introns (p-
value<10-9; OR>1.49) and intergenic regions (p-value<10-9; OR>1.46) (Figure 4.S1). Furthermore, 
hypomethylated CpGs were highly enriched for CpGs distal to the nearest gene (Welch’s t test; p-
value<10-5) while hypermethylated CpGs had a slight enrichment for distal CpGs (Welch’s t test; p-
value<0.039) with a mean distance of 17,709 bp and 14,264 bp, respectively, to the nearest transcription 
start site (TSS)(Figure 4.S1). Taken together, we conclude that significant changes in CpG methylation 
occur at putative regulatory regions distal to TSSs. 
 To determine whether the differentially methylated CpGs regulate genes important for motor 
neuron function, we identified the nearest gene to each differentially methylated CpG and performed 
Gene Ontology enrichment analysis. Hypomethylated CpGs were associated with genes enriched for 
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neuronaI function, including neuron projection guidance, axon guidance, and neuron differentiation while 
hypermethylated CpGs were associated with genes enriched for cell differentiation, including embryonic 
morphogenesis, regulation of cell development, and multicellular organismal development (q-value<10-6; 
FDR-adjusted; Table 4.1). Interestingly, changes in DNA methylation occurred at various stages in MN 
maturation. Roughly 65% of hypomethylated CpGs lost more methylation between D0 and D2 than 
between D2 and D4 while roughly 65% of hypermethylated CpGs gained more methylation between D2 
and D4 than between D0 and D2 (Figure 4.5, right panel; Table 4.S1), suggesting gene activation occurs 
earlier than gene silencing. We conclude that hypomethylated CpGs are associated with genes important 
for motor neuron maturation and that the loss of CpG methylation occurs within two days after 
differentiation. 
 To assess whether the observed loss of methylation is specific to MNs, we determined the 
methylation states of hypomethylated CpGs for astrocytes, a glial cell type. Astrocytes and MNs share a 
common progenitor and, therefore, have a close epigenetic origin in which they stem from one DNA 
methylation profile. We find that CpGs hypomethylated in MNs are enriched for CpGs that are highly 
methylated in astrocytes (Figure 4.6; Fisher’s Exact Test, p-value<10-16). Indeed, 82% of hypomethylated 
CpGs are highly methylated in astrocytes with a percent methylation of 75% or greater, suggesting the 
observed loss of DNA methylation is specific to MNs. Together, we conclude that maturing MNs show 
significant gains and losses of DNA methylation at CpGs associated with genes implicated in neuronal 
functions and cellular differentiation and that the loss of DNA methylation is specific to motor neurons.  
 
Motor neurons show a significant increase in expression of genes associated with active 
demethylation 
 DNA methylation at gene promoters acts to silence genes by recruiting chromatin modifying 
proteins or by preventing transcription factor binding and is therefore negatively correlated with gene 
expression (Watt and Molloy 1988; Robertson 2005). We hypothesized that the observed gains and 
losses of DNA methylation would be associated with gene silencing and gene activation, respectively. To 
test this hypothesis, we performed gene expression profiling of neural progenitor cells (NPC) and 
selected MNs at D0, D2, and D4 (Table 4.S2). We found 142 and 50 genes that showed a statistically 
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significant (q-value<0.05; FDR-adjusted) increase or decrease in expression between D0 and D4 MNs, 
respectively (Figure 4.7; left panel). Upregulated genes were enriched (q-value<0.05; FDR-adjusted) for 
neuronal function, including cell signaling, synaptic transmission, and neuromuscular process while 
downregulated genes were enriched (q-value<0.05; FDR-adjusted) for various biological processes 
including apoptosis and biosynthesis (Table 4.2). Furthermore, upregulated genes were enriched (q-
value<0.05; FDR-adjusted) for ion channels, transporters, and neurotransmitter receptors (Table 4.3). 
Unsupervised hierarchical clustering of differentially expressed genes suggests that the majority of 
expression changes occur with two days of MN differentiation with fewer changes occurring between D2 
and D4 than between D0 and D2 (Figure 4.7; right panel). Therefore, within two days of differentiation, 
motor neurons undergo significant gene activation and gene silencing as they mature into functioning 
neurons. 
 To assess whether differentially methylated CpGs were associated with an expression change, 
we determined the expression level of genes associated with hypomethylated and hypermethylated CpGs 
across NPCs, D0 MNs, D2 MNs, and D4 MNs. We found that 82 and 21 genes upregulated and 
downregulated in D4 MNs, respectively, were associated with differentially methylated CpGs (Fisher’s 
Exact; p-value<10-16; Figure 4.8). Of the 82 upregulated genes, 64 were associated with a distal CpG that 
significantly lost DNA methylation between D0 and D4 MNs (Figure 4.S2) while 13 downregulated genes 
were associated with a distal CpG that gained DNA methylation (data not shown). Taken together, we 
find that as they mature, MNs undergo significant expression changes that correlate with concomitant 
changes in DNA methylation. 
 
Motif scanning identifies factors associated with active gains and losses of DNA methylation in 
maturing motor neurons 
 DNA methylation can prevent the binding of transcription factors (TFs) to DNA by directly 
occluding binding sites or by recruiting methyl-binding proteins (Watt and Molloy 1988). We hypothesize 
that differentially methylated CpGs may lie within gene regulatory regions important for MN maturation 
and differentiation and that the methylation status of these CpGs may regulate TF binding and gene 
regulation. To elucidate whether differentially methylated regions are associated with TF binding, we 
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evaluated 100 bp regions flanking hypomethylated and hypermethylated CpGs for the enrichment of 
known TFs using the Hypergeometric Optimization of Motif EnRichment (HOMER) suite of tools (Heinz et 
al. 2010). We find 96 and 9 predicted motifs corresponding to known cognate TFs that were enriched in 
hypomethylated and hypermethylated regions, respectively (q-value<0.01; FDR-adjusted). To elucidate 
which TFs may contribute to MN function, we performed gene ontology enrichment analysis on the TFs 
that were found predicted by HOMER to bind hypomethylated and hypermethylated regions. We found 
that 14 TFs associated with hypomethylation are enriched for neuronal function (Table 4.4). Indeed, the 
TFs Isl1, Phox2a, Lhx3, Tbx20 are known to play critical roles in spinal and cranial MN differentiation 
(Mazzoni et al. 2013). Of these 14 TFs, 10 show a statistically significant (p-value<0.05; FDR-adjusted) 
expression difference between NPCs and D0 MNs as assessed by microarray analysis (Figure 4.S3). Isl1 
and Lhx3 had the highest increase and decrease in expression, respectively, from NPCs to D0 MNs. We 
also find that hypermethylated regions were enriched for Oct4, a pluripotency factor, and Olig2, a neuro-
oligodendrocyte cell-type specification factor. These findings suggest Isl1 may direct demethylation of 
CpGs during motor neuron maturation while Lhx3 may play a role in maintaining CpGs in a methylated 
state prior to differentiation. 
 
Maturing motor neurons gain 5-hydroxymethylation over time 
 We previously demonstrated that MNs lose DNA methylation at 2,894 CpGs as they mature. 
Because MNs no longer undergo cell division after selection (D0), the loss of DNA methylation we 
observe between D0 and D4 is indicative of an active demethylation pathway, independent of cell 
division. Several mechanisms for active demethylation have been proposed (Branco et al. 2012; Kohli 
and Zhang 2013) but all require the active oxidation of 5-methylcytosine (5mC) to a 5-
hydroxymethylcytosine (5hmC) intermediate by the Ten-eleven translocation (Tet) family of proteins. We 
hypothesized that the loss of 5mC in maturing MNs occurs with a concomitant gain of 5hmC. To test this 
hypothesis, we performed immunocytochemistry on fixed D0, D2, and D4 MNs with an antibody directed 
at 5hmC. Immunocytochemistry showed very little positive staining for 5hmC at D0 and strong 5hmC 
signal at D2 and D4 (Figure 4.9). We conclude that MNs gain significant 5hmC as they mature to 
functional neurons. 
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TET proteins are necessary for proper motor neuron differentiation and maturation 
 Our microarray expression analysis shows a statistically significant increase in Tet2 and Tet3 
expression in D0 MNs as compared to NPCs (Student’s t test; p-value<0.05; Figure 4.S4). Furthermore, 
qRT-PCR analysis of ES cells shows an increase in Tet3 expression as they differentiate into NPCs 
(Figure 4.S5). The observed changes in gene expression of the TET proteins and the observed increase 
in 5hmC in maturing MNs (Figure 4.9) prompted us to hypothesize that the Tet family plays a role in MN 
differentiation and maturation. To determine whether the Tet family members are necessary for MN cell-
type specification and maturation, we created Tet1, Tet2, and Tet3 single knockout, Tet1/Tet2 double 
knockout (DKO), and Tet1/Tet2/Tet3 triple knockout (TKO) Hb9-puro ES cells using the CRISPR/Cas9 
genome engineering system (Figure 4.S6). Similar to wildtype cells, all knockout cell lines formed EBs 
and NPCs when ES cells were induced to differentiate with retinoic acid and sonic hedgehog agonist 
(data not shown). Tet1, Tet2, and Tet3 single knockout NPCs developed into normal MNs and showed 
normal gains of 5hmC by D4 (Figure 4.10). Interestingly, single knockout MNs, unlike wildtype MNs 
showed the presence of 5hmC at D0 as well (Figure 4.10). Immunocytochemistry staining showed a 
dramatic reduction in MN differentiation in DKO cells compared to wildtype cells but showed normal gains 
of 5hmC in the viable MNs that formed (Figure 4.11). TKO cells showed an almost complete inability to 
differentiate into MNs; curiously, the few MNs that did differentiate and mature showed strong 5hmC 
staining (Figure 4.11).  
 Differentiation experiments with single knockout ES cells suggest all three TET proteins can 
convert 5mC to 5hmC and play redundant roles in MN maturation. The presence of viable Tet1/Tet2 DKO 
MNs suggests Tet3 is sufficient for MN differentiation and can compensate for the lack of TET1 and TET2 
protein, which is consistent with experiments showing that Tet1/Tet2 DKO ES cells form viable and 
grossly normal mice (Dawlaty et al. 2013). The significant reduction in differentiation potential of 
Tet1/Tet2/Tet3 knockout NPCs suggests the TET proteins are necessary for normal differentiation. A few 
TKO MNs, however, did successfully differentiate and mature. These TKO MNs seem morphologically 
normal and show strong 5hmC staining. The presence of 5hmC in MNs that completely lack any Tet 
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machinery suggests the TET proteins are not necessary for MN maturation and that an as of unknown 
protein can mediate the hydroxymethylation of cytosine. 
  
DISCUSSION 
 In this study, we show that MNs undergo significant epigenetic and gene expression changes as 
they mature. We leverage an Hb9-puro cell line to culture pure populations of spinal MNs and leverage 
the LCM-RRBS method to interrogate genome-wide DNA methylation of the limited genomic material. We 
find that MN maturation is characterized by a loss of cytosine methylation (5mC) and a gain of cytosine 
hydroxymethylation (5hmC) although gains of cytosine methylation are also observed. We find that the 
majority of methylation loss results in an increase in expression of the nearest gene. Interestingly, 
methylation and expression changes did not always co-occur. Indeed, we find CpGs that require four 
days to become fully demethylated but the CpG’s nearest gene is significantly activated within one or two 
days after differentiation. For example, methylation loss of a CpG near the App gene occurs 2-4 days 
after differentiation yet App expression significantly increases within one day of differentiation (Figure 
4.S7). In most cases, however, CpG methylation correlates well with expression change (Table 4.S3). For 
example, CpGs associated with Ret, on the other hand, show a loss of DNA methylation at Day 2 with a 
concomitant increase in Ret expression (Figure 4.S7). The difference in transcriptional timing and loss of 
DNA methylation suggests other epigenetics factors could be regulating the activation of MN-specific 
transcriptional profiles.  
 Combinatorial TF expression defines a cell’s identify. Isl1, Lhx3, and Hb9 expression characterize 
spinal MNs while Isl1, Phox2a, and Tbx20 expression characterize branchiomotor and visceromotor 
(cranial) neurons (Mazzoni et al. 2013). Interestingly, motif scanning of hypomethylated regions revealed 
the enrichment of putative binding motifs for both spinal (Isl1 and Lhx3) and cranial (Phox2a and Tbx20) 
MN TFs (Table 4.4). Mazzoni et al. showed that Isl1 directly interacts with Lhx3 and Phox2a in a cell-type 
dependent manner, which may explain the enrichment for Phox2a binding motifs. We predict that known 
Isl1-Phox2a binding sites of cranial MNs show an enrichment for hypomethylated regions relative to 
NPCs in cranial MNs. Furthermore, the hypomethylated regions we have identified may also be important 
for proper differentiation and maturation of cranial motor neurons. 
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 We also evaluated the presence of genome-wide cytosine hydroxymethylation (5hmC) in 
maturing MN cultures by immunocytochemistry. We find that MNs have very little 5hmC 24 hours after 
differentiation (Day 0) but gain genome-wide 5hmC within two days of maturation (Figure 4.9). Whole-
genome 5hmC mapping techniques will elucidate where in the genome the 5hmC increases as MNs 
mature and whether the gain of 5hmC correlates with gene expression as is suggested by recent studies 
(Jin et al. 2011; Tan et al. 2013). Hb9 expression peaks during NPC differentiation 4 days after EBs are 
induced with retinoic acid/Shh agonist and marks post-mitotic cells (Li et al. 2008b). Hb9-expressing 
NPCs, therefore, do not undergo any cell division during puromycin selection or maturation. Surprisingly, 
despite seeing no 5hmC in NPCs (Tan et al. 2013) or D0 MNs (Figure 4.9), we observe active 
demethylation at over 23,000 CpGs between NPCs and D0 MNs (data not shown), suggesting the active 
loss of methylation from NPCs to D0 MNs does not occur through the Tet pathway. Because NPCs 
consist of heterogeneous cells expressing different neuronal markers, DNA methylation analysis of Hb9+ 
FACS-enriched NPCs along with genome mapping of 5hmC in Hb9+ NPCs and D0 MNs would validate 
whether the aforementioned hypomethylated events are due to active demethylation mediated by the Tet 
machinery or due to other active demethylating pathways. 
 Finally, we show that Tet1, Tet2, and Tet3 play redundant, compensatory roles in MN 
differentiation and maturation, which is consistent with single knockout mice studies (Dawlaty et al. 2011). 
Expression analysis shows an increase in Tet2 and Tet3 expression between NPCs and D0 MNs (Figure 
4.S4) as well as high expression of Tet3 in whole mouse spinal cords (Figure 4.S5) suggesting Tet2 and 
Tet3 are important for MN function. We find that single knockout ES cells can be induced to differentiate 
into normal MNs that show normal 5hmC gains demonstrating that no single Tet is required for MN 
differentiation and maturation. Furthermore, we find that Tet1/Tet2 double knockout cells also differentiate 
into MNs, albeit less efficiently than wildtype cells, and show normal 5hmC gains, demonstrating that Tet3 
is sufficient for MN differentiation and maturation. Tet1/Tet2/Tet3 triple knockout cells show a striking 
reduction in ability to differentiate but are able to form mature MNs, demonstrating that the presence of 
Tet is necessary for normal differentiation of MNs. Significant validation of the lack of Tet protein as well 
as quantification of morphology, differentiation, and 5hmC levels is necessary to support the experiments 
herein. Tet1/Tet3 and Tet2/Tet3 double knockout studies along with DNA methylation analysis of all 
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knockouts will further elucidate the overlapping role and genome specificity of each of the Tet proteins in 
MN maturation. 
 
Model for active DNA methylation and gene activation in motor neuron differentiation 
 Our findings support a model where neuron-specific transcription factors recruit the Tet 
machinery to actively demethylate enhancer regions and activate genes critical to normal MN function 
(Figure 4.12). In this model, Isl1 binding sites at distal regulatory regions are methylated in NPCs (1). 
Upon NPC differentiation into MNs, Isl1 expression increases, binds at these regions, and recruits the Tet 
demethylases and other factors to remove DNA methylation (2). Upon demethylation by Tet, MN-specific 
target genes (e.g. Ret) are activated (3). Co-immunoprecipitation experiments of Isl1 and Tet will directly 
test whether they interact and form a DNA-binding complex. 
 In conclusion, we present the first known evidence of active demethylation in maturing spinal 
MNs and report the derivation of Tet1, Tet2, and Tet2 single, Tet1/Tet2 double, and Tet1/Tet2/Tet3 triple 
ES knockouts that can be differentiated and selected to create pure MN cultures. We show that all 
knockouts are able to form morphologically mature MNs and that the double and triple knockout lines 
have a significantly reduced ability to differentiate into MNs. The DNA methylation (5mC and 5hmC) and 
gene expression data from this study will inform future experiments to help elucidate the role of cytosine 
methylation in MN differentiation, maturation, and viability. Furthermore, the knockout embryonic stem cell 
lines derived in this study will facilitate research on dissecting the role of Tet family members in the 
differentiation of many other cell types as well as their roles in MN maturation.  
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MATERIALS AND METHODS 
 
Embryonic stem cell cultures 
 Mouse ES cells were cultured on gelatin-coated T75 flasks in complete media consisting of 
Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies, Carlsbad, CA) containing 10% newborn 
calf serum (Life Technologies), 10% fetal bovine serum (Life Technologies), and 30 µM of each of the 
following nucleosides (Sigma): adenosine, cytosine, guanosine, and uridine. For routine culture, ES cells 
were passaged every two days. Briefly, ES cells were washed with DMEM containing 25 mM HEPES 
(Life Technologies) and dissociated with 0.25% trypsin-EDTA (Life Technologies) for 5 min. Trypsin was 
quenched with fresh complete media and cells were transferred to a new gelatin-coated flask at a 1:5 
ratio in fresh complete media containing 1000 U/mL leukemia inhibitory factor (LIF; Millipore, Bellerica, 
MA) and 100 µM β-mercaptoethanol (BME; Life Technologies). All cells were cultured at 37°C in the 
presence of 5% CO2. 
 
Derivation of Tet1, Tet2, Tet3 knockout Hb9-puro embryonic stem cells 
 Plasmids containing the Cas9 open reading frame or a guide RNA (gRNA) targeting Tet1, Tet2, 
or Tet3 were obtained from the Genome Editing Core at Washington University in St. Louis. Hb9-puro 
mouse ES cells were transfected with 0.5 µg of pPB_donor plasmid (which contains a neomycin and 
dsRed construct), 1 µg Cas9 plasmid, and 1 µg of gRNA plasmid directed at Tet1, Tet2, and/or Tet3 
depending on the intended line using lipofectamine 2000 (Life Technologies) one day after passaging to a 
6-well gelatinized plate. One day after transfection, cells were trypsinized and 10% of cells transferred to 
a 10 cm gelatinized dish. After incubating for one day, the neomycin analog, G-418, was added at a 
concentration of 1-0.5 mg/ml. Two days later, media was replaced with fresh complete media containing 
0.5 mg/ml and cultures left to expand for an additional 6 days. Following a media change, individual 
colonies were expanded in individual wells of a gelatinized, 96-well, flat-bottom plate and screening by 
PCR and Illumina sequencing for insertions or deletions in the target position. Putative knockout lines 
were expanded and validated using Sanger sequencing.  
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Motor neuron differentiation 
 Transgenic ES cells were differentiated into MNs using a 2-/4+ RA and smoothened agonist (SAG, 
Millipore) induction protocol as previously described (McCreedy et al. 2012). Approximately 1 x 106 ES 
cells were cultured in suspension on 150 mm petri dishes in modified DFK5 media consisting of 
DMEM/F12 base media (Life Technologies) containing 5% knockout serum replacement (Life 
Technologies), 1x insulin transferrin selenium (ITS; Life Technologies), 50 µM nonessential amino acids 
(Life Technologies), 100 µM β-mercaptoethanol, 5 µM thymidine, and 15 µM of the following nucleosides: 
adenosine, cytosine, guanosine, and uridine. During this process, ES cells aggregate into multi-cellular 
EBs. After the first two days (2-), the EBs were moved to a 15 mL conical and allowed to settle for 5 min. 
The media was aspirated and replaced with 10 mL fresh DFK5 containing 2 µM RA and 600 nM 
Smoothen agonist (SAG). EBs were then cultured for an additional 4 days (4+) with media replaced every 
2 days. 
 
Motor neuron maturation 
 After 2-/4+ RA and SAG induction, cell were dissociated in 0.25% Trypsin-EDTA for 15 minutes 
and quenched with complete media. Dissociated cells were counted and centrifuged at 240 x g for 5 
minutes. Cells were resuspended in DFK5 media containing 5 ng/mL glial-derived neurotrophic factor 
(GDNF; Peprotech, Rocky Hill, NJ), 5 ng/mL brain derived neurotrophic factor (BDNF; Peprotech, Rocky 
Hill, NJ), 5 ng/mL neurotrophin-3 (NT-3; Peprotech, Rocky Hill, NJ), 4 µg/mL puromycin in water (Sigma) 
and plated at ~6 x 104 cells/cm2 in individual wells of a poly-ornithine-coated (Sigma) 6-well plate for 24 
hours. In parallel, for control cultures not receiving puromycin, cells were resuspended in DFK5 media 
with the growth factor cocktail and plated at ~6 x 104 cells/cm2 in individual wells of a poly-ornithine-coated 
coated 6-well plate for 24 hours. Following selection, cells were fixed for immunofluorescence or media 
was replaced with modified DFKNB media consisting of DFK5 and Neurobasal (NB) media (Life 
Technologies) mixed at a 1:1 ratio and supplemented with 1x B27, 5 ng/mL GDNF, 5 ng/mL BDNF, and 5 
ng/mL NT-3. Cells were cultured in DFKNB media for up to 4 additional days. 
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Immunohistochemistry 
 Cells were fixed in 4% (w/v) paraformaldehyde (Sigma) in phosphate buffered saline (PBS) for 15 
minutes at room temperature. Fixed cultures were washed once with PBS and permeabilized with 0.2% 
triton-X in PBS for 10 minutes. Cultures were then blocked for 1 hour at room temperature with 5% 
normal goat serum (NGS; Sigma) in PBS. Primary antibodies were added to blocked cultures overnight at 
4°C at the following dilutions in 2% NGS in PBS: class III β-tubulin (Tuj1, 1:5000, Covance) or 5-
hydroxymethylation (5hmC, 1:250, Active Motif). Primary antibodies were labeled with the appropriate 
AlexaFluor conjugated goat antibodies (Life Technologies) at a 1:1000 dilution in PBS for 1 hours. All 
wells were counterstained with DAPI (1:10000; Sigma) to label cell nuclei. Following 
immunofluorescence, phase contrast and fluorescent images were captured. 
 
Quantification of motor neuron neurite formation 
 Five biological replicates of D0, D2, and D4 wildtype MNs were fixed and stained with class III β-
tubulin as described above (see “Immunohistochemistry). For each time point, 60 images with a ~1/3 
overlap at 10x magnification were taken and combined into one image using the photomerge tool in 
Adobe Photoshop. Each sample image was then cropped to form images of equal size. Cropped images 
were uploaded to the WimNuerite (Wimasis) software for neurite morphology quantification. Student’s t 
test was applied to determine statistical significance. 
 
Electrophysiology 
 D0, D2, D4, and D6 MN cultures were bath perfused with Tyrode’s solution (in mM): 150 NaCl, 4 
KCl, 2 MgCl2, 2 CaCl2, 10 glucose, 10 HEPES, pH adjusted to 7.4 with NaOH. Whole-cell electrodes 
pulled from borosilicate glass capillaries had an open tip resistance of 2 to 5 MOhm when filled with one 
of the following internal solutions (in mM): (1) 140 K-glucuronate, 10 NaCl, 5 MgCl2, 0.2 EGTA, 5 Na-ATP, 
1 Na-GTP, 10 HEPES, pH adjusted to 7.4 with KOH; or (2) 140 Cs-glucuronate, 5 CsCl, 5 MgCl2, 10 
EGTA, 5 Na-ATP, 1 Na-GTP, 10 HEPES, pH adjusted to 7.4 with CsOH. Current and voltage were 
recorded with an Axopatch 200A amplifier, filtered at 1 kHz, digitized at 10 kHz and analyzed off-line with 
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Clampfit software (pClamp 9.2). Ligand-gated channel agonists were dissolved in 160 NaCl, 10 HEPES, 
2 CaCl2 and applied by local perfusion (Kim et al. 2009). 
 
DNA extraction 
 Selected cultures contain viable MNs as well as dead cells adhering to the well which can 
confound DNA methylation analysis. To degrade non-MN DNA, cells were treated with cell-impermeable 
DNase as follows: cells were washed three times with PBS to remove dead cells, 160 µl of DNase 
(10mg/ml; Sigma) in 1 ml of DFK5 and 10mM MgCl2 were added to each well and incubated for 2 hours 
at 37°C, then stained with DAPI or Hoechst to verify complete degradation of non-MN DNA. Cells were 
then washed three times with PBS and scraped off with a rubber scraper and transferred to a 1.5 ml 
Eppendorf tube. Collected cells were spun at 16000 rpm for 10 minutes and the supernatant removed 
with a pipet. DNA samples were purified using NucleoSpin Tissue XS columns (Clontech) following the 
protocol for cultured cells and eluted in 20 µl of nuclease-free water. Genomic DNA was quantified using 
the Quant-it dsDNA High Sensitivity kit (Invitrogen) and the Qubit fluorometer (Invitrogen). 
 
LCM-RRBS 
 LCM-RRBS was performed on three biological replicates of D0, D2, and D4 MNs as described 
previously (Schillebeeckx et al. 2013). Briefly, 10 ng of DNA from each of the nine samples was digested 
with MspI (NEB), end-repaired, and ligated with pre-annealed methylated paired-end Illumina adapters. 
Adapter-ligated fragments were purified using MinElute columns (Qiagen) and bisulfite treated using the 
EZ DNA Methylation Gold Kit (Zymo). Each sample was PCR amplified in triplicate using sample-specific 
indexed primers using Platinum Taq Polymerase (Invitrogen) and 10 melting-annealing-extension cycles. 
All PCR products and replicates were pooled and analyzed by electrophoresis on a 3% 1X Tris-acetate-
EDTA (TAE) NuSieve agarose gel (Lonza). Fragments between 150 bp and 350 bp were gel extracted 
and purified using MinElute columns (Qiagen). To minimize PCR bias, the final PCR library was amplified 
in quadruplicate using 11 PCR cycles. The four replicates are pooled and gel extracted to remove 
remaining adapter dimers and primers, then purified, and sequenced on Illumina HiSeq 2000 machines.  
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Sequence alignment and methylation calling 
 All analysis was performed using the July 2007 (NCBI37/mm9) build of the mouse genome. On 
average 25 million single-end 42-bp raw high quality reads per sample were aligned to the reduced 
reference using RRBSMAP (Xi et al. 2012) filtering against reads that contain adapter sequence. Reads 
that showed less than 90% bisulfite conversion (~1 unconverted non-CpG cytosine per read) were filtered 
to remove those that resulted from incomplete bisulfite converted molecules. Aligned reads with a 
mapping quality of zero were also discarded. The resulting high quality uniquely mapped reads were used 
for methylation calling. We identified the genomic coordinates of all CpGs in the reference sequence and 
assessed percent DNA methylation by calculating the fraction of reads that had an unconverted cytosine 
at the CpG position relative to the total reads. We required that each read have either a “TG” or “CG” 
dinucleotide at the expected CpG coordinate to be considered for analysis. Differentially methylated 
CpGs were determined using a Fisher’s Exact Test comparing the ratio of methylated versus 
unmethylated read for each sample. CpGs were considered hypomethylated or hypermethylated if they 
showed a statistically significant decrease or increase of at least 25% between D0 and D4 MNs, 
respectively. 
 
Microarray expression profiling 
 RNA was extracted from 2-/4+ RA and SAG induced embryonic stem cells (neural progenitor 
cells), D0 MNs, D2 MNs, and D4 MNs using the QIAGEN RNeasy kit. Briefly, cells were resuspended in 
lysis buffer RLT (cat no. 79216, QIAGEN) and β-mercaptoethanol, and then disrupted and lysed using a 
QIAshredder column (cat no. 79656, QIAGEN). RNA was extracted using a QIAGEN RNeasy Mini kit (cat 
no. 74104, QIAGEN) with on-column DNase treatment (cat no. 79254, QIAGEN). Approximately 2 mg of 
total RNA per sample was used to prepare cDNA using SuperScript® III, First-strand Synthesis system 
(cat no. 18080-051, Invitrogen). Array hybridization was performed by the GTAC Microarray Core facility 
at Washington University. Briefly, 50ng of total RNA was used to generate biotinylated cDNA, according 
to the standard NuGen WT-Ovation Pico RNA Amplification kit. Following fragmentation with NuGen 
Encore Biotin Module, 2.5 ug of cDNA were hybridized onto Mouse Gene 1.0 ST Arrays (Affymetrix) in 
the GeneChip Hybridization Oven 640 for 18 hr at 45°C. GeneChips were then washed and stained in the 
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Affymetrix Fluidics Station 450 and were scanned using the Affymetrix GeneChip 7G 3000 Scanner. The 
scanned raw .CEL files were analyzed to export signal intensity values, using Affymetrix Expression 
Console software with Affymetrix default RMA Gene analysis settings. Probe summarization (Robust 
Multichip Analysis, RMA), quality control analysis, and probe annotation were performed according to 
recommended guidelines (Expression Console Software, Affymetrix). We determined statistical 
significance using the Student’s t test and corrected for multiple hypothesis testing using the Benjamini & 
Hochberg’s method, leaving a total of 252 probes (q-value < 0.05). Statistically significant upregulated 
and downregulated probes correspond to 142 and 50 genes, respectively (Table 4.S2).  
 
Motif scanning analysis 
 Differentially methylated regions were defined as 200 bp genomic windows flanking a 
hypomethylated or hypermethylated CpG. If the CpGs were in a cluster separated by less than  
200 bp, then the window was defined to be 100 bp upstream of the first CpG and 100 bp downstream of 
the second CpG. Motif scanning was performed on hypomethylated and hypermethylated regions 
independently by using the Hypergeometric Optimization of Motif EnRichment (HOMER) suite of tools 
HOMER to identify enrichment of known TFs (Heinz et al. 2010). Only motifs with q-values < 0.01 
(Benjamini-Hochberg corrected) were considered enriched. We found 92 and 9 sequence motifs enriched 
in hypomethylated and hypermethylated regions, respectively, which were used for gene ontology (GO) 
enrichment analysis using HOMER tools. GO terms associated with biological processes were Bonferonni 
corrected for multiple hypotheses, filtered to remove those with a corrected p-value > 0.01, and ranked 
according to fold enrichment leaving 149 GO terms. Biological processes associated with neuronal 
function are listed in Table 4.4. 
 
Quantitative Reverse Transcription Polymerase Chain Reaction 
 Tet1, Tet2, and Tet3 expression of Hb9-puro embryonic stem cells, embryoid bodies, 2-/2+ 
embryoid bodies, and neural progenitor cells was determined by qRT-PCR using pre-validated TaqMan 
probes (Life Technologies) (Figure 4.S5). RNA was extracted following the protocol mentioned above and 
1.5 ml of cDNA was used to run Taq-Man qPCR reactions, using TaqMan® Universal Master Mix II, 
94 
without UNG (cat no. 4440043, Life Technologies), plus commercially available TaqMan primers to Tet1 
(Mm01169087_m1), Tet2 (Mm00524395_m1) and Tet3 (Mm00805756_m1) genes. All data were 
normalized to the endogenous control 18S ribosomal RNA (Rn18S, Mm03928990_g1) (Life 
Technologies) and quantitative measurements determined using the ΔΔCΤ approach. 
 
DNA Methylation Datasets 
 Embryonic stem cell, neuronal progenitor cell, and astrocyte processed DNA methylation calls 
were downloaded from NCBI Gene Expression Omnibus repository under accession numbers GSE30206 
and GSE11034 (Meissner et al. 2008; Stadler et al. 2011). 
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FIGURE 4.1 
 
 
Figure 4.1 Schematic of in vitro differentiation protocol for creating pure motor neuron 
populations. Embryonic stem cells are differentiated into embryoid bodies (EBs) in DFK5 media for two 
days and further induced down the neural lineage with retinoic acid and sonic hedgehog agonist for four 
days to form cell aggregates that express neural progenitor markers Olig2 and Hb9/MNR2. Neural 
progenitor cells (NPCs) are dissociated and plated on poly-ornithine plates in DFK5 media containing 
puromycin and neurotrophic factors. Twenty-four hours after selection (Day 0), media is replaced and 
cells cultured for four days (Day 4). Gray boxes represents one day. See Materials and Methods for 
additional culturing details. 
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FIGURE 4.2 
 
Figure 4.2 Immunocytochemistry of motor neurons after puromycin selection. Cultures were fixed 
with paraformaldehyde and stained with class III β-tubulin (β-tubIII, recognized by Tuj1 antibody) at 24 
hours (Day 0), two days (Day 2), or four days (Day 4) after puromycin selection to visualize neurite 
growth.  
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FIGURE 4.3 
 
Figure 4.3 Quantification of the morphological features of motor neurons over time. Motor neurons 
exhibit the growth of processes from Day 0 to Day 4 as quantified by total networks (top left), cell area 
(top right), number of neurite branching points (middle left), total length of neurites (middle right), and 
number of total neurites (bottom). Each time point represents the average of five biological replicates. 
Error bars show the standard error of the mean. * p-value < 0.05; ** p-value <0.01; ****p-value <0.001. 
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FIGURE 4.4 
 
Figure 4.4 Quantification of electrophysiological features of motor neurons over time. (Top row) 
Whole-cell current density (pA/pF) was recorded of D0, D2, D4, and D6 motorneurons in response to 
agonists for specific ligand-gate ion channels; K: AMPA/kainate, N: NMDA, Gly: glycine, and Gaba: 
GABA receptors. (Bottom row) Left panel shows whole-cell capacitance (pF) of motor neurons at D0, D2, 
D4, and D6 post-selection and the right panel shows whole-cell input resistance across D0, D2, D4, and 
D6 time points. 
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FIGURE 4.5 
 
Figure 4.5 Motor neurons gain and lose DNA methylation with time. DNA methylation changes 
between D0 and D4 motorneurons was assessed using a Fisher’s Exact Test. (Left panel) Dot plot of the 
inverse log2 p-value as a function of percent methylation difference between D0 and D4 motor neurons. 
CpGs passing Bonferonni multiple-hypothesis corrections with a percent methylation change of less than 
-25 or greater than 25 were considered as hypomethylated (blue) and hypermethylated (yellow), 
respectively. Horizontal dotted line represents the Bonferonni corrected p-value cutoff and the vertical 
dotted lines show a -25 and 25 percent methylation difference cutoff. (Right panel) Unsupervised 
hierarchical clustering heatmap of percent methylation for the 2,896 hypomethylated and the 1,153 
hypermethylated CpGs in D0, D2, and D4 motor neurons. Each row represents an individual CpG. Yellow 
denotes high (e.g. 100) percent methylation levels and blue denotes low (e.g. 0) percent methylation 
levels at a particular time point. 
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TABLE 4.1 
GO	  Term Description P-­‐value FDR	  q-­‐value Enrichment 
GO:0097485 neuron	  projection	  guidance 5.77E-­‐10 2.58E-­‐07 3.05 
GO:0007411 axon	  guidance 5.77E-­‐10 2.49E-­‐07 3.05 
GO:0001525 angiogenesis 1.06E-­‐08 2.73E-­‐06 2.54 
GO:0010975 regulation	  of	  neuron	  projection	  development 3.18E-­‐08 7.88E-­‐06 2.27 
GO:0045664 regulation	  of	  neuron	  differentiation 1.04E-­‐10 5.78E-­‐08 2.2 
GO:0051960 regulation	  of	  nervous	  system	  development 7.45E-­‐13 9.64E-­‐10 2.13 
GO:0016477 cell	  migration 2.62E-­‐11 1.91E-­‐08 2.13 
GO:0031344 regulation	  of	  cell	  projection	  organization 3.70E-­‐08 8.61E-­‐06 2.13 
GO:0050767 regulation	  of	  neurogenesis 1.77E-­‐11 1.47E-­‐08 2.12 
GO:0051270 regulation	  of	  cellular	  component	  movement 8.85E-­‐11 5.15E-­‐08 2.09 
GO:0048598 embryonic	  morphogenesis 5.28E-­‐11 2.56E-­‐08 2.75 
GO:0007389 pattern	  specification	  process 2.16E-­‐08 4.57E-­‐06 2.5 
GO:0048731 system	  development 4.49E-­‐11 2.28E-­‐08 2.37 
GO:0045597 positive	  regulation	  of	  cell	  differentiation 5.12E-­‐09 1.32E-­‐06 2.27 
GO:0051960 regulation	  of	  nervous	  system	  development 7.15E-­‐09 1.66E-­‐06 2.25 
GO:0007275 multicellular	  organismal	  development 2.56E-­‐14 9.94E-­‐11 2.24 
GO:0051094 positive	  regulation	  of	  developmental	  process 1.04E-­‐10 4.64E-­‐08 2.17 
GO:0000122 
negative	  regulation	  of	  transcription	  from	  RNA	  polymerase	  II	  
promoter 5.45E-­‐08 9.91E-­‐06 2.17 
GO:0060284 regulation	  of	  cell	  development 5.27E-­‐08 9.74E-­‐06 2.09 
GO:0045892 negative	  regulation	  of	  transcription,	  DNA-­‐dependent 1.78E-­‐09 5.30E-­‐07 2.04 
 
Table 4.1 Gene Ontology (GO) enrichment analysis of the genes nearest to differentially 
methylated CpGs. GO term p-values were adjusted for multiple hypothesis (FDR<5%) and ranked 
according to enrichment. The top ten GO terms of genes associated with hypomethylated (upper) and 
hypermethylated CpGs (lower) are shown. 
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FIGURE 4.6 
 
Figure 4.6 CpGs hypomethylated in motorneurons are hypermethylated in NPCs and astrocytes. 
Unsupervised hierarchical clustering of the methylation status of hypomethylated CpGs in NPCs, D0 
motor neurons, D2 motor neurons, D4 motor neurons, and astrocytes. The heatmap shows that 87% and 
82% of hypomethylated CpGs are highly methylated (>=75%) in NPCs and astrocytes, respectively. The 
colored bar in the lower portion represents the expected result for motor neuron-specific methylation loss. 
Each row of the heatmap represents an individual CpG. Yellow denotes high (e.g. 100) percent 
methylation levels and blue denotes low (e.g. 0) percent methylation levels. 
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FIGURE 4.7 
 
 
FIGURE 4.7 Gene expression profiling of neural progenitors and motor neurons. Microarray 
hybridization was performed on RNA isolated from neural progenitor cells (NPC), day 0 motor neurons 
(D0), day 2 motor neurons (D2), and day 4 motor neurons (D4). Genes differentially expressed between 
D0 and D4 motor neurons were identified using Student’s t test and corrected for multiple hypothesis 
using Benjamini & Hochberg’s (FDR) method. (Left panel) Dot plot of the inverse log2 p-value as a 
function of the log2 ratio of D0 and D4 expression. Red dots represent statistically significant upregulated 
probes and green dots represent statistically significant downregulated probes. Horizontal dotted line 
represents the multiple hypothesis corrected significant cutoff (q-value<0.05). (Right panel) Unsupervised 
hierarchical clustering heatmap of all probes differentially expressed between D0 and D4 motor neurons. 
Red and green indicate low and high expression levels, respectively. (A.U.) Arbitrary Units. Each sample 
represents the average of three biological replicates. 
  
103 
TABLE 4.2 
GO	  Term Description P-­‐value FDR	  q-­‐value Enrichment 
GO:0035235 ionotropic	  glutamate	  receptor	  signaling	  pathway 5.07E-­‐06 4.91E-­‐03 33.82 
GO:0035249 synaptic	  transmission,	  glutamatergic 1.71E-­‐05 1.04E-­‐02 25.37 
GO:0007215 glutamate	  receptor	  signaling	  pathway 5.55E-­‐05 2.80E-­‐02 19.02 
GO:0051966 regulation	  of	  synaptic	  transmission,	  glutamatergic 7.09E-­‐05 3.05E-­‐02 17.90 
GO:0007270 neuron-­‐neuron	  synaptic	  transmission 1.00E-­‐05 7.28E-­‐03 17.29 
GO:0050905 neuromuscular	  process 1.35E-­‐05 8.69E-­‐03 11.56 
GO:0007268 synaptic	  transmission 8.73E-­‐10 1.01E-­‐05 11.14 
GO:0007267 cell-­‐cell	  signaling 1.65E-­‐08 6.41E-­‐05 7.64 
GO:0044700 single	  organism	  signaling 7.35E-­‐08 2.14E-­‐04 6.73 
GO:0023052 signaling 7.35E-­‐08 1.71E-­‐04 6.73 
GO:0034645 negative	  regulation	  of	  muscle	  cell	  apoptotic	  process 2.24E-­‐05 4.34E-­‐02 54.17 
GO:0009059 cellular	  macromolecule	  biosynthetic	  process 3.02E-­‐06 3.51E-­‐02 3.43 
GO:0044249 macromolecule	  biosynthetic	  process 3.93E-­‐06 2.28E-­‐02 3.36 
GO:1901576 cellular	  biosynthetic	  process 7.35E-­‐06 2.85E-­‐02 2.91 
GO:0009058 organic	  substance	  biosynthetic	  process 1.09E-­‐05 3.17E-­‐02 2.83 
GO:0010656 biosynthetic	  process 1.51E-­‐05 3.52E-­‐02 2.77 
 
Table 4.2 Gene Ontology enrichment of biological processes for genes differentially expressed 
between D0 and D4 motorneurons. GO term p-values were adjusted for multiple hypotheses (FDR<5%) 
and ranked according to enrichment. All GO categories that pass multiple hypothesis corrections are 
shown for upregulated (top) and downregulated (bottom) genes. 
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TABLE 4.3 
GO	  Term Description P-­‐value FDR	  q-­‐value Enrichment 
GO:0005219 ryanodine-­‐sensitive	  calcium-­‐release	  channel	  activity 4.28E-­‐05 7.62E-­‐03 152.19 
GO:0048763 calcium-­‐induced	  calcium	  release	  activity 1.28E-­‐04 2.09E-­‐02 101.46 
GO:0004971 alpha-­‐amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazole	  propionate	  
glutamate	  receptor	  activity 
2.55E-­‐04 3.69E-­‐02 76.1 
GO:0005234 extracellular-­‐glutamate-­‐gated	  ion	  channel	  activity 1.69E-­‐06 4.41E-­‐04 43.48 
GO:0004970 ionotropic	  glutamate	  receptor	  activity 2.30E-­‐06 5.61E-­‐04 40.58 
GO:0008066 glutamate	  receptor	  activity 9.77E-­‐06 2.25E-­‐03 28.99 
GO:0004890 GABA-­‐A	  receptor	  activity 2.10E-­‐04 3.29E-­‐02 25.37 
GO:0016917 GABA	  receptor	  activity 3.38E-­‐04 4.72E-­‐02 21.74 
GO:0005230 extracellular	  ligand-­‐gated	  ion	  channel	  activity 2.05E-­‐07 6.16E-­‐05 16.65 
GO:0005231 excitatory	  extracellular	  ligand-­‐gated	  ion	  channel	  activity 2.15E-­‐04 3.24E-­‐02 13.53 
 
Table 4.3 Gene Ontology enrichment analysis of functional categories for genes upregulated 
between D0 and D4 motorneurons. GO term p-values were adjusted for multiple hypotheses (FDR<5%) 
and ranked according to enrichment. The top ten GO terms of upregulated genes are shown. 
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FIGURE 4.8 
 
 
Figure 4.8 Differentially methylated CpGs are associated with differentially expressed genes. For 
all differentially methylated CpGs, the expression level of the nearest gene was compared between D0 
and D4 motorneurons. The plot shows the expression change relative to the difference in DNA 
methylation between D0 and D4 motorneurons. Red dots represent upregulated genes and green dots 
represent downregulated genes (p-value<0.05, Student’s t test).  
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TABLE 4.4 
GO	  Term	   Description	   Genes	   P-­‐value	   FDR	  q-­‐value	   Enrichment	   Rank	  
GO:48665	   neuron	  fate	  specification	   Isl1,	  Lhx3,	  Atoh1,	  Foxa2	   2.08E-­‐07	   2.52E-­‐03	   76.37	   6	  
GO:21522	  
spinal	  cord	  motor	  neuron	  
differentiation	   Isl1,	  Phox2a,	  Lhx3,	  Tbx20	   4.61E-­‐07	   5.58E-­‐03	   63.01	   7	  
GO:21517	   ventral	  spinal	  cord	  development	   Isl1,	  Phox2a,	  Lhx3,	  Tbx20	   7.48E-­‐07	   9.04E-­‐03	   56.01	   10	  
GO:48663	   neuron	  fate	  commitment	   Isl1,	  Smad4,	  Lhx3,	  Atoh1,	  Pax7,	  Foxa2	   1.01E-­‐09	   1.22E-­‐05	   55.59	   11	  
GO:21515	   cell	  differentiation	  in	  spinal	  cord	   Isl1,	  Phox2a,	  Lhx3,	  Pax7,	  Tbx20	   2.90E-­‐08	   3.50E-­‐04	   55.27	   12	  
GO:21510	   spinal	  cord	  development	   Isl1,	  Phox2a,	  Lhx3,	  Pbx3,	  Pax7,	  Tbx20	   2.53E-­‐09	   3.06E-­‐05	   47.85	   13	  
GO:30182	   neuron	  differentiation	   Isl1,	  Phox2a,	  Smad4,	  Pbx3,	  Stat3,	  
Pax7,	  Mef2c,	  Tbx20,	  Foxa2,	  Lhx2,	  
Lhx3,	  Atoh1	  
5.96E-­‐10	   7.21E-­‐06	   10.33	   62	  
GO:48699	   generation	  of	  neurons	   Isl1,	  Phox2a,	  Smad4,	  Pbx3,	  Atf1,	  
Stat3,	  Pax7,	  Mef2c,	  Tbx20,	  Foxa2,	  
Lhx2,	  Tcf3,	  Lhx3,	  Atoh1	  
3.81E-­‐10	   4.60E-­‐06	   8.04	   88	  
GO:22008	   neurogenesis	   Isl1,	  Phox2a,	  Smad4,	  Pbx3,	  Atf1,	  
Stat3,	  Pax7,	  Mef2c,	  Tbx20,	  Foxa2,	  
Lhx2,	  Tcf3,	  Lhx3,	  Atoh1	  
8.26E-­‐10	   9.99E-­‐06	   7.58	   95	  
 
Table 4.4 Gene Ontology (GO) enrichment analysis on transcription factors enriched for a 
sequence motif in hypomethylated regions. We identified 149 statistically enriched GO terms (q-
value<0.01; FDR-adjusted) associated with hypomethylated regions and ranked them according to 
enrichment fold. Table 4.4 presents those GO terms and TFs associated with neuronal function. No GO 
terms were found to be enriched for hypermethylated regions. 
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FIGURE 4.9 
 
Figure 4.9 Motor neurons gain 5-hydroxymethylation with time. Puromycin-selected cultures were 
fixed and stained with β-tubulin class III (β-tubIII) and an antibody targeting 5-hydroxymethylation (5hmC) 
at 24 hours (Day 0), two days (Day 2), or four days (Day 4) after selection to visualize neurite growth and 
the presence of 5hmC. 
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FIGURE 4.10 
 
 
Figure 4.10 Tet single knockout motor neurons show 5-hydroxymethylation. Puromycin-selected 
cultures were fixed and stained with β-tubulin class III (β-tubIII) and an antibody targeting 5-
hydroxymethylation (5hmC) at 24 hours (Day 0), two days (Day 2), or four days (Day 4) after selection to 
visualize neurite growth and the presence of 5hmC. Single knockout NPCs differentiate into normal motor 
neurons that look morphologically normal through Day 4. Single knockout lines also show normal gains in 
5hmC by Day 4. 
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FIGURE 4.11 
 
Figure 4.11 Tet double and triple knockout motor neurons show 5-hydroxymethylation. Unselected 
cultures were fixed and stained with β-tubulin class III (β-tubIII) and an antibody targeting 5-
hydroxymethylation (5hmC) at 24 hours (Day 0), two days (Day 2), or four days (Day 4) after puromycin 
selection to visualize neurite growth and the presence of 5hmC. Double knockout (DKO) and triple 
knockout (TKO) show a significantly reduced ability to differentiate into motor neurons (MNs) as 
demonstrated by the lower number of normal MNs at Day 0, Day 2, and Day 4. DKO and TKO MNs also 
show 5hmC staining by Day 4 as demonstrated by the co-staining of β-tubulin class III (white) and 5hmC 
(red). Cells not positive for β-tubulin class III, presumably glial precursors, showed significant 5hmC 
staining in wildtype, DKO, and TKO cultures as shown by the large 5hmC positive areas (red). Note that 
5hmC staining for DKO Day 0 failed.  
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FIGURE 4.12 
 
Figure 4.12 Model for active demethylation and gene activation. Our study finds motor neuron-
specific transcription factor (TF) binding sites are actively demethylated during motor neuron 
differentiation and maturation. These findings support a model in which regions that regulate motor 
neuron-specific genes (e.g. Ret) contain TFs binding sites (e.g. Isl1) that are methylated in neuron 
progenitor cells (1). During differentiation, Isl1 binds these regulatory regions and recruits the Tet 
demethylation machinery, which removes the DNA methylation (2). Upon demethylation, the target gene 
is activated (3).   
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SUPPLEMENTARY FIGURES AND TABLES 
FIGURE 4.S1 
 
 
Figure 4.S1 Genomic distribution of differentially methylated CpGs. (Top panel) Background (left), 
hypomethylated (middle), and hypermethylated (right) CpGs were classified as located in promoters, 
exons, introns, or intergenic regions. (Bottom panel) Histogram of the distance to the nearest UCSC 
defined transcription start site for background (left), hypomethylated (middle), and hypermethylated (right) 
CpGs. Background, hypomethylated, and hypermethylated CpGs are located at a mean distance of 5,740 
bp, 17,709 bp, and 14,262 bp from the nearest transcription start site (TSS), respectively.  
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FIGURE 4.S2 
 
Figure 4.S2 Hypomethylated CpGs and attendant gene expression. Unsupervised hierarchical 
clustering was performed on the methylation status of hypomethylated CpGs across NPCs, D0, D2, and 
D4 motorneurons (left). The absolute expression level of the gene nearest to the hypomethylated CpG is 
plotted across NPCs, D0, D2, and D4 motorneurons (right). Yellow denotes high (e.g. 100) percent 
methylation levels and blue denotes low (e.g. 0) percent methylation levels. Red and green indicate low 
and high expression levels, respectively. (A.U.) Arbitrary Units. Each sample represents the average of 
three biological replicates. 
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FIGURE 4.S3 
 
 
Figure 4.S3 Expression of transcription factors with enriched sequence motifs at hypomethylated 
regions. Heatmap of the absolute expression level of each transcription factor across NPC, D0, D2, and 
D4 timepoints. Rows are sorted on the ratio of NPC to D0 expression. Isl1, Pbx3, Stat3, and Smad4 show 
a statistically significant increase in expression from NPC to D0 while Foxa2, Tbx20, Tcf3, Atf1, Phox2a, 
and Lhx3 show a statistically significant decrease in expression. A.U.: arbitrary units.  
  
114 
FIGURE 4.S4 
 
 
Figure 4.S4 Absolute expression of Tet and Dnmt families across NPC, D0, D2, and D4. Expression 
levels were determined by Affymetrix Mouse Gene 1.0 ST microarray. (A.U.) Arbitrary Units. * p-
value<0.05; *** p-value<0.005 (Student’s t test).  
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FIGURE 4.S5 
 
Figure 4.S5 Wildtype expression of Tet1, Tet2, and Tet3 across various tissues. qRT-PCR analysis 
of Tet expression in wildtype embryonic stem cells (ES), embryoid bodies (EB), EBs induced with retinoic 
acid/shh agonist for two days (NPC (2-/2+)), EBs induced with retinoic acid/ssh agonist for four days 
(NPC (2-/4+)), and various tissues. Values are normalized to ES expression. (a.u.); arbitrary units. ns, not 
significant; ** p-value <0.01; *** p-value < 0.05; ****p-value <0.001.   
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FIGURE 4.S6 
 
 
 
Figure 4.S6 Sanger sequence validation of knockout alleles. A portion of the wildtype and knockout 
Tet1, Tet2, or Tet3 allele is represented for either (A) Tet1, Tet2, or Tet3 single knockouts, (B) Tet1/Tet2 
double knockout, or (C) Tet1/Tet2/Tet3 triple knockout.  
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FIGURE 4.S7 
 
 
Figure 4.S7 DNA methylation and expression of putative Isl1-regulated genes App and Ret. (Left 
panel) DNA methylation heatmap of hypomethylated CpGs associated with App (1 CpG) and Ret (3 
CpGs) were found to be enriched for the Isl1 sequence motif. All CpGs show significant loss of DNA 
methylation by D4 after differentiation and are specific to motor neurons. (Right Panel) Heatmap of App 
and Ret absolute expression across time shows App is activated upon differentiation (D0) while Ret is 
gradually activated through D2 and D4 after differentiation. Yellow denotes high (e.g. 100) percent 
methylation levels and blue denotes low (e.g. 0) percent methylation. White denotes missing data. Red 
and green indicate low and high expression levels, respectively. (A.U.) Arbitrary Units. Each sample 
represents the average of three biological replicates. 
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TABLE 4.S1 
https://cgs.wustl.edu/~maxim/Thesis/Chapter4/Table4.S1.xlsx 
Table 4.S1 List of CpGs that show a statistically significant gain or loss of DNA methylation 
between D0 and D4 motor neurons. The table contains the DNA methylation status and read coverage 
for each CpG across embryonic stem cells, neural progenitor cells, D0 motor neurons, D2 motor neurons, 
D4 motor neurons, and astrocytes as well as categorizes each CpG as changing early (from D0 to D2) or 
late (from D2 to D4). The URL address above contains a link to Table 4.S1. 
 
TABLE 4.S2 
https://cgs.wustl.edu/~maxim/Thesis/Chapter4/Table4.S2.xlsx 
Table 4.S2 List of differentially expressed probes. The table contains a tab with normalized 
expression levels of all probes (“Expression_Master”), a tab listing the probes that are differentially 
expressed between NPCs and D0 motor neurons (“NPCvD0”), a tab listing the probes that are 
differentially expressed between D0 and D4 motor neurons (“D0vD4”), a tab listing probes downregulated 
from D0 to D4 motor neurons, and a tab listing probes upregulated from D0 to D4 motor neurons. The 
URL address above contains a link to Table 4.S2. 
  
TABLE 4.S3 
https://cgs.wustl.edu/~maxim/Thesis/Chapter4/Table4.S3.xlsx 
Table 4.S3 List of CpGs that show a statistically significant gain of DNA methylation and are 
associated with genes that increase in expression and CpGs that show a statistically significant 
loss of DNA methylation and are associated with genes that decrease in expression between D0 
and D4 motorneurons. The table contains the DNA methylation status and expression of its associated 
gene of ES cells, NPCs, D0 motor neurons, D2 motor neurons, and D4 motor neurons. The URL address 
above contains a link to Table 4.S3. 
  
119 
CHAPTER 5: CONCLUDING REMARKS AND DISCUSSION 
 
 The onset of next-generation massively paralleled sequencing as a commoditized tool has 
significantly advanced our understanding of the role of DNA methylation in normal development, health, 
and disease. Before the start of this thesis, whole genome or genome-wide methylation maps were non-
existent. Researchers dissected the methylation patterns of single loci under various conditions or in 
various cell states. Currently, whole genome patterns of 5-methylcytosine (5mC) is being catalogued 
across human tissues and disease states. What’s more, within the past five years the field has 
established the importance of 5-hydroxymethylcytosine (5hmC), a novel genomic mark, in early 
development and has elucidated several mechanisms of active DNA demethylation. We now have a more 
complete understanding of the factors involved in establishing, maintaining, reading, and erasing DNA 
methylation. Several questions (among many) are still outstanding in the field. 
 
What is the informative unit of DNA methylation? 
 A question that has always been at the forefront of the DNA methylation field is whether individual 
CpGs or multiple CpGs together account for functional regulation. In other words, can each individual 
CpG inform biology or does a region have to reach a methylation threshold to effect its role in a cell? Until 
recently, Differentially Methylated Regions (DMRs) and the average methylation status of all CpGs within 
a CpG Island (CGI), were thought to be the only informative unit for transcriptional regulation. The high 
density of CpGs within 200-500 base pair CGIs alluded to a mechanism in which the absolute level of 
CpG methylation across the entire region dictated gene regulation. Furthermore, because CGIs are 
enriched at gene promoters, the natural inclination has been to ascribe the CGI unit with a regulatory 
function controlled by CpG methylation. The focus on CGIs is an unintended consequence of the 
introduction of genome sequencing and the desire to interrogate as many CpG dinucleotides as possible 
relative to experimental costs. Naturally, focusing on has CGIs allowed for a fairly comprehensive, 
genome-wide evaluation but biased the field toward interrogating promoter methylation. Covariance 
analysis of the methylation status of CpGs and their nearest neighborhoods has strengthened the notion 
that the CpGs within large genome regions have a similar methylation status. These studies have shown 
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that if a CpG is highly methylated, the probability is high that its nearest neighbor is also methylated. 
Furthermore, many studies have shown that entire CGIs can show differential methylation between 
normal cell types and that cancer, in particular, loses methylation boundaries which results in large, 
megabase blocks of hypomethylated regions. The methylation profiling of adrenocortical neoplasias 
featured in this thesis, also demonstrates that larger regions, namely CGIs, can exhibit large methylation 
changes in disease models. 
 On the other hand, many examples abound from the 1980s and 1990s showing that the 
methylation status of an individual CpG is sufficient to disrupt the binding of transcription factors or to 
recruit methyl-binding proteins. Although the entire region could often not be analyzed, it is now clear that 
individual CpGs can affect transcription. The DNA-binding factor CTCF insulates the effects of distal 
enhancers from promoters to regulate expression and contains multiple potential CpG sites within its 
binding motif. The methylation of one of these CpG sites prevents DNA binding and gene repression. The 
methylation of a single CpG can also recruit proteins with methyl-binding domains. Their binding to 
methylated DNA recruits histone modifying proteins to establish repressive chromatin states. My study on 
the changing methylation landscape of maturing motor neurons provides evidence for both models 
suggesting individual CpGs can be informative and that the DNA methylation state of a cluster of CpGs 
confers biological information. Many of the CpGs I observed to gain or lose methylation between D0 and 
D4 motor neurons were the only differentially methylated CpG associated with a gene. The dramatic 
change in methylation observed (>25%) as well as the importance of many of the nearest genes suggests 
these CpGs are biologically important and play a regulatory role. Many other differentially methylated 
CpGs, however, were located within 200 base pairs of each other (clustered). Most often, these CpGs all 
showed a change in methylation status in the same direction though some instances were observed in 
which one CpG gained methylation and its nearest neighbor lost methylation. The former case supports 
the idea that large genomic regions are the informative unit while the later case suggests each CpG plays 
a unique role. Why nearby CpGs would both gain and lose methylation, however, is yet to be determined. 
From my studies, it is evident that single CpG and multi-CpG methylation changes occur and both are 
most likely biologically relevant. 
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Why does CpG methylation not correlate with expression on the global level? 
 The first studies of the functional role of DNA methylation definitively showed that methylation is 
associated with a transcriptionally repressive state. We have since come to better understand the 
dynamic interplay between chromatin state and DNA methylation state, but still are unable to predict 
transcriptional expression based on DNA methylation. What’s more, global methylome and transcriptome 
studies show very poor correlation between DNA methylation and expression. The poor overall 
correlation could be due to several reason, all of which reflect a gap in our understanding and represent 
unique opportunities for future discovery. 
 One explanation for the poor correlation between methylation and expression could simply be 
due to our limited knowledge of the information content of each CpG. In other words, we still are unsure 
which CpGs regulate which genes. 3D chromatin mapping experiments have shown that the genome 
forms complex physical interactions between distal genomic regions. For example, enhancers have been 
shown to interact with gene prompters tens of thousands of kilobases away. Similarly, proximal CpGs 
may not provide the most predictive power for determining expression. The genomic description of the 
differentially methylated CpGs identified in my study of maturing motor neurons (Figure 4.S1) shows that 
most methylation changes occur 10-15 kilobases from transcription start sites (TSSs). Most putative 
enhancers are also found at roughly the same distance from TSSs as these differentially methylated 
CpGs. As more whole genome datasets across multiple cell types become available, correlations can be 
made between the methylation status of every CpG and the expression level of every gene to identify 
regulatory CpGs. 
 Moreover, the biologically significance of methylation levels further confounds our interpretation of 
DNA methylation and precludes correlative studies. In theory, because of the binary nature of DNA 
methylation, the methylation of a CpG within one cell can exist in only one of three states: 100% 
methylated (both alleles methylated), 50% methylated (one allele methylated, one allele unmethylated), or 
0% methylated (both alleles unmethylated). Empirically, CpG methylation is bimodally distributed between 
fully methylated (100%) and fully unmethylated (0%) states. Imprinted loci that are 50% methylated are 
the exception. Furthermore, intermediate methylation states, percent methylation that is not 0, 50, or 
100%, are also observed. The observation of intermediate methylation states (e.g. 30% or 70%) could 
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mean the presence of technical artifacts. Since all studies to date are not single cell and, therefore 
percent methylation of a CpG is the average methylation of all alleles in all cells, the observation of 
intermediate methylation most likely suggests the CpG methylation state varies among cells. The lack of 
correlation between methylation and expression could, therefore, be due to the fact that methylation is a 
binary variable while gene expression is a discrete variable. Single-cell transcription and methylation 
mapping experiments are necessary to more accurately describe the relationship between individual CpG 
methylation and gene expression.  
 
What is the role of CpH methylation? 
 The methylation of cytosine outside of the CpG context was first demonstrated to occur in 
embryonic stem (ES) cells and subsequently lost upon differentiation. Recently, the presence of CpH 
(H=A, C, or T) methylation was discovered in the mammalian brain. CpH methylation occurs primarily 
within the gene body, whereas CpG methylation is distributed across the genome. Like methylation at 
CpGs, CpH methylation in the brain is negatively correlated to gene transcript abundance. In ES cells 
however, CpH methylation is positively correlated to gene transcript abundance.  
 The key to understanding the role of CpH methylation may lie in its asymmetry. Because the 
CpA, CpC, and CpT nucleotide pairs do not contain a cytosine on its opposite strand, methylation can 
only occur on one strand. When a cell with CpH methylation divides, one cell could inherit the hemi-
methylated chromosome pairs while another cell could inherit the completely unmethylated 
chromosomes, effectively erasing the CpH methylation. Stem cells are known to undergo obligatory 
asymmetrical replication in which one pluripotent or multipotent cell divides into one mother cell that is 
identical to the original stem cell and into one daughter cell that is differentiated. The asymmetric division 
of CpH methylation may be a marker for stemness and instruct the dividing cell to remain in the 
pluripotent or multipotent state. The daughter cell that receives the unmethylated DNA strands would be 
signaled to differentiate due to the lack of CpH methylation. Experiments that can specifically disrupt CpH 
methylation in ES cells or synthetically introduce CpH methyl marks are necessary to test this hypothesis 
and elucidate CpH function.  
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How is DNA methylation directed? 
 Although we have a thorough understanding of the methyltransferase machinery, we have yet to 
determine how DNA methylation is directed to specific genomic sequences. Dnmt1 is primarily 
responsible for maintaining DNA methylation states through cell divisions by faithfully adding a methyl 
group to the cytosines of hemi-methylated, recently replicated, DNA. Dnmt3b is active early in 
development where it adds methyl groups to completely unmethylated pericentric regions and some 
repetitive elements. Dnmt3a more broadly methylates DNA across various genomic features throughout 
development and in adult tissues. Dnmt3l confers some specificity to direct Dnmt3a to imprinted loci and 
repetitive elements. The general specificity of each of the de novo methyltransferases can be explained 
by differences in their DNA binding domains or interaction with Dnmt3l, but factors that determine cell 
type-specific deposition of methyl groups is still unclear. 
 An important question underlying how DNA methylation status is determined is to understand 
what is the default methylation state of DNA: is the natural tendency of the methyltransferase machinery 
to methylate all cytosines with some sequences excluding the Dnmts or is the default state of the cell to 
be unmethylated with Dnmts directed to specific sequences by chaperones or cofactors? This question is 
further complicated when considering the process of cell division and the process of passive versus 
active demethylation. Studies have shown that Sp1 is associated with unmethylated sequences, 
especially CGIs. The additional of Sp1 binding sites to DNA that is methylated results in the prevention 
(or loss) of methylation while the mutation of Sp1 binding sites in unmethylated DNA results in gains of 
methylation within that region. Experiments with the Epstein-Barr virus suggest that binding of 
transcription factors alone is sufficient to prevent methylation of DNA in the case of replication-dependent 
mechanisms. These studies suggest a model where DNA-binding factors exclude the methyltransferase 
machinery from binding and methylating DNA.  
 Studies of the Oct4 and p15 promoters, however, suggest a different model in which specific 
factors direct the addition of methylation at unmethylated regions. In this case, the Oct4 promoter 
acquires methylation upon differentiation. The methylation state in differentiated cells results from the 
binding of G9A and subsequent recruitment of DNMT3A and DNMT3B to the Oct4 promoter.  
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Aberrant methylation gains in cancer can also teach us about the default state of DNA. p15, a 
tumor-suppressor genes, is highly methylated in the breast cancer cell line, MCF7. This methylation 
seems to be due to DNMT3A and mediated by ZNF217. Knockdown of ZNF217 by siRNA results in 
complete loss of methylation at the p15 promoter suggesting that ZNF217 directs the methylation at the 
p15 promoter by recruiting DNMT3A.  
 Most likely, depending on the cellular context, both models described occur. My work in mapping 
methylation in maturing motor neuron suggests that specific factors can direct the removal and additional 
of DNA methylation at specific loci in an active, non-replication-dependent manner. 
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